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Summary 
 
 
The expression of Tumor protein D52 (TPD52) family members is deregulated 
in many types of cancer. When overexpressed, it is suggested that they 
increase cell proliferation and migration/invasion as well as avoid apoptosis. 
Deregulation in the expression of the TPDs is therefore linked to poor 
prognosis. Little characterisation has been carried out to date, but it is known 
that the TPDs are found in association with components of the membrane 
trafficking pathway. The aim of this work is to uncover how the least studied 
member of the family, TPD54, affects cellular processes involved in 
carcinogenesis, such as cell migration and invasion. By using the 
knocksideways method, we have been able to map the cellular localisation 
of TPD54 and have identified association partners. These associations have 
been confirmed by immunoprecipitation and mass spectrometry analysis. 
Amongst these was the small GTPase Rab14. We have also found that TPD54 
is involved in the trafficking of receptors containing a dileucine motif in their 
cytosolic tail, but not a tyrosine-based or NPXY motif. With the mapping of 
the localisation of TPD54, we hypothesise that TPD54 is on the recycling 
route following the Golgi apparatus, and in association with Rab14, regulates 
the trafficking of receptors containing a dileucine motif. Integrins are receptors 
controlling cell migration. They can be trafficked through the Golgi apparatus 
before being recycled back to the plasma membrane. This recycling route is 
not well characterised. We therefore hypothesise that TPD54 regulates this 
route with Rab14, and that this is the reason why TPD54 is important for cell 
migration, and that a defect in its function can cause cancer. 
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Chapter 1 – Introduction 
 
 
1.1!Vesicle trafficking 
1.1.1! Overview of vesicle trafficking 
After their synthesis in the endoplasmic reticulum (ER), membrane proteins 
such as receptors, are translocated through the Golgi apparatus for post 
translational modification and then sent to the plasma membrane in vesicles. 
These vesicles will merge with the plasma membrane and the newly 
synthesised receptors will be ready for their first round of ligand binding. The 
types of ligands they will bind varies a lot, going from nutrients to growth 
factors and hormones. This is how mammalian cells are able to process signals 
sent by the environment and neighbouring cells. When a ligand is “caught”, 
the receptor will be internalised and sent inside the cell. There, the ligand is 
released, and the receptor can be recycled by being transported back to the 
cell surface for more rounds of internalisation. However, ligand binding to a 
receptor is not a prerequisite for internalisation. Indeed, some receptors are 
internalised constitutively whether or not a ligand is bound. 
Another way that the cell interacts with its environment is by remodelling it. 
Whether it is during embryo development or cancerous invasion, cells can 
remodel the extracellular matrix (ECM) by internalising these molecules and 
degrading them. 
The trafficking of all these molecules is done by lipid vesicles transported by 
motors on the cytoskeleton. The vesicles are transported between a series of 
compartmentalised, membrane-formed organelles (Figure 1.1). There are a 
few different pathways that a newly internalised vesicle can take, and this 
route is dependent on the cargo inside the vesicle. The shortest one is the 
recycling pathway (orange arrows in Figure 1.1). The quickest way for a 
receptor to go back to the plasma membrane is to unload its ligand in the first 
  
2 
sorting hub, the sorting endosomes. Then, it can go back on the cell 
membrane through a short or long recycling pathway, leaving the tubular 
region of the sorting endosomes. A receptor can also go on the endolysosomal 
pathway, going through the late endosomes and leading to degradation in the 
endolysosomes (red arrows on Figure 1.1). Cargoes can be transported to the 
Golgi apparatus from the endosomes in a retrograde manner (Figure 1.1, blue 
arrows) and go back to the endosomes in an anterograde manner (Figure 1.1, 
green arrows). Finally, some molecules, like the ECM constituents collagen or 
fibronectin, are synthesised in the ER and secreted outside. These proteins 
take the biosynthetic pathway (purple arrows, Figure 1.1). 
 
Figure 1.1: Pathways of vesicle trafficking. After invagination at the plasma membrane, a 
transport vesicle will go to the sorting endosomes. It has two different regions: an early 
endosomal region from which the fast recycling pathway starts and from which the 
maturation into late endosomes will happen, and a recycling endosomal region formed of 
tubules from which the slow-recycling pathway starts. The recycling pathways lead the 
cargoes from the endocytosed vesicles back to the plasma membrane (orange arrows). The 
late endosomes lead to the multivesicular body (MVB) and ultimately degradation with the 
lysosomes (red arrows). A route to the Golgi apparatus is possible (retrograde pathway, 
blue arrows) from either the late endosomes, the early part, or the recycling part of the 
sorting endosomes. An opposite route is also possible, going from the Golgi to these 
endosomes (anterograde pathway, green arrows). Finally, newly synthesised receptors go 
from the endoplasmic reticulum to the plasma membrane, passing and maturing through 
the Golgi apparatus (biosynthetic pathway, purple arrows). 
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This first section will describe the vesicle trafficking pathways and the main 
proteins acting on the different steps. 
 
1.1.2! Endocytosis 
Endocytosis is the process by which cells internalise extracellular material. It 
is needed for nutrient internalisation and can be hijacked by pathogens to 
enter the cell. It is also a way of keeping homeostasis in the lipid content of 
the plasma membrane (Doherty and McMahon, 2009). There are different 
types of endocytosis. Macropinocytosis forms large vesicles of a diameter of 
up to 5 µm (Swanson and Watts, 1995), which function in the uptake of fluids 
and nutrients, in an actin-dependent manner (Bloomfield and Kay, 2016).  
Another type of endocytosis uses membrane invaginations coated with 
caveolin, the caveolae, for internalisation. In endothelia, for example, 
molecules go from one side of the endothelium to the other, by traversing the 
cells in caveolae (Cheng and Nichols, 2016).  
The best studied type of endocytosis is clathrin-mediated endocytosis (CME). 
There, triskelia of clathrin molecules assemble in a coat around a vesicle 
containing the receptors to be internalised (Heuser and Kirchhausen, 1985; 
Pearse, 1976; Roth and Porter, 1964). CME involves a series of steps tightly 
regulated by many proteins. It is initiated by an enrichment of receptors. The 
adaptor protein complex AP2 binds the cytoplasmic tail of the receptor and 
recruits the clathrin coat. AP2 is the adaptor between the plasma membrane, 
the receptor (cargo) and the clathrin coat, since clathrin cannot bind the 
receptors directly (Collins et al., 2002). To be internalised, the receptor must 
have an endocytic motif on its cytosolic end. This will in turn be bound by an 
adaptor protein (Bonifacino and Traub, 2003). There are three main endocytic 
motifs: a dileucine motif ([D/E]XXXL[L/I/M], where X is any amino acid), a 
tyrosine-based motif (YXX#, where # is a bulky hydrophobic amino acid) and 
the [F/Y]XNPX[Y/F] motif. Dileucine and tyrosine motifs can both be bound 
by AP2. Dileucine motifs are bound by the !-$2 subunits (Kelly et al., 2008) 
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whereas tyrosine motifs are bound by the µ2 subunit (Ohno et al., 1995). 
Although both motifs can bind AP2, they do not compete with each other as 
the $ and µ subunits are on opposite sides of the adaptor (Marks et al., 1996). 
The NPXY motif will be bound by the PTB (phosphotyrosine-binding) domain 
of alternative adaptors, like DAB2, ARH or Numb (Garcia et al., 2001; Mishra 
et al., 2002; Santolini et al., 2000).  
The formation of the clathrin coat is followed by a deformation in the 
membrane, forming a clathrin-coated pit. BAR domain-containing proteins, 
such as SNX9, have affinity for curved membrane. SNX9 will bind AP2 and 
recruit the enzyme dynamin (Bendris and Schmid, 2017). Upon GTP 
hydrolysis, dynamin undergoes a conformational change and allow 
membrane fission at the neck of the pit (Sweitzer and Hinshaw, 1998). Once 
freed from the plasma membrane, the pit is called clathrin-coated vesicle 
(CCV). It will eventually lose its clathrin coat with the help of auxilin and 
Hsc70 and be transported inside the cell towards the early endosomes.  
1.1.3! Rab GTPases 
The Rab proteins are small GTPases of roughly 25 kDa that can be seen as 
master regulators of the trafficking pathways. Being GTPases, they cycle 
between a GTP-bound, active state, and a GDP-bound, inactive state. This 
cycling regulates the numerous steps of the trafficking pathway, from vesicle 
uncoating after invagination, to vesicle transport by motor proteins and vesicle 
fusion (Barr, 2013; Stenmark, 2009; Wandinger-Ness and Zerial, 2014; Zhen 
and Stenmark, 2015). The Rab GTPases are also responsible for endosome 
maturation (discussed below).  
About 8000 Rab proteins have been identified so far throughout 247 genomes. 
In humans, 66 (isoforms included) can be found (Diekmann et al., 2011; 
Klopper et al., 2012). The great variety of Rab GTPases results from the fact 
that some are tissue specific, while each one of them is mainly associated with 
one organelle, assuring the correct trafficking to and from this organelle (Table 
1.1). However, Rab protein localisation can overlap in the endosomal system 
  
5 
(Eathiraj et al., 2005), which can lead to formation of Rab-specific domains 
on one organelle (Sonnichsen et al., 2000). 
Table 1.1: List of human Rab GTPases and their localisation. 
Rab GTPase Localisation/function 
Rab1 ER to Golgi trafficking 
Rab2 Golgi to ER trafficking 
Rab3 Secretion, mainly in neurons 
Rab4 Fast recycling, sorting endosomes to PM 
Rab5 Endocytosis, sorting endosomes 
Rab6 Golgi apparatus 
Rab7 Late endosomes,  
Rab8 Nucleus and PM, cilia 
Rab9 Late endosome to Golgi apparatus 
Rab10 GLUT4 exocytosis 
Rab11 Slow recycling, sorting endosomes, 
perinuclear region 
Rab12 Recycling, autophagosomes 
Rab13 EGF endocytosis, tight junctions, 
recycling 
Rab14 Phagosomes, GLUT4 exocytosis, 
endosomes 
Rab15 Recycling 
Rab17 Autophagosomes, recycling,  
filopodia, melanosomes 
Rab18 Lipid droplets, ER 
Rab19 Endosomes, Golgi apparatus 
Rab20 Phagosomes, ER 
Rab21 Endocytosis of integrins 
Rab22 Sorting endosomes 
Rab23 Cilia 
Rab24 ER, late endosomes,  
Rab25 Recycling of integrins, epithelial cells 
Rab26 Lysosomes 
Rab27 Melanosomes, secretion 
Rab28 GLUT4 trafficking, nucleus 
Rab29 (Rab7L1) Endosomes to Golgi apparatus 
Rab30 Golgi apparatus 
Rab31 Golgi apparatus, endosomes 
Rab32 Endosomes, lysosome-related 
Organelles, mitochondria 
Rab33 ER, Golgi, autophagosomes 
Rab34 Macropinosomes 
Rab35 Fast recycling, endosomes 
Rab36 Melanosomes 
Rab37 Insulin exocytosis 
Rab38 Endosomes, lysosome-related 
organelles 
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Rab39 Secretion, caspase-1 binding 
Rab40 Filopodia 
Rab41 ER to Golgi 
Rab43 ER to Golgi 
 
A genetic study has identified six supergroups amongst the Rab GTPases, 
classifying them according to their evolution from the last eukaryotic common 
ancestor (LECA) to humans (Table 1.2) (Klopper et al., 2012). This study allows 
us to understand similarities between certain members of the Rab GTPases 
large family. 
 
Table 1.2: Regrouping of Rab GTPases present in vertebrates according to their evolution 
from the latest eukaryotic common ancestor (LECA) (adapted from Köpper et al., 2012). 
 LECA Vertebrata 
Group I 
Rab1 
Rab1a 
Rab1b 
Rab35 
Rab33a 
Rab33b 
Rab19 
Rab43 
Rab30 
Rab8 
Rab8a 
Rab8b 
Rab13 
Rab12 
Rab15 
Rab10 
Rab3a 
Rab3b 
Rab3c 
Rab3d 
Rab26 
Rab27 
Rab27a 
Rab27b 
Rab34 
Rab36 
Rab45 
Rab44a 
Rab44b 
Rab18 
Rab18 
Rab40a 
Rab40aL 
Rab40c 
Rab40d 
Group II 
Rab5 
Rab5a 
Rab5b 
Rab5c 
Rab17 
Rab21 Rab21 
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Rab22 
Rab22a 
Rab22b 
Rab24 
Rab24 
Rab20 
RabX1  
Group III 
Rab7 
Rab7a 
Rab7b 
Rab9a 
Rab9b 
Rab23 Rab23 
Rab29  
Rab32 
Rab32 
Rab38 
Rab7L1 Rab7L1 
Group IV 
Rab2 
Rab2a 
Rab2b 
Rab39a 
Rab39b 
Rab42 
Rab4 
Rab4a 
Rab4b 
Rab11 
Rab11a 
Rab11b 
Rab25 
Rab14 Rab14 
Group V Rab6 
Rab6a 
Rab6b 
Rab6c 
Rab41 
Group VI 
Rab28 Rab28 
RabL4 RabL4 
 
1.1.3.1 The Rab cycle 
Rab GTPases cycle between an active and inactive state, and this cycle can 
be mainly described as such: a GDI (GDP dissociation inhibitor) escorts the 
Rab-GDP to the correct ‘donor’ membrane. A Rab GEF (guanine nucleotide 
exchange factor) will activate the Rab by exchanging GDP for GTP. Effectors 
(proteins that can bind Rab GTPases only in their GTP-bound state) can then 
bind the Rab proteins and allow them to regulate the pathway on which they 
are until the Rab proteins reach an ‘acceptor’ membrane. A GAP (GTPase 
activating protein) will inactivate the Rab GTPase by hydrolysing GTP into 
GDP. The GDI will be able to bind the Rab-GDP to recycle it back to the 
donor membrane, for another cycle (Figure 1.2) (Stenmark, 2009). 
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Figure 1.2: The Rab GTPase cycle. 1-2. A GDI escorts the Rab-GDP to the right initial 
donor membrane. 3. A GEF activates the Rab GTPase by changing the GDP for GTP. 4. 
The GTP-bound Rab can bind effectors and together regulate the trafficking pathway. 5. 
On the acceptor membrane, a GAP inactivates the Rab GTPase by hydrolysing GTP into 
GDP and the GDI can escort the Rab-GDP back for another cycle. 
 
To be inserted into membranes, Rab GTPases needs prenylation (addition of 
a geranylgeranyl group) at its C-terminal, by a GGT (geranylgeranyl 
transferase) and a REP (Rab escort protein). The REP escorts the prenylated 
Rab to the right membrane (Leung et al., 2006). This geranylgeranyl group is 
hydrophobic, so when it is not hidden in membrane, the Rab GTPase needs 
to be chaperoned by the GDI, which hides the hydrophobic tail (Goody et al., 
2005). The Rab’s association with the GDI is how it can stay soluble (Ullrich 
et al., 1993). It is thought that the GDI-Rab complex can ‘sample’ many types 
of membranes, inserting and extracting the Rab from these membranes, until 
the association of the GTPase with a membrane is stabilised, generally by the 
presence of the Rab’s specific GEF (Barr, 2013). By changing GTP for GDP, 
the GDI cannot extract the Rab anymore, and the effectors can bind the Rab 
and further stabilise it on the donor membrane (Blumer et al., 2013; 
Gerondopoulos et al., 2012; Pylypenko et al., 2006; Wu et al., 2010).  
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1.1.3.2 Rab GTPases in trafficking pathways 
The Rab GTPases control the trafficking pathways via their binding with their 
multiple effectors while in GTP-bound state. These effectors have a broad 
range of functions: they can be phosphatases, kinases, motors, tethers, 
adaptors, membrane fusion regulators, etc. (Gillingham et al., 2014). To add 
another level of complexity, some effectors for one Rab can be GAPs or GEFs 
for other Rabs. For example, the Rab9 effectors SGSM1 and SGSM2 are GAPs 
for Rab32, Rab33 and Rab36 (Nottingham et al., 2011; Nottingham et al., 
2012). By binding to the activated late endosomal Rab9, SGSM1 can 
inactivate the melanosome-related Rab32 and regulate their biogenesis 
(Ohbayashi et al., 2017). Another example is the HOPS complex. It is an early 
endosome-related Rab5 effector and a GEF for the late endosome-related 
Rab7. By binding to the activated Rab5, it can in turn activate Rab7, allowing 
the maturation of the early endosome in a late endosome (Rink et al., 2005).  
As mentioned above, Rab GTPases are master regulators of the trafficking 
pathway via their association with different binding partners that will control 
every step of trafficking, from vesicle budding to vesicle fusion to the acceptor 
membrane.  
Rab5-GDI complex has been shown to be required for clathrin-coated vesicle 
assembly in vitro (McLauchlan et al., 1998) . The same GTPase and its GEF 
RME-6 are important for uncoating of AP2 on newly budded endocytic 
vesicles. AAK1 is responsible for AP2 phosphorylation, which increases AP2 
binding to PI(4,5)P2 (Conner and Schmid, 2002). In an opposite way, RME-6 
promotes dephosphorylation of AP2, making its binding to PI(4,5)P2 unstable, 
which makes AP2 fall off the vesicle (Semerdjieva et al., 2008). 
Once the vesicle is uncoated, it travels along the cytoskeleton towards its final 
destination. For shorter translocations, vesicles utilise the actin cytoskeleton. 
One of the motor protein ‘walking’ along actin is myosin V (Mehta et al., 
1999). A few Rab GTPases (Rab3, Rab6, Rab8, Rab11, Rab14, Rab25, Rab27, 
Rab39) have been found to interact directly with myosin Va or Vb (Lapierre 
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et al., 2001; Lindsay et al., 2013; Nagashima et al., 2002) therefore making 
actin a molecule that many types of endosomes, melanosomes and secretion 
vesicles can use to reach their destination.  
For longer trajectories, vesicles will rather use the microtubules. Dynein and 
the different members of the kinesin family are the motors used by the 
trafficking organelles moving along microtubules (Aniento et al., 1993; 
Bonifacino and Neefjes, 2017). Like for myosin V, many Rab GTPases can 
bind microtubule-associated motors. For example, Rab5 interacts with Kif16B 
to translocate early endosomes (Hoepfner et al., 2005; Nielsen et al., 1999). 
Rab4 has a role in the regulation of KifC2: when the GTP is hydrolysed, KifC2 
motility is increased (Bananis et al., 2004). Rab7 is involved in the recruitment 
of dynein and is important for the transport of lysosomes, together with two 
effectors of Rab7’s, RILP and ORP1L (Cantalupo et al., 2001; Johansson et al., 
2007; Jordens et al., 2001). 
Once the vesicle has reached its destination, Rab GTPases also regulate the 
fusion of the vesicle with the acceptor membrane. One good example for this 
is Rab5 and its effector EEA1 (early endosome antigen 1), resident of the 
sorting endosomes. It has been known for a while that EEA1 interacts with the 
SNARE syntaxin 6 or 13 (McBride et al., 1999; Simonsen et al., 1999; 
Simonsen et al., 1998), but it is only recently that Rab5-GTP has been shown 
to induce a conformational change in the long rod-shaped EEA1 that allow 
the tether to bring two vesicles together for subsequent fusion (Murray et al., 
2016). 
Since Rab GTPases affect so widely all parts of the trafficking pathway, it is to 
be expected that a deregulation in their expression can lead to generalised 
diseases like cancer. For example, high expression levels of Rab25 is a marker 
for breast and ovarian cancers (Cheng et al., 2004). It has been shown to be 
one of the few Rabs that can bind directly to the cytoplasmic tails of the 
extracellular matrix receptor integrins, specifically integrin !5"1 (Caswell et 
al., 2007). By doing so, Rab25 regulates the recycling of the integrins and an 
overexpression of the protein is linked with increased invasion (Caswell et al., 
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2007; Dozynkiewicz et al., 2012). In a similar manner, Rab21 also binds 
integrin "1 and control its endocytosis, therefore affecting cells attachment to 
their substrate and motility (Pellinen et al., 2006).  
 
1.1.4 Endosomes 
The classical view is that endosomes are distinct compartments, each having 
a defined set of proteins contributing to their function (Johannes and Popoff, 
2008; Lieu and Gleeson, 2011; Pfeffer, 2009). However, it is becoming clear 
that such a precise segregation cannot be done. Endosomes are very dynamic 
organelles with different regions on one compartment, sorting receptors to 
different places, and losing proteins and gaining new ones while scission and 
maturation happen (Figure 1.3) (Bonifacino and Rojas, 2006; Huotari and 
Helenius, 2011; Johannes and Wunder, 2011; Progida and Bakke, 2016; Scott 
et al., 2014; Sonnichsen et al., 2000). Here, the traditional early endosomes 
and recycling endosomes will be called sorting endosomes (Hsu et al., 2012). 
It has been shown to have different microdomains characterised by either 
proteins (Sonnichsen et al., 2000) or lipids (Yoshida et al., 2017), further 
reinforcing the idea of sorting endosome rather than having separate early and 
recycling endosomes. The sorting endosome is the main hub for receptor 
sorting, since the internalised receptors can take one of the three available 
pathways from there: a recycling pathway to go back to the plasma 
membrane, a retrograde pathway to the trans-Golgi network (TGN) or a 
pathway leading to degradation in the endolysosomes.  
 
1.1.4.1 Arrival in the endosome 
The first region to be reached by internalised receptors is the early region of 
the sorting endosome, or early endosome. Its lipid composition is different 
than the plasma membrane (phosphatidylinositol 3-phosphate (PI(3)P) instead 
of PI(4,5)P2, respectively). Rab5 and its effector Vps34, alongside the inositol 
5-polyphosphatase OCRL1 (oculocerebrorenal syndrome of Lowe) are 
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responsible for the changes in lipid composition (Prosseda et al., 2017; Shin 
et al., 2005). Once the lipid composition is changed, Rab5 also recruits EEA1 
(Simonsen et al., 1998) which binds one endosome’s PI(3)P (Patki et al., 1997) 
on one end, and another endosome’s Rab5 (Simonsen et al., 1998) on the 
other end. The binding of Rab5 induces a conformation change in EEA1 and 
instead of having a long, rod shape, EEA1 collapses to bring the two vesicles 
closer for fusion (Murray et al., 2016). EEA1 and Rab5 are therefore 
responsible for tethering incoming endocytic vesicles and preparing them for 
fusion with the endosome. 
 
 
Figure 1.3: The sorting endosome. The sorting endosome is a sorting hub for receptors. 
They will be sorted through associations with different residents of the endosome. These 
proteins form domains that can be associated with the traditional view of early endosome 
(Rab5, Rab4), early endosome maturing towards becoming a late endosome (Rab5, Rab7, 
ESCRT), and recycling endosome (Rab4, Rab11). Alongside the recycling region of the 
sorting endosome, two complexes can also sort and recycle receptors either towards the 
Golgi apparatus or the plasma membrane (retromer and retriever). 
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As mentioned earlier, the sorting endosome is thought to have three regions, 
determined by the heterogeneity of the protein repartition. The part receiving 
the endocytic vesicle is the early endosome region. It is mainly characterised 
by the presence of Rab5 and EEA1, but also Rab4 and APPL1, although APPL1 
colocalises only sparsely. Indeed, only about 30% of endosomes contain both 
EEA1 and APPL1 (Kalaidzidis et al., 2015). It is thought that these 
APPL1/EEA1-positive endosomes are sorting hubs where receptors are sorted 
for fast or slow recycling (Kalaidzidis et al., 2015).  
CORVET (class C core vacuole/endosome tethering complex), is another 
protein complex associated with the early region of the endosomes. It binds 
Rab5 and facilitates tethering and fusion of vesicles to the endosomes 
(Balderhaar et al., 2013; Peplowska et al., 2007).  
 
1.1.4.2 Endosomal recycling 
Once in the sorting endosome, cargoes are “scanned” and sorted either for 
degradation or recycling. Example of protein having such a role are SNX17, 
which sends the ECM receptor integrins out or RCP, which sends the 
transferrin receptor (TfR) back to the surface (Bottcher et al., 2012; Peden et 
al., 2004). The fast recycling pathway is Rab4-dependent and sends receptors 
back to the plasma membrane either directly from the early endosomal region, 
or through the recycling endosomal region of the sorting endosomes 
(Vandersluijs et al., 1992; Wandinger-Ness and Zerial, 2014). This recycling 
endosomal part is characterised by the presence of Rab4, Rab11 and its 
tubular morphology. One of the main molecules used for studying receptor 
recycling is the transferrin receptor. It has been shown that the TfR is mainly 
colocalised with Rab5, 5 minutes post-internalisation, colocalised with Rab4 
after 7 minutes, gradually losing its colocalisation with Rab5 after 7 minutes 
until 30 minutes, and colocalises with Rab11 on the slow recycling pathway 
after 30 minutes, to be completely returned to the plasma membrane after 60 
minutes (Sonnichsen et al., 2000). This shows that internalisation is very quick 
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and that TfR can get returned to the plasma membrane via both recycling 
pathways (Ullrich et al., 1996).  
 
1.1.4.3 Endolysosomal degradation 
If a receptor needs to be downregulated after internalisation, it will be sent for 
degradation on the endolysosomal pathway and tagged with ubiquitin 
molecules. This is achieved by a series of endosome maturing steps starting 
in the sorting endosome. First, the so-called “Rab switch” needs to occur 
(Huotari and Helenius, 2011) (Figure 1.4). When Rab5-GDP arrives near an 
endosome, the GEF Rabex-5 activates Rab5 which can then bind to the 
endosome, and Rabaptin-5, a Rab5 effector, promotes Rabex-5 activity 
(Horiuchi et al., 1997; Lippe et al., 2001). The switch occurs when Ccz1 and 
Mon1 bind Rab5 and displace Rabex-5/Rabaptin-5. Rab5 will then return to 
its GDP-bound, inactive state. Then, Ccz1/Mon1 can move GDI from Rab7 
which activates Rab7, and Rab7/Ccz1/Mon1 bind the maturing endosome’s 
membrane (Kinchen and Ravichandran, 2010; Poteryaev et al., 2010; 
Wurmser et al., 2000). The newly acquired Rab7 and Ccz1 can in turn recruit 
HOPS, a Rab7 effector. The late endosomal Rab9 also plays a role in the 
maturation since it binds the Rab5 GAP SGSM3, making Rab9 a player in 
Rab5 inactivation (Gillingham et al., 2014; Kucera et al., 2016). 
The lipids of the late endosomal membrane are mainly made of PI(3,5)P2. 
PIKfyve is responsible for the lipid composition change (Odorizzi et al., 1998; 
Zolov et al., 2012). At the same time, the Hrs subunit of ESCRT-0 can bind 
the PI(3)P and the ubiquitin tags of the receptors in the sorting endosomes 
going to the degradative pathway. After binding of the other ESCRT 
complexes, the receptors will be invaginated within the endosome and this 
intralumenal vesicle (ILV) will be pinched off. This process is also used as a 
way to inactivate signalling receptors (Huotari and Helenius, 2011; Scott et 
al., 2014). The late endosomes mature gradually by losing “early” 
components and characteristics. Structurally, tubules are lost and ILVs are 
gained, SNARES necessary for fusion with other early endosomes are also lost, 
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as well as the ability to recycle receptors directly to the plasma membrane, 
and lysosomal proteins are transported from the Golgi apparatus to the late 
endosomes (Huotari and Helenius, 2011). The compartment acidity also 
changes, going from 6.2 to 5.5-5.0. The acidification is needed for the 
enzymatic activity of lysosomal proteins and the uncoupling of the receptors 
and their ligand (Scott et al., 2014). At this stage, the late endosome can be 
called multivesicular body (MVB). MVB will use microtubule motors to move 
towards the perinuclear region and ultimately fuse with lysosomes to form the 
degradative endolysosomes (Huotari and Helenius, 2011). There is at least 
one escape route from the late endosome, by returning to the Golgi apparatus 
in a Rab9 dependent manner (Barbero et al., 2002).  
The cation-independent mannose-6-phosphate receptor (CIMPR) is one 
example of transmembrane protein able to escape the degradative route. It is 
needed to bring newly synthesised lysosomal enzymes to the lysosomes. 
These enzymes are tagged with mannose-6-phosphate in the Golgi, which 
bind CIMPR. CIMPR will then be sent to the endosomes in AP1- and GGA-
dependent manner (Doray et al., 2002). CIMPR reaches the sorting endosome 
during the Rab switch and can therefore be colocalised with Rab5 and Rab7 
(Kucera et al., 2016). Being on the endolysosomal pathway, CIMPR will 
eventually free its ligand in the acidic environment of the late endosomes and 
return to the Golgi apparatus in a Rab9-dependant way for another round of 
trafficking (Ganley et al., 2004; Riederer et al., 1994). TIP47, a putative Rab9 
effector  is also thought to be required for the retrograde trafficking of CIMPR 
(Carroll et al., 2001; Diaz and Pfeffer, 1998), although controversy exists on 
this matter, since another team has suggested that TIP47 does not bind to Rab9 
and does not affect the recycling of CIMPR, and is indeed involved in lipid 
droplets metabolism (Bulankina et al., 2009).  
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Figure 1.4: Endosome maturation. The early region of the sorting endosome will undergo 
maturation in order to become a late endosome, then a multivesicular body (MVB) that 
will eventually fuse with a lysosome for the degradation of ubiquitinated receptors. For an 
efficient degradation, the endolysosome needs lysosomal enzymes. After their synthesis, 
they are translocated to the Golgi apparatus where they will be tagged with mannose-6-
phosphate. This tag will be recognised by transporters like CIMPR and the lysosomal 
enzymes will be transported to the endosomes. a) Zoom on the Rab switch. Rab5-GDP are 
transported to early endosomes with their chaperone, GDI. When Rab5-GDP is inserted 
into the membrane, Rab5-GDP becomes Rab5-GTP by the action of the GEF Rabex-5. The 
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effector Rabaptin in turns binds Rab5-GTP and positively regulates Rabex-5 to keep Rab5 
activated.  It takes the complex Mon1/Ccz1 to displace Rabaptin and stop this activation 
cycle. Then, the Rab9 effector SGSM3 inactivates Rab5-GTP with its GAP activity. 
Mon1/Ccz1 is a GEF for Rab7 and activates it, while Rab5-GDP is taken by GDI for another 
cycle. b) Zoom on ESCRT segregation of ubiquitinated receptors into intralumenal vesicles 
for degradation. 
 
1.1.4.4 Retrograde transport from the sorting endosome 
CIMPR does not only return to the Golgi apparatus via Rab9, but also from 
the sorting endosomes in a retromer-dependant manner (Arighi et al., 2004; 
Seaman, 2004). Retromer is a complex formed by a combination of sorting 
nexin 1 (SNX1) or SNX2 and SNX5, SNX6 or SNX32, along with Vps26, Vps29 
and Vps35 (Horazdovsky et al., 1997; Rojas et al., 2007; Seaman et al., 1998; 
Wassmer et al., 2007). The membrane-bending ability of the SNXs create 
tubules on the endosomal membrane. Receptors accumulates in these tubules 
which will be recognised by the Vps proteins. The Vps proteins form a coat 
for the transport to the Golgi apparatus (Gallon and Cullen, 2015). Rab5 is 
needed for the presence of the SNX-Vps complex (Rojas et al., 2008) and Rab7 
binds to Vps35, which will stay bound throughout the endosomal maturation 
(Rojas et al., 2008; Seaman et al., 2009; van Weering et al., 2012). Retromer 
is also needed for the completion of the maturation since Vps29 binds the 
Rab7 GAP TBC1D5 which inactivates Rab7 (Mukhopadhyay et al., 2007; 
Seaman et al., 2009). Although the retromer is generally involved in the 
endosome/TGN retrograde pathway, it has been shown to also be involved in 
transport of the "2-adrenergic receptor from endosomes to the plasma 
membrane in a SNX27- and Rab4-dependant manner (Temkin et al., 2011). 
The retromer-dependent trafficking of CIMPR needs the WASH complex 
(Gomez and Billadeau, 2009). WASH is made of five subunits (WASH1, 
strumpellin, SWIP, FAM21 and CCDC53) and is the main actin nucleating 
factor on endosomes (Derivery et al., 2009; Seaman et al., 2013). It 
colocalises with early endosomal markers like Rab5 and EEA1 (Duleh and 
Welch, 2010) or late endosomal/MVB marker like Rab7 and CD63 (Zech et 
al., 2011). It recruits the Arp2/3 complex, which in turn promotes actin 
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polymerisation. This is thought to create WASH-positive domains on the 
endosomes and therefore to organise actin around these domains in order to 
segregate proteins into them and arrange recycling routes out of the 
endosomes (Derivery et al., 2012; Puthenveedu et al., 2010).   
Recently, a new protein complex, called retriever, involved in endosomal 
recycling has been identified (McNally et al., 2017). Much like the retromer, 
the retriever is a trimer. It is formed of DSCR3, C16orf62 and Vps29 and it 
interacts with SNX17. The retriever has been identified because SNX17 is 
involved in the recycling of "1 integrin from the endosomes in a retromer-
independent manner (Steinberg et al., 2012). 
Finally, there is some evidence for a retrograde pathway to the Golgi from the 
recycling endosomes, notably in a Rab11- and RCP-dependent manner (Jing 
et al., 2010). However, this pathway has yet to be defined, since recycling 
endosomes are poorly characterised on a molecular level (Johannes and 
Wunder, 2011). 
 
1.2 Cell migration 
Whether it is leucocytes chasing a bacterium, mesenchymal cells in an 
embryo or epithelial cells closing a wound, cellular migration is an important 
process utilised by many cell types in normal conditions. Although this 
process is highly controlled, deregulation in one of the many steps can occur 
and can lead to cancer and metastases. Indeed, an increased migratory ability 
is a hallmark of cancer (Paul et al., 2017).  
 
1.2.1 Steps of cell migration 
In order to start the migrating process, cells have to establish polarity. They 
need a leading edge and a trailing end. Although cells can be polarised 
spontaneously (Wedlich-Soldner and Li, 2003), polarity is generally 
established in response to chemotactic signals secreted by neighbouring cells 
and bound to the extracellular matrix (ECM). The main chemotactic molecules 
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are cytokines and growth factors like platelet-derived growth factor (PDGF), 
epidermal growth factors (EGF) and keratinocyte growth factors (KGF). These 
molecules will bind the receptors and initiate a signalling cascade inducing 
polarity (Majumdar et al., 2014; Maritzen et al., 2015). The plasma membrane 
composition also helps to establish polarity. PI3K is kept at the cell front and 
generates PI(3,4,5)P3, which can amplify the response to chemotactic signals 
(Cain and Ridley, 2009; Funamoto et al., 2002; Iijima et al., 2002).  
The morphology of a polarised cell changes whether the cell is migrating in a 
2D or 3D environment. A cell migrating through tissues like a leucocyte 
through an endothelium will adopt an amoeboid or mesenchymal shape: 
elongated front for better insertion between other cells and rounded, 
deformable back (Friedl, 2004). The cell crawls forwards and, in the case of 
leucocytes, can move rapidly because of low interaction points with the ECM 
or other cells (Friedl et al., 1998). In the case of cells migrating on a 2D 
substrate, they will have an elongated tail and a lamellipodium at the leading 
edge. The lamellipodium is composed of a polymerising network of actin 
filaments. It is this polymerisation that pushes forward the plasma membrane 
for the cell to move (Keren and Shemesh, 2017). In both cases, cells migrating 
in 2D or 3D rely on actin protrusions in the plasma membrane for movement, 
except in the case of bleb migration, a type of migration used in 3D substrates. 
These cells use extensions in the anterior plasma membrane caused by 
hydrostatic pressure exerted by the actomyosin cortex (Mierke, 2015). 
Another variation of the bleb migration is the formation of lobopodia, small 
bleb formations on a cylindrical protrusion at the front of the cell (Petrie et al., 
2012).  
The actin polymerisation in the leading edge is the result of the signalling 
cascade initiated by the growth factor/chemokine binding to their receptors at 
the cell surface. The small GTPase Cdc42 is activated by this cascade. It is 
essential for maintenance of the cell polarity in most cell types (Heasman and 
Ridley, 2008; Nobes and Hall, 1999). It keeps the Golgi apparatus oriented in 
the direction of the movement and makes sure that the lamellipodium activity 
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stays at the cell front by recruiting the actin cytoskeleton at the front and 
activates another GTPase, Rac (Nobes and Hall, 1995). Rac is also activated 
by the binding of growth factors to their receptors. It activates the nucleation 
promoting factor (NPF) which in turn activates the actin nucleator Arp2/3. To 
keep Rac functioning at the lamellipodium, it is recycled in an Arf6-dependent 
manner to the cell front, ensuring furthermore the maintenance of polarity 
(Palamidessi et al., 2008). This recycling also creates a gradient of 
concentration of Rac at the front and another small GTPase, Rho is kept at the 
cell rear. Rho is responsible for the maintenance of cellular adhesions to the 
ECM (Nobes and Hall, 1999).  
Once the protrusion is made, contraction of the actomyosin cortex will retract 
the tail and allow the cell to move. Rho, Rac and Ras (responsible for the 
turnover of the cellular adhesions (Nobes and Hall, 1999)) all play a role in 
this process. Non-muscle myosin II is activated by Rho at the front of the cell 
and induces contraction and tail retraction (Chrzanowska-Wodnicka and 
Burridge, 1996; Nalbant et al., 2009; Vicente-Manzanares et al., 2009). While 
the cell contracts and the tail retracts, the adhesions at the back need to be 
removed and replaced at the front. It is the adhesions at the front that allow 
force transmission through the actin stress fibres (Ridley et al., 2003). As well 
as controlling the turnover of adhesions, Ras is also required for the stress 
fibres turnover (Nobes and Hall, 1999).  
When these migratory steps are deregulated, cells can become cancerous and 
induce metastases. Cellular adhesions are weaker or recycled more rapidly. 
Cell migration isn’t growth factor-dependent anymore, and other chemotactic 
signals increase even more cell motility. There is also an increased release of 
proteases into the ECM in order to invade more efficiently (Hanahan and 
Weinberg, 2000; Porther and Barbieri, 2015a; Porther and Barbieri, 2015b). 
This shows that each and every step of cell migration needs to be tightly 
regulated in healthy individuals. 
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1.2.3 Cellular adhesion assembly 
Cellular adhesions are the anchor points into the cell’s environment. They are 
a direct link between the ECM components and the actin stress fibres. The 
main constituents of the ECM are collagen, elastin, fibronectin (FN), laminin, 
glycoproteins, proteoglycans and glycosaminoglycans (Keren and Shemesh, 
2017). The ECM is secreted by the cells and serves as a physical scaffold for 
the cells to be embedded in. The ECM proteins are generally large. For 
example, FN is made of 2 subunits of about 250 kDa bound covalently 
together, and laminin is a trimer of between 400 and 800 kDa.  
Adhesions are made of many different proteins, which are added while the 
adhesion is maturing until its turnover. Nascent adhesions are the first clusters 
to be made. They form in the lamellipodium and will either disassemble or 
mature (Alexandrova et al., 2008). It has been shown recently that, at least in 
fibroblasts, the addition of adhesion component is initiated by an increase in 
the plasma membrane tension following protrusion formation (Pontes et al., 
2017). The next maturation stage is the focal complex. Its formation is myo II-
dependent and is positioned at the border between the lamellipodium and the 
lamellum. Finally, the mature form is a focal adhesion (FA). They are at the 
end of actin bundles and measure between 2 and 10 µm (Valdembri and 
Serini, 2012).  
The central constituent of the FAs are the integrins. These receptors for ECM 
components are made of a dimer of an ! and " subunit. There are 18 different 
! integrins and 8 " integrins, for a total of 24 different heterodimers (Paul et 
al., 2015). Every cell type presents integrins, except for erythrocytes (De 
Franceschi et al., 2015). Integrin dimers exist in three conformations: inactive, 
primed and active (Figure 1.5). The ligand binds the active form, although it 
is also thought that the primed form can bind ligands (Adair et al., 2005). 
Integrins are activated from the inside by talin. It binds to the " subunit and 
induces a conformational change separating the two dimers and straightening 
them to allow ligands to bind with higher affinity (Iwamoto and Calderwood, 
2015; Kim et al., 2003; Luo and Springer, 2006; Tadokoro et al., 2003; 
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Vinogradova et al., 2002). After talin, vinculin is recruited, then !-actinin, 
before this complex can be linked to the actin fibres (Parsons et al., 2010). 
Talin, !-actinin, vinculin and kindlin are responsible for the clustering of 
multiple integrin dimers and the growth of the adhesion (Ellis et al., 2014; 
Humphries et al., 2007; Roca-Cusachs et al., 2013; Ye et al., 2013). During 
the maturation process, paxillin is also recruited, which will in turn recruit 
other structural and signalling molecules (Brown and Turner, 2004) (Figure 
1.6). 
 
 
Figure 1.5: Structure of integrin dimer. The Three conformations available for an integrin 
dimer.  
 
There are two other adhesion types, which are more specialised. Podosomes 
are ring-shaped adhesions present in fast moving cells and invadopodia are 
present in invasive cells. Generally, these adhesions are called podosomes in 
normal cells, while the term invadopodia is used for cancer cells. Invadopodia 
are the site of active ECM degradation by proteases, which allow cancer cells 
to invade more efficiently (Linder et al., 2011). 
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1.2.4 Cellular adhesion disassembly and integrin recycling 
To allow the cell to move, adhesions need to be removed and their 
components have to be recycled. The inactive integrins, for example on the 
dorsal side of a migrating cells on a 2D substrate, also have to be internalised 
to be brought at a new adhesion site.  
 
 
Figure 1.6: Sagittal plane of a focal adhesion. Integrins dimer formed of an ! and " subunit 
binding the extracellular matrix. Inside the cell, the focal adhesion components (e.g. talin, 
vinculin, paxillin, !-actinin, focal adhesion kinase…) are the link between the integrins 
and the actin stress fibre. 
 
On adhesion sites, the first step for the adhesion disassembly is matrix 
degradation by matrix metalloproteinases (MMPs). They will cleave, for 
example, FN bound to its main receptor, !5"1 integrins (Shi and Sottile, 
2011). The adhesion will then be able to be recycled.  MT1-MMP, a type of 
MMP, is brought to the plasma membrane in a Rab4- or Rab11-dependent 
pathway, if it comes from somewhere else on the plasma membrane, or in a 
Rab8-dependent manner from the Golgi apparatus (Bravo-Cordero et al., 
2007). MMPs also arrive at the surface through filopodia, giving these 
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structures the ability to invade. Rab40b has been involved in this process 
(Jacob et al., 2013). Another step of disassembly is integrin and talin cleavage 
by calpain (Bate et al., 2012; Franco et al., 2004). Cleaved talin is important 
for adhesion turnover by allowing release of the focal adhesions components 
(Saxena et al., 2017). Microtubules have also been involved in the turnover 
of FAs. They make contact with the FAs with the tethers CLASP1 and CLASP2 
(Stehbens et al., 2014). Microtubules deliver the endocytic machinery 
necessary for the internalisation of the integrins. Clathrin and the alternative 
adaptors ARH and Dab2 are needed for this (Ezratty et al., 2009; Ezratty et al., 
2005; Kaverina et al., 1999). AP2 has also been shown to be important for the 
internalisation of adhesions. The kinase PIPK1" is recruited to the adhesions 
and generates PI(4,5)P2 and allows AP2 to do the internalisation of integrin "1 
(Chao et al., 2010). Different adaptor proteins can bind different types of 
integrins: Dab2 regulates !5"1 dimer internalisation in the mid region of the 
cell, while Numb regulate the endocytosis of the dimer on the leading edge 
(Teckchandani et al., 2012).  
Although clathrin-mediated endocytosis clearly internalises integrins, this can 
also be done via clathrin-independent endocytosis. Caveolin-1 can internalise 
!5"1and !v"3 integrins (Galvez et al., 2004; Shi and Sottile, 2008), and in 
cholestoreol-depleted cells, integrins can enter the cells via lipid rafts  (Fabbri 
et al., 2005). 
There are three models for the recycling of integrins, which all occur 
depending on the situation. The first and main model is the treadmill-like 
model in which integrins are removed from the back of the cell and placed at 
the front, allowing an efficient forward migration (Bretscher and Aguado-
Velasco, 1998). In the second one, integrins are also recycled from the front 
of the cell allowing it to keep a pool of integrins available for fast migrating 
cells (Caswell et al., 2007; Laukaitis et al., 2001). Finally, in the third model, 
some integrins are trafficked from the front to the back in a 
Kif1C/microtubules-manner, allowing the adhesions in the tail to mature and 
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the tail to steer for a directional migration (Theisen et al., 2012). This is also 
the case in cancer cells, where integrins are first sent to the lysosomes. Instead 
of being degraded, the integrins are recycled back to the rear end in a CLIC3- 
and Rab25-dependant manner (Dozynkiewicz et al., 2012). 
Integrin recycling is a well-studied but complex field of membrane traffic. 
Many different routes are taken by many different heterodimers, depending 
on the identity of these dimers, or their activation state (De Franceschi et al., 
2015; Iwamoto and Calderwood, 2015; Paul et al., 2015; Rainero and 
Norman, 2013). Integrin recycling is efficient, the surface pool can be 
recycled within 30 minutes (Paul et al., 2015). This is the main fate for the 
integrins, only few of them are degraded. The half-time of the degradation 
process is approximately 12-24h (Lobert et al., 2010).  
Both active and inactive integrins are internalised in a Rab5/Rab21-dependant 
manner (Arjonen et al., 2012; Pellinen et al., 2006). There is an endocytic 
motif (NPXY) on the cytosolic chain of integrin "1, which can be recognised 
by Numb and Dab2 (Nishimura and Kaibuchi, 2007). After entering the 
sorting endosomes, the integrin dimers will be recycled differently according 
to the situation. It has been found that active integrins can be sent to the 
lysosomes for degradation or back to the plasma membrane either in a direct 
way, via ACAP1-, RCP- and Rab11-dependant pathway or indirectly as 
mentioned earlier, in a Rab25- and CLIC3-dependant pathway (Arjonen et al., 
2012; Caswell and Norman, 2008; Dozynkiewicz et al., 2012; Li et al., 2005; 
Powelka et al., 2004). Inactive integrins will rather be sent back to the plasma 
membrane either in a Rab25-dependant, local manner (Caswell et al., 2007) 
or via the short, Arf6- and Rab4-dependant recycling pathway (Arjonen et al., 
2012). At least for the recycling of integrin "1, Ras GTPase-activating protein 
1 (RASA1) displaces Rab21 to allow the integrin recycling (Mai et al., 2011). 
The WASH complex has also been involved in the recycling of integrins. By 
recruiting the actin nucleator Arp2/3, integrin-containing vesicles are 
transported to recycling endosomes by actin-dependant motors. It has been 
shown that in the absence of WASH, integrin !5"1 is sent to the lysosomes 
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for degradation (Duleh and Welch, 2010; Zech et al., 2011). The NPXY motif 
present on the " subunit of the integrin dimer can also be bound by SNX17 
which sends it back to the plasma membrane, in a retriever-dependant way 
(Bottcher et al., 2012; McNally et al., 2017; Steinberg et al., 2012). Finally, if 
the integrins are ligand-bound, they become ubiquitilated, which is 
recognised by the ESCRT machinery and the integrins will be invaginated into 
ILVs and send for degradation in the endolysosome (Lobert et al., 2010). 
The recycling of integrins not only has a direct effect on migration by allowing 
new adhesions to be made, it also has an effect on the persistence of the 
migration. Indeed, there is a balance between two dimers. The recycling of 
!5"1 integrins allow cells to move rapidly in a random manner, whilst the 
recycling of !v"3 integrins allow a more persistent migration (Danen et al., 
2005; White et al., 2007). One type of recycling also inhibits the other, 
allowing the cell to either scan its environment or migrate in the same 
direction (White et al., 2007).  
 
1.3 Tumor protein D52 (TPD52) family 
The TPD52 family members are short proteins of about 200 amino acids. 
There are four members in humans, TPD52, TPD53, TPD54 and TPD55. The 
proteins are encoded by the genes TPD52, TPD52L1, TPD52L2 and TPD52L3, 
respectively. These genes are all on different chromosomes (8q21.13, 
6q22.31, 20q13.33 and 9p24.1 respectively). While the first three are 
ubiquitously expressed, TPD55 is restricted to testis (Cao et al., 2006). All four 
members have a coiled-coil domain in the N-terminal region (Figure 1.7).  
TPD52 is the most well studied member of the family, as well as being the 
first identified. It was cloned 20 years ago, from breast cancer cells (Byrne et 
al., 1995). TPD53 and TPD54 were then cloned shortly afterwards (Byrne et 
al., 1996; Byrne et al., 1998; Nourse et al., 1998) and TPD55 ten years later 
(Cao et al., 2006). 
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A plethora of articles have been written in the past 4 years, all stating that a 
deregulation of the level of the TPDs in different cancer cells cause abnormal 
migration, survival or proliferation. However, some of these articles (He et al., 
2015; Wang et al., 2014b; Xu et al., 2015; Yang et al., 2015) present strikingly 
similar results, use erroneous controls or shRNAs for their target gene 
depletions (Byrne and Labbe, 2017), and the majority does not propose any 
mechanistic explanation for these alterations (Fujita and Kondo, 2015; Goto 
et al., 2014; He et al., 2015; Kumamoto et al., 2016; Li et al., 2017; Mukudai 
et al., 2013; Wang et al., 2014a; Wang et al., 2016; Yang et al., 2015; Yu et 
al., 2017; Zhao et al., 2017; Zhu et al., 2016). However, one thing that seems 
clear, is that the TPDs have some role in cell migration and/or invasion, on 
adhesion and on the cell cycle. 
 
 
Figure 1.7: Alignment of the TPD52 family members. The four members of the family 
aligned according to their amino acid sequence. The coiled-coil domain is highlighted in 
yellow. TPD52 has a phosphoserine marked in red. “*” means conserved residue. “:” 
means strongly similar, “.” means weakly similar.  
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Early work on the TPDs have established their upregulation in cancer cells is 
caused by duplication and this leads to their tumorigenic effect (Balleine et 
al., 2000; Byrne et al., 1998; Lewis et al., 2007; Wilson et al., 2001). TPD53 
has been shown to be expressed at the highest level at the G2/M transition 
(Boutros and Byrne, 2005) and phosphorylation of TPD52 on serine at 
position 176 is important for normal cytokinesis  (Thomas et al., 2010a). This 
suggests that the TPDs might indeed be regulated by the cell cycle, especially 
that this serine is conserved in all 4 members of the family (Figure 1.7). It also 
has been shown that the PI3K/Akt pathway is activated when TPD52 is 
overexpressed in the human colon carcinoma cell line SW480 (Li et al., 
2017). This pathway regulates signalling, from cytokines to growth factors. A 
deregulation is therefore likely to induce carcinogenesis (Spangle et al., 2017). 
Another pathway deregulated with a TPD52 overexpression is the NF-%B 
pathway. NF-%B controls transcription of cytokines increasing cell 
proliferation (Sun, 2017). It has been shown that TPD52 affects this pathway 
by binding NF-%B. This results in increased levels of TIMP and RECK RNA, 
which are two inhibitors of MMP-9 and MMP-2 (matrix metalloproteinase) 
(Dasari et al., 2017). MMPs are responsible for degradation of the ECM, 
allowing cells to invade (Hastie and Sherwood, 2016). An overexpression of 
TPD52 confers to the cells an increased ability to invade their surroundings. 
Finally, it has been shown that an overexpression of TPD52 decreases ATM-
mediated DNA repair signalling (Chen et al., 2013). ATM (ataxia 
telangiectasia mutated) is a member of the PIKK family that phosphorylates 
proteins in response to DNA damage in order to induce DNA repair (Clouaire 
et al., 2017). The residues on TPD52 required for this role are aa 151-171 
(Chen et al., 2013). This region is not conserved in TPD53 which has an 
insertion in this site, and not very conserved in TPD54 and TPD55, making 
this role likely to be unique to TPD52 (Figure 1.7). 
Another role for TPD52 is its putative role in lipid droplet biogenesis. Lipid 
droplets (LDs) are contained by a phospholipid monolayer and act as fat 
reserve and storage for excess fatty acids (Chen et al., 2016). They are thought 
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to be formed in the ER and translocated to the Golgi apparatus before being 
released in the cytoplasm (Fujimoto and Parton, 2011; Wilfling et al., 2014). 
There was good evidence for investigating the role of TPD52 in lipid 
biogenesis. A screen made in obese vs lean mice showed that Tpd52 was 
upregulated up to 5-fold in obese mice (Nadler et al., 2000). In C. elegans, a 
depletion of TPD52 orthologue F13E6.1 is linked to decreased lipid storage 
(Ashrafi et al., 2003). In a yeast two-hybrid (Y2H) assay, TPD52 has been 
shown to bind perilipin-1, a protein associated with lipid droplets (Yamaguchi 
et al., 2006). Finally, proteomic studies say that TPD52 and TPD54 could 
interact with cholesterol in HeLa cells (Hulce et al., 2013) and are thought to 
be able to bind PI(3,4,5)P3 (Catimel et al., 2009). It is only recently that the 
link between TPD52 and LDs has been directly investigated. It has been 
confirmed that TPD52 is present in the LDs fraction of human breast 
carcinoma cells MDA-MB-231. It also colocalises with the cis-Golgi marker 
GM130 and with Arl1, a GTPase involved in golgin recruitment and LDs 
formation (Kamili et al., 2015). It therefore seems that TPD52 might 
accompany LDs out of the Golgi apparatus.  
The TPDs have also been linked to trafficking in other contexts. A Y2H assay 
has suggested that TPD52 can bind Rab5c. It has been confirmed with a GST-
pulldown. The same Y2H result was found for TPD53, although the authors 
only mentioned the pulldown confirmation and didn’t show the data in the 
article (Shahheydari et al., 2014). TPD52 could also be co-
immunoprecipitated with ExoS a Pseudomonas aeruginosa toxin able to 
inhibit Rab5 functions (Simon and Barbieri, 2014; Zhang et al., 2007). TPD52 
is also found in colocalisation with Rab27a and Lamp1 when phosphorylated 
in CHO cells (Thomas et al., 2010b). This phosphorylation is the same 
phosphorylation site found to be important for cytokinesis (Thomas et al., 
2010a) and is known to be Ca2+-dependent (Thomas et al., 2002). Ca2+-
dependent signal induces secretion of digestive enzymes in pancreatic acinar 
cells. In these cells, TPD52 is thought to regulate secretion. At resting state, 
TPD52 colocalises with TGN38 (rat orthologue of the trans-Golgi network 
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protein TGN46) and after stimulation of secretion, TPD52 is found under the 
apical plasma membrane and colocalises with early, late and recycling 
endosomes, regulating exocytosis of digestive enzymes (Messenger et al., 
2013).  
Finally, TPD53 has been shown in vitro to enhance the binding of 
synaptobrevin 2 and syntaxin 1, two SNAREs required for membrane fusion. 
The coiled-coil domain of TPD53 is required for this and it binds directly to 
synaptobrevin 2 (Proux-Gillardeaux et al., 2003). The coiled-coil domain is 
featured in each member of the TPD52 family (Figure 1.7). It might be possible 
that if TPD53 is a SNARE, the other members might also be.  
What we need to focus on is the fact that TPD54 has not yet been well 
characterized, being the ubiquitously expressed member of the TPD52 family 
the least studied. It seems clear that it has a role in membrane trafficking since 
it might be able to bind lipids (Catimel et al., 2009; Hulce et al., 2013) and 
by sequence similarity to TPD52 and TPD53. TPD54 is also probably involved 
in regulation of cell migration and adhesion (Mukudai et al., 2013). The 
molecular mechanisms behind these roles are still elusive. 
 
1.4 Aim of the thesis 
We want to provide mechanistic insight into the role of TPD54 in membrane 
trafficking and cell migration, in order to finally explain why a deregulation 
in the expression level of the protein causes pathologies like cancer. 
To do so, we will try to understand which type of membrane trafficking vesicle 
TPD54 is associated to and assess the consequences of depleting HeLa cells 
of TPD54, either by knockdown or knockout, as well as rapidly rerouting the 
protein for a more precise phenotype, less likely to be compensated by the 
cells. 
We will also use similar tools to understand the role of TPD54 in cell 
migration in a 2D environment. We will try to link the potential role in cell 
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migration to its association to membrane trafficking components by 
investigating the role of TPD54 in the recycling of integrins. 
 
  
  
32 
Chapter 2 – Material and methods 
 
 
2.1 Cell culture 
2.1.1 Cell maintenance 
HeLa cells (HPA/ECACC #93021013) were grown in Dulbecco Modified 
Eagle Medium (DMEM) (GIBCO 32430) supplemented with 1% antibiotics 
(100 U/ml penicillin, 100 µg/ml streptomycin) and 10% foetal bovine serum 
(FBS). RPE1 cells (HD-PAR-541 clone 7724) were grown in Ham’s F12 
Nutrient Mixture (Sigma, D6421) supplemented with 1% antibiotics 
(pen/strep), 10% FBS, 2.3 g/l sodium bicarbonate and 2 mM L-Glutamine. 
Both cell types were kept at 37°C with 5% CO2 and the growth medium was 
changed every 3-4 days. HeLa cells were kept for a maximum of 30 passages 
and RPE1 cells for 20 passages. 
 
2.1.2 siRNA transfection 
Cells were plated on coverslips or in plates for a confluency of 50% on day 1 
(10x104 cells/ml). On day 2, Lipofectamine 2000 (Thermo Fisher Scientific) 
was used to transfect the siRNAs according to the manufacturer’s protocol. 
The oligonucleotides used are listed in table 2.1. If DNA was also transfected, 
the siRNA lipoplexes were left on the cells for ~6 h before plasmid 
transfection, otherwise, they were left until the next morning. Cells were 
processed 24-72h post-transfection. If two genes were knocked down, the 
total amount of oligonucleotides was doubled. 
 
2.1.3 DNA transfection 
Cells were plated on coverslips or in plates for a confluency of 50% on day 1 
(10x104 cells/ml). On day 2, GeneJuice (EMD Millipore, 70967) was used to 
transfect plasmids according to the manufacturer’s protocol. Medium was 
changed the next day and cells were processed 24-72 h post-transfection. 
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Table 2.1: Oligo sequences 
Protein target siRNA sequence (5’ – 3’) 
TPD54, oligo 1 CUCACGUUUGUAGAUGAAA 
TPD54, oligo 2 GUCCUACCUGUUACGCAAU 
TPD54, oligo 3 CAUGUUAGCCCAUCAGAAU 
Rab4a (Keil and Hatzfeld, 2014) GAACGAUUCAGGUCCGUGA 
Rab11a (Shafaq-Zadah et al., 
2016) 
GACGACGAGUACGACUACC 
GL2 (luciferase, control) CGTACGCGGAATACTTCGA 
 
2.2 Molecular biology 
2.2.1 Cloning: general protocol 
The gene of interest was either first amplified by polymerase chain reaction 
(PCR) and then digested with restriction enzymes alongside the vector, or 
directly cut from a donor vector and pasted into an acceptor vector. In both 
case, the digested vector and insert were ligated with Quick ligase (NEB, 
M2200) and transformed in XL10 E. coli. Colonies were then tested by 
extracting their plasmidic DNA with GeneJET Plasmid Miniprep Kit (Thermo 
Sientific, K0503) and by digesting this DNA with the same restriction enzymes 
used for earlier digestion. The clones giving two bands of the right size were 
sent for sequencing to GATC Biotech UK. The clone giving the correct 
sequence was added to the Royle Lab plasmid collection. 
 
2.2.2 Cloning: constructs made 
Table 2.2: List of constructs cloned for this study 
Construct name Technique used for insert Primers used 
(PGK) GFP-TPD54 XV:79 Cut and paste NA 
pIRES-EGFP-TPD54 PCR GL027 – GL028 
GFP-MAL2 PCR GL056 – GL057 
GFP-Rab1a PCR GL050 – GL051 
GFP-Rab2a PCR GL052 – GL053 
GFP-Rab6 PCR GL048 – GL049 
GFP-Rab14 PCR GL054 – GL055 
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Table 2.3: List of primers and their sequence 
Primer 
identifier 
Protein 
target 
Sequence (5’ – 3’) Annealing T 
(°C) 
GL027 
TPD54 
GCGGCTAGCATGGACTCCGCCGGCC 52 
GL028 GCGCTCGCGTTAGAAAGGTGCGGGATC 
GL048 
Rab6 
GCGAAGCTTAATGTCCACGGGCGGAG 50 
GL049 GCGGGTACCTTAGCAGGAACAGCCTC 
GL050 
Rab1a 
GCGGAGCTCAATGTCCAGCATGAATCCC 52 
GL051 GCGGGTACCTTAGCAGCAACCTCCACC 
GL052 
Rab2a 
GCGGAGCTCAATGGCGTACGCCTATCTC 52 
GL053 GCGGGTACCTCAACAGCAGCCGCCC 
GL054 
Rab14 
GCGGTCGACaaATGGCAACTGCACCATACAAC 56 
GL055 GCGGGTACCCTAGCAGCCACAGCCTTC 
GL056 
Mal2 
GCGAAGCTTAATGTCGGCCGGCGGAG 54 
GL057 GCGGGTACCTTACGGTCGCCATCTTCG 
 
2.2.3 Plasmids used 
Table 2.4: List of plasmids in this study 
Construct Database 
identifier 
Insert Vector Restriction 
sites 
Author/ 
Supplier 
(CMV) GFP-
TPD54 
VIII:44 TPD54 pEGFP-C1 XhoI/MfeI Royle Lab 
mCherry-
TPD54 
X:14 TPD54 pmCherry-C1 XhoI/MfeI Royle Lab 
GFP-FKBP-
TPD54 
X:17 FKBP-
TPD54 
pEGFP-C1 XhoI/MfeI Royle Lab 
mCherry-FKBP-
TPD54 
X:33 FKBP-
TPD54 
pmCherry-C1 PspOMI/ 
BamH1 
Royle Lab 
mCherry-FKBP-
TPD52 
X:32 FKBP-
TPD52 
pmCherry-C1 PspOMI/ 
BamH1 
Royle Lab 
FLAG-TPD54 VIII:45 TPD54 pFLAG-C1 XhoI/MfeI Royle Lab 
pMito-mCherry 
(K70N)-FRB 
XV:81 MitoTrap pMito – Royle Lab 
pMito-paGFP-
FRB 
VII:29 MitoTrap pMito AgeI/BsrGI Royle Lab 
GFP-FKBP IX:28 FKBP pEGFP-C1 NheI/BglII Royle Lab 
CD8-8xA VII:32 CD8-
8xA 
pIRES-Neo2 – MS Robinson 
CD8-YAAL VII:33 CD8-
YAAL 
pIRES-Neo2 – MS Robinson 
CD8-EAAALL VII:34 CD8-
EAAALL 
pIRES-Neo2 – MS Robinson 
CD8-FANPAY VII:35 CD8-
FANPAY 
pIRES-Neo2 – MS Robinson 
CD8-CIMPR VII:31 CD8-
CIMPR 
pIRES-Neo2 – MS Robinson 
GFP I:02 – pEGFP-C1 – Royle Lab 
pmNeonGreen-
Rab4a 
XIII:77 Rab4a pmNeonGreen XhoI/BamHI Allele Biotech 
GFP-Rab5 X:30 Rab5a pEGFP-C3 BsrGI/BamHI F Barr 
GFP-Rab8 XI:16 Rab8a pDEST53 – M Nachury 
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GFP-Rab9 X:27 Rab9a pEGFP-C3 – F Barr 
GFP-Rab11a X:40 Rab11a pEGFP-C2 – P Caswell 
GFP-Rab25 X:41 Rab25 pEGFP-C2 – P Caswell 
GFP-EEA1 XI:21 EEA1 pEGFP-C1 XhoI/EcoRV S Corvera 
LAMP1-GFP XI:18 LAMP1 pEGFP-N3 EcoRI/SalI E 
Dell’Angelica 
mCherry-
OCRL1 
VIII:16 OCRL1 pmCherry-C1 XhoI/XmaI C Merrifield 
GFP-Vamp2 I:64 Vamp2 pEGFP-C1 HindIII/EcoRI Royle Lab 
GFP-SNX5 IV:26 SNX5 pEGFP-C1 – P Cullen 
GFP-TACC3 VI:14 TACC3 pEGFP-C1 XmaI/XbaI Royle Lab 
CD8-FRB-
mCherry 
(K70N) 
XII:53 FRB pMitoTrap – Royle Lab 
Integrin-!5-
GFP 
XI:14 Integrin-
!5 
pEGFP-N3 KpnI/KpnI R Horwitz 
pmNeonGreen-
TfR 
XIII:81 TfR pmNeonGreen – Allele Biotech 
 
2.3 Biochemistry 
2.3.1 Western blotting 
Cell lysates were obtained by scraping the cells in 30-50 µl of RIPA buffer 
(10 mM HEPES pH 7.4, 150 mM NaCl, 0.1% SDS, 1% Triton-X100) on ice. 
The lysate was left on ice for 15 min, vortexed regularly, and then centrifuged 
at 14 000 rpm for 15 min at 4°C in an Eppendorf Centrifuge 5417R. The 
protein content in the supernatant was quantified with the Bradford method 
and an equal amount of protein was loaded with 5X Laemmli sample buffer 
(250 mM Tris-Cl pH 6.8, 10% SDS, 0.5% bromophenol blue, 50% glycerol, 
25% "-mercaptoethanol) for a final concentration of 1X, in a 9x6 cm 4-15% 
acrylamide gel and ran at 100-150 V until the blue line is at the bottom of the 
gel. The proteins were then transferred to a nitrocellulose membrane using a 
semi-dry Trans-Blot Turbo (BioRad) at 2.5 A for 6 min. Total proteins were 
revealed with Ponceau stain and the membrane was then blocked for 1 h in 
5% milk in TBS-T (20 mM Tris, 150 mM NaCl, 0.1% Tween 20, pH 7.6). The 
primary antibodies (see table 2.5 for specific dilution) were diluted in 2% milk 
in TBS-T and the membrane was incubated in this solution for the amount of 
time and at the temperature indicated in table 2.5. The membrane was then 
washed by incubation in TBS-T for 5 min, 3 times. The HRP-conjugated 
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secondary antibodies were diluted 1:10 000 in 2% milk in TBS-T and the 
membrane was incubated in the solution at room temperature for 1 h. The 
membrane was then dried with absorbant paper and secondary antibodies 
were detected by ECL. The membrane was put in a cassette and a radiological 
film captured the luminescence. The film was developed with a Xograph 
Compact X4 developer. 
 
Table 2.5: Antibodies used for western blotting 
Primary antibody target Supplier Working concentration 
Rabbit anti-TPD54 Dundee Cell 
products 
1:1000 (RT, 1h) 
Rabbit anti-Rab4 Cell Signaling 
(2167) 
1:1000 (4°C, O/N) 
Rabbit anti-Rab11a Abcam (ab65200) 1 µg/ml (1:1000) (4°C, 
O/N) 
Mouse anti-clathrin 
heavy chain TD.1 
hybridoma 1:1000 (RT, 1h) 
Mouse anti-GFP clones 
7.1 and 13.1 
Sigma Roche 
(118144600010) 
1:1000 (RT, 1h) 
Mouse anti-!-tubulin 
DM1 
Abcam (ab7291) 1: 10 000 (RT, 1h) 
 
2.3.2 Integrin recycling assay 
The ELISA plate (maxisorp 96 wells, Thermo Scientific) was prepared the day 
before the experiment by incubating the wells with 50 µl/well of 5 µg/ml of 
anti-integrin !5 antibodies (BD Biosciences, 555651) in 0.05 M Na2CO3 
pH 9.6, overnight at 4°C. 20x10 cm dishes were needed per condition, and 
labelled as follows: 1: total, 2-4: blank, 5-8: internal pool, 9-12: 10 min 
recycling, 13-16: 20 min recycling, 17-20: 30 min recycling. RPE1 cells were 
serum starved (growth medium +antibiotics –serum) for 30 min at 37°C. Two 
washes were made with 5 ml of cold PBS and the surface receptors were 
labelled with 0.133 mg/ml of EZ-Link Sulfo-NHS-SS-Biotin (Thermo scientific, 
21331) in PBS by gently rocking (7 see-saw movements/min) the cells at 4°C 
with 3 ml of the biotin solution for 30 min. The cells were washed twice with 
5 ml of cold PBS on ice and 5 ml of warm growth medium serum-free was 
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added to plates 5-20, while plates 1-4 were left on ice. Plates 5-20 were 
incubated at 37°C for 30 min to allow internalisation of the receptors. Plates 
5-20 were washed with 5 ml of cold PBS on ice.  
The surface of the cells was reduced to remove non-internalised receptors by 
washing plates 2-20 once with 5 ml of cold reduction buffer (50 mM Tris pH 
7.5, 102.5 mM NaCl, pH adjusted to 8.6) and then putting 3 ml of reduction 
buffer and 1 ml of reduction buffer containing mesna (sodium 2-
mercaptoethane sulfonate) (390 mg of mesna was added to 26 ml of reduction 
buffer, mixed thoroughly and 39 µl of 10 N NaOH was added). The plates 
were rocked at 4°C for 20 min, while plate 1 was left on ice. The cells were 
washed twice with 5 ml of cold PBS. Plates 1-8 were left on ice with PBS 
while warm serum-free growth medium was added to plates 9-20. These 
plates were incubated at 37°C for 10, 20 or 30 min. Plates 2-20 were then 
reduced again for 20 min with the same method as described above. 1 ml of 
reduction buffer containing iodoacetamide (IAA, 442mg in 26 ml PBS) was 
added to the 4 ml of reduction buffer to quench the reduction reaction, and 
left for 10 min. This reduction step gets rid of the labelled recycled receptors, 
leaving labelled only the internal receptors in the cells.  
At this point, the ELISA plate was blocked with 5% BSA in PBS-T at room 
temperature for ~1h. Plates 1-20 were washed twice with 5 ml of cold PBS on 
ice. Lysates were obtained by scraping the cells with a total of 100 
µl/condition of lysis buffer (200 mM NaCl, 75 mM Tris pH 7.5, 15 mM NaF, 
1.5 mM Na3VO4, 7.5 mM EDTA, 7.5 mM EGTA, 1.5% Triton-X100, 0.75% 
Igepal, protease inhibitors), passing the lysate through a 27G needle and 
centrifuging the lysate at 13 000 rpm for 15 min at 4°C. The ELISA plate was 
washed twice with PBS-T and 50 µl of lysate was put in each well. The plate 
was covered with parafilm and incubated at 4°C overnight.  
The plate was then washed with PBS-T five times and 50 µl of 1 µg/ml 
streptavidin-HRP, 1% BSA in PBS-T was added to each well and left at 4°C 
for 1 h. Five more washes were performed with PBS-T and 50 µl of detection 
reagent (add 0.56 mg/ml of ortho-phenylenediamine dihydrochloride in 
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ELISA buffer (25.4 mM NaHPO4, 12.3 mM citric acid, pH 5.4) mix thoroughly 
and add 0.003% H2O2) was added to the wells. The plate was incubated at 
room temperature in the dark and after 10-20 min, the plate was read at 450 
nm with a Varioskan Flash (Thermo Scientific). 
 
2.4 Imaging 
2.4.1 Widefield microscopy 
For widefield microscopy, a Nikon Eclipse Ti-U microscope was used with a 
CoolSNAP Photometrics Myo camera after illumination with a laser at 488, 
568 or 633 nm, and using a 20X (0.50 NA) air, a 40X ELWD (0.60 NA) air, 
60X (1.40 NA) oil or 100X (1.40 NA) oil objectives. If needed, the cells were 
kept at 37° C in a temperature-controlled chamber (OKOlab). Images were 
acquired with NIS Elements acquisition software. The pixel seize is as follow: 
100X objective: 0.0453 µm, 60X objective: 0.07566 µm, 40X objective: 
0.1135 µm, 20X objective: 0.22698 µm. 
 
2.4.2 Confocal microscopy 
For confocal microscopy, a spinning disk confocal system (Ultraview Vox, 
Perkin Elmer) with a 100X 1.4 NA oil objective on with a single Hamamatsu 
ORCA-R2 camera after excitation with a laser at 488, 561, and 640 nm, 
operated by Volocity 6.0 software (Perkin Elmer). The pixel size with the 100X 
objective is 0.06896µm. 
 
2.4.3 Correlative Light Electron Microscopy (CLEM) 
Nicholas I. Clarke carried out the CLEM experiment. HeLa cells expressing 
pMito-PAGFP-FRB (plasmid VII:29) and mCherry-FKBP-TPD54 (plasmid X:33) 
were imaged on gridded glass MatTek dishes (P35G-1.5-14-CGRD, Mat-Tek 
Corporation, Ashland, MA, USA) using widefield microscope with standard 
filter sets for visualization of mCherry. Light and epifluorescence micrographs 
were acquired with 20X air and 100X oil objectives, at 37°C. A 20X air 
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objective was used to record the photo-etched grid coordinate of the cell of 
interest with brightfield illumination. With a 100X oil objective, the same cell 
of interest was found and imaged. Rapamycin (200 nM) was added in media. 
Control cells had no rapamycin added. Once TPD54 had been rerouted to 
the mitochondria, cells were fixed in 3% glutaraldehyde and 0.5% PFA in 
0.05 M phosphate buffer pH 7.4 for 1 h. Aldehydes were quenched in 50 mM 
glycine solution and thoroughly washed in dH2O. Cells were post-fixed in 1% 
osmium tetroxide and 1.5% potassium ferrocyanide for 1 h and then in 1% 
tannic acid for 45 min to enhance membrane contrast. Cells were rinsed in 
1% sodium sulphate then twice in dH2O before being dehydrated in grade 
series ethanol and embedded in EPON resin (TAAB). The coverslip was 
removed from the polymerized resin and the grid was used to relocate the cell 
of interest. The block of resin containing the cell of interest was then trimmed 
with a glass knife and serial 70 nm ultrathin sections were taken using a 
diamond knife on an EM UC7 (Leica Microsystems) and collected on formvar 
coated hexagonal 100 mesh grids (EM resolutions). Sections were post-stained 
with Reynolds lead citrate for 5 mins. Electron micrographs were recorded 
using a JEOL 1400 TEM operating at 100 kV using iTEM software. 
 
2.5 Cell biology 
2.5.1 Knockout (KO) cell line generation using CRISPR-Cas9 method 
1. Target sequence generation 
Three different sequences were chosen in TPD52L2 exon 1 using the CRISPR 
design tool (tools.genome-engineering.org) developed by the Zhang Lab 
(Cong et al., 2013). The three sequences least likely to have an off-target 
somewhere else in the genome were chosen. The sequences of the primers 
generated with these oligonucleotides can be found in table 2.6. The primers 
were inserted in px459 vector with BbsI restriction enzyme. The plasmid 
generated are numbered XII:24 (target sequence 1), XII:25 (target sequence 2) 
and XII:26 (target sequence 3). 
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Table 2.6: CRISPR-Cas9 target sequences 
 
2. Cell line generation 
In a 6-well plate, low passage HeLa cells were seeded for 50% confluency on 
day 1. Plasmids XII:24, 25 and 26 and the empty vector (plasmid XI:44) were 
transfected with GeneJuice (EMD Millipore 70967) according to the 
manufacturer’s protocol. After 24 h, transfected cells were selected with 
1 µg/ml of puromycin. Once the control cells were dead, the remaining cells 
were seeded in 20 cm dishes (~100 cells/dish) and grown in growth medium 
until colonies were visible with the naked eye. Individual colonies were 
isolated with cloning rings and grown in 96-well plates. A total of 100 
colonies were isolated. When the cells reached confluency, they were seeded 
in duplicate in 6-well plates, one for DNA extraction and one for protein 
extraction. 
 
3. KO verification 
A cell lysate was made for each clone by scraping cells in RIPA buffer (see 
section 2.3.1 for detailed protocol on how to make a cell extract). Proteins 
were loaded on a 12% polyacrylamide gel and the level of expression of 
TPD54 was assessed by Western Blot using rabbit anti-TPD54 antibody and 
mouse anti-CHC as loading control. The genomic DNA of the clones for 
Primer name Primer sequence (5’ – 3’) 
TPD54 target sequence 1 F (GL001) caccgTCGCGGATTACGAAACGCCG 
TPD54 target sequence 1 R (GL002) aaacCGGCGTTTCGTAATCCGCGAc 
TPD54 target sequence 2 F (GL003) caccgTTTCGTAATCCGCGATGCGA 
TPD54 target sequence 2 R (GL004) aaacTCGCATCGCGGATTACGAAAc 
TPD54 target sequence 3 F (GL005) caccgACCGCTGTCGCGGGCGCTAT 
TPD54 target sequence 3 R (GL006) aaacATAGCGCCCGCGACAGCGGTc 
  
41 
which TPD54 was not expressed was extracted with Qiagen’s QIAampDNA 
Blood kit. TPD54 first exon and the three most likely off-target 
(Chr13:44259709, Chr1:82946499 and NELL1) were sequenced to check for 
mutations. The sequencing primers are listed in table 2.7. The potential off-
targets were at least 100 bp downstream of the sequencing primers. 
 
Table 2.7: Sequencing primers for the KO cell line 
 
2.5.2 Mitotic progression 
TPD54 KO HeLa cells were seeded in a 12-well plate transfected with H2B-
mCherry (plasmid V:41) and pEGFP-C1 (plasmid I:02) or GFP-TPD54 (plasmid 
VIII:44). 48 h post-transfection, the cells were imaged in imaging medium 
with a 40X air objective on a widefield microscope. 20 fields were imaged 
per condition during 12 h, at a 3-min frame rate. The movies were imported 
in ImageJ and mitotic stages were assessed by the shape of the nucleus. 
 
2.5.3 Immunofluorescence 
Cells were fixed 24-48 h post transfection with 3% PFA, 4% sucrose in PBS 
for 15 min. Membranes were permeabilised with 0.5% Triton-X100 in PBS for 
10 min and the cells were blocked with 5% goat serum, 3% BSA in PBS for 
1 h. The cells were incubated with primary antibodies diluted in blocking 
solution (see table 2.8 for specific dilutions) for 1 h (50 µl solution per 
coverslip). If actin was stained, TRITC-phalloidin (Sigma, P1951) was added 
with the primary antibodies at a concentration of 2.5 µg/ml for 1 h. The cells 
Primer name Primer sequence (5’ – 3’) 
TPD54 exon 1 F (GL0019) ggttcgcccgcagtttc 
TPD54 exon 1 R (GL0020) gaacccaaactacgggag 
NELL1 intron F (GL0021) GGAAGCATGACTCTCTTTC 
NELL 1 intron R (GL0022) GGCCTTTTTCAGGAGATG 
Chr13:44259709 F (GL0023) CTGATACAGGGAAATCAG 
Chr13:44259709 R (GL0024) GTTTTGCCTCCTTGACAC 
Chr1:82946499 F (GL0025) GTATAGATCTTTCTCACTG 
Chr1:82946499 R (GL0026) CAATTCTCAGCAATATCTG 
  
42 
were then washed by incubating them 3 times with PBS for 5 min. The 
secondary antibodies conjugated with Alexa-Fluor (Invitrogen) were diluted 
1:500 in blocking solution and left on the cells for 1 h. A final wash was done 
by 3 incubations of 5 min with PBS. Coverslips were then rinsed by being 
dipped in dH2O and left to dry, cells up, for a few minutes. The coverslips 
were mounted on slides with mowiol, and once the mowiol is dry, put at 4°C 
in the dark. 
 
Table 2.8: Antibodies used for immunofluorescence 
 
2.5.4 Immunoprecipitation (IP) 
A cell lysate was prepared by scraping HeLa cells (2x10 cm dishes per 
condition) on ice in lysis buffer (10 mM Tris-Cl pH 7.5, 150 mM NaCl, 
0.5 mM EDTA, 0.5% NP-40) (total of 500 µl buffer per condition). The lysate 
was passed through a 27G needle 3 times and left to rest on ice for 15 min 
while vortexed regularly. The lysates were then centrifuged at 14 000 rpm in 
an Eppendorf Centrifuge 5417R for 15 min at 4°C. The supernatant was 
quantified and an equal amount of proteins was put onto 10 µl of GFP-Trap 
beads (Chromotek, gta-20) washed with 500 µl of exchange buffer (10 mM 
Tris-Cl pH 7.5, 150 mM NaCl, 0.5 mM EDTA). The supernatant/beads mix 
was incubated at 4° C for 1 h while rotating. The beads were then centrifuged 
at 14 000 rpm for 1 min at 4°C. The supernatant was discarded and the beads 
were washed once with 500 µl of exchange buffer and a 1 min centrifugation 
at 4°C, then three times with 500 µl of wash buffer (10 mM Tris-Cl pH 7.5, 
Primary antibody name Supplier Working concentration 
Mouse anti-CD8 (untagged) Biorad (MCA1226GA) 10 µg/ml (1:100) 
Rabbit anti-CIMPR (IFGR2) Thermo Fisher (PA3-850) 1:500 
Mouse anti EEA1 clone 14 BD Biosciences 1 µg/ml (1:250) 
Rabbit anti-GM130 Sigma (G7295) 0.6 µm/ml (1:2000) 
Rabbit anti-LAMP1 D2D11 Cell Signaling (9091) 1:200 
Sheep anti-TGN46 AbD Serotec (AHP500G) 1.25 µg/ml (1:200) 
Mouse anti-Vinculin Sigma (V9264) 0.2 µg/ml (1:5000) 
Mouse anti-VPS26 CL2287 Abcam (ab212530) 3.2 µg/ml (1:250) 
Rat anti-Integrin "1 mAb13 P. Caswell Lab 10 µg/ml (1:100) 
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500 mM NaCl, 0.5 mM EDTA) and 1 min centrifugation at 4°C. The beads 
were resuspended in 15 µl of Leammli buffer and incubated at 95°C for 5 min 
before being loaded on a 4-15% acrylamide gel. 
 
2.5.5 Mass spectrometry analysis 
Three 10 cm dishes were seeded with HeLa cells for each condition. DNA 
was then transfected as follows: condition 1- pEGFP-C1 (plasmid I:02) and 
pIRES-CD8-YAAL (plasmid VII:33), condition2- pEGFP-C1 and pIRES-CD8-
EAAALL (plasmid VII:34), condition 3- GFP-TPD54 (plasmid VIII:44) and 
pIRES-CD8-YAAL, condition 4- GFP-TPD54 and pIRES-CD8-EAAALL. GFP 
was immunoprecipitated with GFP-Trap beads as described in 2.4.4. The 
beads were then loaded on a 4-15% acrylamide gel and ran until the proteins 
have migrated in the gel for 1-2 cm. The lanes were cut with a clean razor 
blade and sent in a 1.5 ml tube to FingerPrints proteomics facility in Dundee, 
UK. This was done twice, giving 4 repeats of a GFP IP and 4 repeats of a GFP-
TPD54 IP. The original idea was to verify is TPD54 can bind directly to the 
dileucine motif. No CD8 was found in the protein list after mass spectrometry, 
but the dataset obtained could still be used as TPD54 interactors. These 
interactors were classified according to the score and classified according of 
their degree of enrichment when compared to the GFP alone interactors, and 
according to whether or not their presence is significantly higher (p<0.05) in 
TPD54 samples vs GFP samples. 
 
2.5.6 Transferrin uptake and recycling assay 
HeLa cells were serum starved (DMEM +antibiotic –FBS) for 30-60 min at 
37°C and incubated at 4°C for 30 min with 25 µg/ml of AlexaFluor 488-
conjugated transferrin (Thermo Fisher Scientific, 11550756) (50 µl/coverslip). 
The coverslips were then dipped in dH2O, placed in warm growth medium 
and incubated at 37°C for 5-75 min to allow internalisation and recycling. 
  
44 
Cells were then fixed and processed for immunofluorescence as described in 
section 2.4.3. 
 
2.5.7 Knocksideways (KS) 
1. Theory 
KS is based on the dimerization of two protein domains after the addition of 
rapamycin. The normal target for rapamycin is the FKBP domain of FKBP12, 
a propyl isomerase. After binding, the rapamycin-FKBP complex then binds 
to the FRB (FKBP and rapamycin-binding) domain of mTOR. The technique 
relies on the fact that the FKBP and FRB domains can be fused to other 
proteins, allowing them to dimerise as well (Robinson et al., 2010). The idea 
here was to express a MitoTrap (mitochondria with the yeast outer membrane 
protein Tom70p fused to FRB and dark-mCherry) (Robinson et al., 2010) and 
TPD54 fused to a fluorescent tag and FKBP. By adding rapamycin, mCherry- 
or GFP-FKBP-TPD54 will be brought to the mitochondria, and anything that 
will bind to TPD54 will be brought as well (Figure 2.1). 
 
 
Figure 2.1: Knocksideways. Schematic representation of the knocksideways to test the 
potential association between protein X and Y. Protein X is fused to mCherry and FKBP, 
the mitochondria are tagged with a MitoTrap containing an FRB domain and protein Y is 
fused to GFP. Proteins X and Y could be on vesicles or in the cytosol. Knocksideways is 
induced by adding rapamycin, which will first bind FKBP, then the FKBP-rapamycin 
complex will dimerise will the FRB domain on the MitoTrap. Protein X will be rerouted to 
the mitochondria and if protein Y is associated with X, it will also be rerouted to the 
mitochondria. 
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2. Image acquisition 
TPD54 siRNA treated HeLa or RPE1 cells were seeded in fluorodishes (World 
Precision Instruments) and transfected with dark-MitoTrap (pMito-mCherry 
(K70N)-FRB, plasmid XV:81), mCherry-FKBP-TPD54 (plasmid X:33) or GFP-
FKBP-TPD54 (plasmid X:17) and a GFP-, mNeonGreen- or mCherry-tagged 
protein of interest. In the case of CD8-chimera co-KS, cells were surface 
labelled with AlexaFluor 647-conjugated anti-CD8 antibodies before KS. In 
imaging medium containing 100 nM MitoTracker Deep Red FM (Thermo 
Fisher scientific, M22426), cells were brought to the confocal microscope 
with a 60X oil objective or a 100X 1.4 NA oil objective. Cells of interest were 
imaged by either taking stills or movies of 12 frames/min, for 5 minutes. KS 
was induced by applying 200 nM rapamycin (Alfa Aesar) to the cells. In the 
case of movies, rapamycin was added 30 s after the start of the movie. The 
cells chosen were expressing low to medium amount of fusion proteins. 
 
3. Quantification 
Pre- and post-rapamycin confocal images of HeLa cells were analysed to 
assess the efficiency of co-rerouting of bait proteins. In ImageJ, 10 ROIs of 8x8 
pixels (0.05 µm/px) were placed over mitochondria in the pre- and post- 
images and the mean grey value was measured in these ROIs for the bait and 
for the TPD54 channel. These 10 ROIs were then averaged and compared to 
the pixel intensity average of 10 other ROIs taken in the cytoplasm of the same 
channels. The ratio of the proteins on mitochondria versus in cytoplasm was 
measured for pre- and post-rapamycin images. 
 
2.5.8 Timed KS 
We wanted to know if the knocksideways of the CD8-chimera could be done 
as soon as the receptors enter the cell or if it needed to reach a certain 
compartment. Do to this, TPD54 siRNA treated HeLa cells were seeded on 
coverslips and transfected with dark-MitoTrap (plasmid XV:81), mCherry-
FKBP-TPD54 (plasmid X:33) and one of the CD8-chimera (plasmids VII:31-
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35). 24 h post-transfection, cells were labelled with 10 µg/ml AlexaFluor 488-
conjugated anti-CD8 antibodies (AbD Serotec, MCA1226A488) at 4°C for 30 
min (50 µl/coverslip). Cells were incubated at 37°C in warm growth medium 
for 5, 30, 60, 90 or 120 min. KS was then induced by adding 200 nM 
rapamycin at 37°C. After 5 min, cells were fixed with PFA as described in 
section 2.4.3 and mounted on slides with mowiol. 
 
2.5.9 CD8-chimera tracking 
1. Image acquisition 
HeLa cells expressing a combination of CD8-chimera and trafficking markers 
were labelled with AlexaFluor 647-conjugated anti-CD8 antibodies (AbD 
Serotec MCA1226A647, 1:100) at 37°C and imaged immediately in the case 
of early trafficking markers or after up to 2 h for the late markers. Confocal 
microscope 10-min movies were taken at a frame rate of 12 images/min with 
a 100X 1.4 NA oil-immersion objective.  
 
2. Colocalisation 
Movies were imported in ImageJ and CD8-positive and membrane trafficking 
markers-positive particles were found with the ComDet v.0.3.5 plugin 
(particle size: 9px, SNR: 5). The output was fed in the Igor Pro code 
“ColocAnalysis” 
(https://github.com/quantixed/PaperCode/tree/master/Wood2017). The code 
calculates if the particles in the two channels overlap over time and compares 
the degree of colocalisation to the likelihood of that colocalisation to be due 
to chance (overlap of the particles in the two channels at random time points). 
 
2.5.10 2D cell migration 
1. Image acquisition 
RPE1 cells were seeded on 10 µg/ml fibronectin- or 20 µg/ml laminin-coated 
LabTek dishes 24-72 h post transfection. Before bringing the cells under the 
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microscope, the growth medium was exchanged for imaging medium 
(Leibovitz L-15 (GIBCO, 21083-027), 10% FBS and 1% 
penicillin/streptomycin). Cells were imaged with a widefield microscope at 
37°C. Movies were acquired for 12 h with a 20X air objective, using 
brightfield illumination, taking one frame every 10 min, 20 fields of view per 
condition, at minimum laser power. If cells were also expressing a fluorescent 
plasmid, the appropriate epifluorescence image was taken every 10th frame.  
 
2. Image analysis 
Up to 10 cells in the field of view at the start of the movie were tracked until 
they either left the field of view or entered mitosis. The cells were tracked 
using the Manual Tracking plugin in ImageJ. The tracks were then processed 
in Igor Pro with the “LoadMigration” code available at 
https://github.com/quantixed/CellMigration, which calculates the cumulative 
distance (µm) covered by the cells, the instantaneous velocity (µm/min) (cell 
speed at any given point of the movie), the frequency of this instantaneous 
velocity, the directionality ratio (d/D; where d is the shortest distance between 
point A and B, and D is the actual length of the path taken by the cell to go 
from A to B), the mean squared displacement (quantification of movement 
over time), the direction autocorrelation (which reflects the propensity of the 
cell for changing direction over time), the average speed of the cells for the 
whole movie (µm/min) and the variance in that speed (µm/min). 
 
2.5.11 Cell shape analysis 
Brightfield movies from the 2D migration experiments were used. A time 
frame was selected halfway through the movie and images from each 
condition were analysed. A USB-linked pen (Wacom) was used to draw an 
ROI on the periphery of the cells with the freehand selection tool. The area 
and the perimeter were measured and quantified using Igor Pro. 
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2.6 Figure preparation 
Data were collected with Microsoft Excel or Igor Pro v.6.37 and graphs were 
made with Igor Pro. Immunofluorescence figures were prepared in ImageJ 
v.2.0.0-rc-43/1.51q. Nicholas I. Clarke prepared the electron micrographs. 
Figures were assembled in Adobe Illustrator CS5 v.15.0.0. 
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Chapter 3 – TPD54 is associated with membrane 
trafficking components 
 
 
3.1 Introduction 
Our interest in the TPDs comes from a proteomics study which 
compared clathrin coated structures (CCSs) in mitotic and interphase cells 
(Kaur et al., 2014). The aim of this study was to find endocytic proteins with 
a “mitotic moonlighting” role, a role in mitosis that is independent of their 
trafficking function (Royle, 2013). These proteins were likely to be enriched 
on CCSs during interphase and lost from CCSs during mitosis. The main 
finding of this study was that clathrin-mediated endocytosis is arrested in 
mitotic cells because of the unavailability of the actin cytoskeleton to perform 
its endocytic role since it is required for maintaining a mitotic cortex. It was 
therefore unsurprising to find in this proteomic screen many clathrin or actin 
interactors. However, it was also found that both TPD54 and TPD52 were 
among the top hits for candidate endocytic proteins having a mitotic role as 
well (Figure 3.1). 
Very little is known about the TPDs but it is thought that they are associated 
with membrane trafficking components (Borner et al., 2006; Sathasivam et al., 
2001). The potential role of TPDs in the cell cycle has also been highlighted 
(Boutros and Byrne, 2005; Thomas et al., 2010a). It then appears that the TPDs 
could be good candidates for being one of those trafficking proteins having a 
mitotic moonlighting role. In this chapter, we investigate this possibility with 
the best TPD candidate, TPD54. 
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Figure 3.1: TPD54 and TPD52 are lost from mitotic CCSs (adapted from Kaur et al., 2014). 
Ratio of enrichment of proteins found in a mass spectrometry analysis of CCSs isolated 
from interphase or mitotic HeLa cells. TPD52 and TPD54 are highlighted in orange. The 
dotted line represents the mean abundance and the grey area is ±2 standard deviations. 
Inset: Relative abundance of the proteins found at a specific enrichment ratio, with a 
Gaussian function fitted to the data. 
 
3.2 TPD54 is tightly associated with membrane trafficking 
vesicles 
The role of TPD54 in membrane trafficking is still unclear, despite the 
fact that the protein was identified more than 20 years ago (Byrne et al., 1995). 
In order to better understand the cellular localisation of TPD54, the 
knocksideways (KS) technique was used. We have used it as “an in-cell 
immunoprecipitation”: we transfect TPD54, use it as a bait and co-transfect 
other proteins to use them as pray. A protein being co-knocked sideways with 
TPD54 is associated with the latter, both acting on the same pathway. 
To determine where on the trafficking pathway TPD54 is, Rab proteins were 
used as pray. The well-characterised Rab4, 5, 7, 9 and 11 have been chosen 
in this assay. They are markers of the early endosomes and fast recycling 
pathway, the early endosomes, the late endosomes, the late endosome-Golgi 
apparatus pathway, and the recycling endosomes, respectively (Zerial and 
McBride, 2001).  
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As shown in figure 3.2, before adding rapamycin, TPD54 is mainly cytosolic 
and sometimes vesicular, the GFP control is diffuse and the Rab GTPases are 
vesicular. After rapamycin was added, mCherry-KFBP-TPD54 covered the 
mitochondria. GFP-Rab4 and GFP-Rab11 partially follow TPD54, whereas 
the localisation of GFP, GFP-Rab5, GFP-Rab7 and GFP-Rab9 is unaltered. 
This suggests that TPD54 is binding to Rab4 and Rab11. Although, it could 
also mean that we capture whole vesicles and that we pick Rab4 and Rab11 
because they are on the same vesicle or finally, that they are on the same 
vesicle and bind together. 
To test this, we looked at rerouted cells with correlative light electron 
microscopy (CLEM) (Figure 3.3). First, cells expressing the MitoTrap and GFP-
FKBP-TPD54 were imaged on a gridded dish and then knocksideways was 
induced by adding rapamycin. The cells were fixed and processed for electron 
microscopy (figure 3.3A). The same cell was found to make sure that the 
imaged cell was knocked sideways. As seen in figure 3.3B, in rapamycin-
treated cells, the mitochondria are studded with small homogenous and 
regular vesicles of about 25 nm. This was only visible for cells expressing GFP-
FKBP-TPD54, suggesting that when we knock TPD54 sideways, we bring 
entire transport vesicles rather than bringing only TPD54 and its binding 
partners (Figure 3.3C). 
Another membrane trafficking-associated binding partner of the TPDs is 
MAL2 (myelin and lymphocyte 2). MAL2 is a membrane-bound protein, 
having a role in transcytosis (de Marco et al., 2006) and is mainly expressed 
in polarized epithelial cells and hepatocytes. It has been found to bind the 
TPDs in a yeast two-hybrid assay and it has further been confirmed by 
immunoprecipitation that TPD52 and MAL2 are binding partners (Wilson et 
al., 2001) and are linked to poor prognosis when both are overexpressed in 
either ovarian carcinoma (Byrne et al., 2010) or colorectal cancer (Li et al., 
2017). We wanted to know if i) the knocksideways technique was reliable for 
detecting binding partners and ii) if TPD54 was indeed a binding partner of 
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MAL2. As seen in figure 3.4, we could confirm the association between MAL2 
and TPD52, as previously found by Wilson and colleagues (2001), but unlike  
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Figure 3.2: Knocksideways of TPD54 reroutes Rab4 and Rab11 to the mitochondria 
specifically. Representative confocal micrographs showing the effect of mCherry-FKBP-
TPD54 knocksideways upon either A) GFP, GFP-Rab4, GFP-Rab5, B) GFP-Rab7, GFP-
Rab9 or GFP-Rab11 in HeLa cells also expressing dark-MitoTrap. KS was induced by 
adding 200 nM rapamycin to the cells (dark orange bars). Mitochondria are labelled with 
far-red MitoTracker. Scale bar: 10 µm. Inset: 5X zoom.  
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Figure 3.3: TPD54 knocksideways reroutes vesicles to mitochondria. A) HeLa cells 
expressing GFP-FKBP-TPD54 and MitoTrap were treated with rapamycin on gridded dishes 
allowing the same cells to be imaged with electron microscopy. B) Electron micrographs 
of mitochondria in cells exposed to rapamycin and expressing GFP-FKBP or GFP-FKBP-
TPD54. Scale bar: 500 nm. C) Schematic representation of what happens to TPD54-
positive vesicles after a knocksideways. 
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their yeast two-hybrid assay results, our knocksideways experiment suggests 
no interaction between TPD54 and MAL2. Taken together, our data show that 
the knocksideways is a good technique to assess protein-protein interactions. 
With it, we have found that TPD54 is associated with Rab4- and Rab11-
positive vesicles, and that TPD52 but not TPD54 is an interactor of MAL2. 
 
Figure 3.4: TPD52 but not TPD54 is associated to MAL2. Representative widefield 
micrograph showing the effect of the knocksideways of mCherry-FKBP-TPD54/52 on GFP-
MAL2. KS was induced by adding 200 nM rapamycin to the cells. Mitochondria are 
labelled with far-red MitoTracker. Scale bar: 10 µm. Inset: 7x zoom. 
 
3.3 Generation of a TPD54 KO cell line 
To gain insight into the cellular function of TPD54, a knockout (KO) 
cell line was generated using the CRISPR-Cas9 system (Cong et al., 2013). 
Briefly, oligonucleotides were designed to target exon 1 of TPD54, which is 
common to all TPD54 isoforms. These ‘target sequences’ will position the 
nuclease Cas9 within exon 1 and induce a double strand break which might 
then be repaired with an insertion or a deletion (indel) likely to cause a reading 
frameshift. Using this technique, two HeLa TPD54KO clones (clone 2.2 and 
2.4) were generated with the target sequence no.2 (see section 2.4.1) showing 
no expression for clone 2.4 and barely any for clone 2.2 (Figure 3.5A), since 
the genomic DNA sequence of both of these clones exhibited no start codon 
(Figure 3.5B).  
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Figure 3.5: TPD54 knockout cell lines. A) Western blot showing two clones still expressing 
TPD54 (clones 1.20 and 3.3) and two clones expressing no TPD54 (clones 2.2 and 2.4). 
Clathrin heavy chain (CHC) is used as a loading control. B) Sequencing of TPD52L2 exon 
1 of clones 2.4 and 2.2. Clone 2.4 exhibits no start codon, while clone 2.2 has a mutation 
at the start codon, making it impossible for the protein to be expressed. 
 
One of the pitfalls of using this technique for knocking out genes is the 
possibility of having off-target effects by introducing indels at other sites 
(Komor et al., 2017). The three most likely off-target regions were also 
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sequenced and showed no difference when compared to parental genomic 
DNA. 
Since TPD54 has an apparent a role in membrane trafficking, a few organelles 
were stained in clone 2.4 in order to detect a defect. Early endosomes (Rab5), 
late endosomes (Rab7) and the Golgi apparatus (TGN46) were stained. No 
problem was detected in early or late endosomes (data not shown), but the 
majority of TPD54 KO cells exhibited a fragmented Golgi phenotype (Figure 
3.6A). In control cells the Golgi (TGN46) was focused, but in KO cells, the 
Golgi is vesicular, suggesting unstable cisternae. This phenotype was 
quantified by calculating the ratio of the area of the Golgi dispersal over the 
area of the cell, meaning that a value near 1 reflects a very fragmented Golgi 
(Figure 3.6B). The phenotype could be rescued by the transient expression of 
FLAG-TPD54. FLAG-TACC3, a protein bearing a coiled-coil domain like 
TPD54, was used as a control to show the specificity of the rescue. The effect 
of an overexpression of TPD54 or TACC3 was also assessed and showed no 
significant difference with control cells. Finally, both TPD54 KO clones 
showed a similar Golgi phenotype (Figure 3.6C), suggesting that this 
phenotype isn’t specific to one clone and re-enforcing the hypothesis that this 
fragmented Golgi phenotype is due to the loss of TPD54 and not the result of 
CRISPR-Cas9 or an off-target effect. 
Another pitfall of working with KO cells is the possibility for these cells to 
adapt to the lack of the protein targeted. After a while, the Golgi apparatus of 
both clones became more similar to the parental cells until no significant 
difference remained. TGN46 antibodies and TPD54 KO clone aliquots were 
changed, and the phenotype was still lost, making it plausible that the cells 
adapted to loss of TPD54. 
In order to check if the same phenotype could be studied with RNA 
interference, HeLa cells were transfected with siRNA targeting TPD54 3’ UTR 
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Figure 3.6: TPD54 KO cells show Golgi apparatus cisternae instability. A) Representative 
widefield micrograph showing the trans Golgi network marker TGN46. Scale bar: 10 µm. 
B) Quantification of the dispersal of the Golgi apparatus in parental cells or TPD54 KO 
cells expressing either the control construct FLAG-TACC3, FLAG-TPD54 or no plasmid. 
n=3. C) Comparison between TPD54 KO clones 2.4 and 2.2. n=3. Dots are single cells 
and bars are mean and standard deviation. p values from Tukey post-hoc comparison. 
*<0.05, ***<0.001. 
  
59 
(Figure 3.7). The expression is reduced by more than 50 % after only 24 h and 
was almost undetectable after 48 h (Figure 3.7A). No significant difference 
was found between the Golgi dispersal of siGL2 transfected cells and siTPD54 
transfected cells (48 h). Also, cells receiving the siRNA transfection mix and 
the DNA transfection exhibited a tight Golgi phenotype (dispersal index 
around 0.1). Taken together, the data suggests that TPD54 might have a role 
in Golgi cisternae stability although this could not be repeated in knockdown 
conditions.  
 
 
Figure 3.7: RNA interference TPD54 does not destabilise the Golgi apparatus. A) Western 
blot showing the depletion of TPD54 using siRNA. ! tubulin is used as a loading control. 
B) Quantification of the Golgi fragmentation in siRNA treated HeLa cells for 48 h. n=1. p 
values from Tukey post-hoc comparison. Dots are single cells and bars are mean and 
standard deviation. 
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3.4 TPD54 KO cells do not show a mitotic defect 
 TPD54 most probably has a role in membrane trafficking (Figures 3.2 
and 3.3) (Borner et al., 2006; Proux-Gillardeaux et al., 2003) and is a good 
candidate for also having a role in mitosis (Figure 3.1) (Kaur et al., 2014). We 
then wanted to know if TPD54 might have a mitotic moonlighting role. Before 
the loss of the Golgi phenotype, a mitotic progression experiment was 
conducted with the TPD54 KO cell line clone 2.4 (Figure 3.8). The mitotic 
stage was assessed by expressing the DNA marker H2B-mCherry. The time 
required to go through each mitotic phase was estimated and no difference 
was found between parental HeLa cells and TPD54 KO cells. Overexpression 
of GFP-TPD54 had no impact on the progression through mitosis. Taken 
together, the data suggests that a lack of TPD54 does not impair the normal 
progression of mitosis.  
 
3.5 Discussion 
The first aim of the project was to determine whether or not TPD54 is a 
membrane trafficking protein with a mitotic moonlighting role. TPD54 is 
indeed associated with membrane trafficking components since Rab4 and 
Rab11 positive vesicles can be rerouted to the mitochondria after a TPD54 
knocksideways (Figures 3.2 and 3.3). It is possible to note that the rerouting 
of TPD54 to the mitochondria is more efficient then the rerouting of Rab4 and 
Rab11. This could be due to either a higher expression of Rab4 and 11 than 
TPD54, or that the hypothetical binding to these Rab GTPases is only 
transient. Also, the vesicles seen on the electron micrographs look particularly 
regular. It is then unlikely that recycling endosomes are rerouted since they 
exhibit a tubular shape (Ullrich et al., 1996) that would have been seen by 
EM. It is therefore more likely that TPD54 is associated with transport vesicles, 
probably on the recycling pathway since members of both the fast (Rab4) and 
the slow (Rab11) recycling pathway (Stenmark, 2009) are rerouted with 
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Figure 3.8: TPD54 KO cells can go through mitosis at a normal pace. Boxplot showing 
the rate at which TPD54 KO HeLa cells clone 2.4 go through each mitotic stage (NEB: 
nuclear envelope breakdown). n=3. Box represents the higher and lower quartile, bar is 
the median value, and the whiskers show 10th and 90th percentile. On the left: 
representative widefield micrograph of nuclei marked by expressing H2B-mCherry. p 
value: Tukey post-hoc comparison. 
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TPD54. We have also been able to confirm an interaction between MAL2 and 
TPD52 but not TPD54 (Figure 3.4), unlike previously found (Wilson et al., 
2001).  
This is probably due to the fact that yeast two-hybrid assays can result in false-
positives (Rao et al., 2014) and that only TPD52 binding to MAL2 was 
confirmed by immunoprecipitation. We are therefore confident that 
knocksideways is an effective technique for the detection of protein 
associations, however the technique is inadequate to confirm protein-protein 
binding. 
A fragmented Golgi phenotype was also quantified and rescued with a TPD54 
KO HeLa cell line (Figure 3.6), but this phenotype disappeared over time and 
could not be repeated with RNA interference, even though the depletion was 
almost complete after 48 h (Figure 3.7). This is puzzling given the fact that the 
fragmented phenotype could be rescued and was observed in two different 
KO cell lines.  
Finally, in the same KO cell line, no detectable defect in mitotic progression 
was found (Figure 3.8), suggesting that if TPD54 has a role in mitosis, this role 
is subtle or that TPD54 affects the ability of the mitotic checkpoints to detect 
a problem that TPD54 would cause. It is also impossible at the moment to 
rule out a role for TPD54 in mitosis, since the experiment would need to be 
done with RNA interference: it seems that the use of CRISPR-Cas9 technique 
for knocking out TPD54 was not effective at keeping the early phenotypes 
observed. RNA interference is therefore a better solution for depleting the 
protein, since it can be done quickly (more than 50 % depletion after 24 h 
(Figure 3.7) and the cells are less likely to adapt within this window of 
opportunity.  
 
We have so far been unsuccessful at finding a mitotic moonlighting role for 
TPD54. However, we have established that the protein is probably involved 
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the trafficking of vesicles on the recycling pathways. We also have an efficient 
way of depleting the protein (KD) or moving it quickly from its normal location 
(KS) and as such, probably inactivating it. We will therefore next investigate 
the cellular roles of TPD54 using these tools. 
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Chapter 4 – TPD54 is required for normal cell migration 
 
 
4.1 Introduction 
 In the past few years, many clinical articles have been published, 
suggesting that TPDs either increase (He et al., 2015; Xu et al., 2015; Yang et 
al., 2015; Yu et al., 2017; Zhao et al., 2017) or decrease (Kato et al., 2017; 
Mukudai et al., 2013) cellular migration, invasion or proliferation. These 
studies all used cancer cell lines, and alterations in the processes mentioned 
are hallmarks of cancer.  Although the authors come to different conclusions, 
TPD54 does appear to have a role in cell motility. Exactly what this role is 
and the mechanism behind it is still unclear. 
We have shown so far that TPD54 is associated with the recycling Rab 
GTPases Rab4 and Rab11. One key step in cell migration and invasion is the 
trafficking of the integrins (Caswell and Norman, 2006), and two of the 
pathways the integrins are trafficked on are the Rab4 and Rab11-mediated 
recycling pathways (Roberts et al., 2001; Roberts et al., 2004; Woods et al., 
2004). Since TPD54 has a potential a role in cell migration and invasion, and 
because we found that it is associated with proteins important for cell motility, 
we decided to investigate the function of TPD54 in cell migration. 
 
4.2 TPD54 is required for 2D cell migration 
 To look at the role of TPD54 in cell migration, a 2D migration assay 
was performed with cells depleted of TPD54 plated on dishes coated with the 
ECM protein, fibronectin. Movies of RPE1 cells migrating freely were recorded 
over 12 hours and the cells were tracked until they reached mitosis or exited 
the field of view (Figure 4.1). Three different siRNAs targeting the 3’ UTR of 
TPD54 were assessed individually, and all resulted in a significant decrease 
in migration speed (Figure 4.1A). This indicates that the migration phenotype 
described is unlikely to be due to an off-target effect of a given siRNA.  
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Figure 4.1: TPD54 depletion in RPE1 cells decreases 2D migration speed. A) 2D migration 
of RPE1 cells seeded on fibronectin and transfected with control or three different TPD54 
siRNA. n=1. Dots are individual cells, horizontal bar is mean value and vertical bars are 
standard deviation. p values from Tukey post-hoc comparison. * <0.05, **<0.01. B) 
Directionality ratio, mean squared displacement and histogram of instantaneous velocity 
of RPE1 cells seeded on fibronectin and transfected with either control siRNA or TPD54 
siRNA 2. n=3. Mean + SEM is shown. 
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Single cell tracking revealed a number of statistics on cell motility. Analysis 
showed that only the migration speed is impaired in TPD54 depleted RPE1 
cells. The directionality ratio is not different (Figure 4.1B) meaning that the 
TPD54 KD cells do not make more or less turns than the control cells. Also, 
the instantaneous velocity is functions of migration speed; it is then expected 
that control cells have faster bursts of speed than the TPD54 depleted cells. 
Finally, the slope of the MSD is not different between control and KD cells, 
meaning the cells explore their environment in a similar manner. The only 
difference is the error in the measurement (intercept) is higher in control cells, 
probably because of greater migratory speed (Figure 4.1B). Since all three 
siRNAs against TPD54 resulted in a similar migration phenotype, we continue 
the experiments with the siRNA siTPD54 2, since it is efficient in HeLa 
(Chapter 3 Figure 3.7) and in RPE1 (Figure 4.2A).  
The ECM on which the cells migrate is composed of many types of proteins 
(Randles et al., 2017), and very motile or static cells utilise different molecules 
for attachment. Epithelial cells, which are more static, rely on integrin !6"1 
to anchor themselves to laminin and on integrins in hemidesmosomes to 
stabilise the epithelium. More motile cells depend mainly on integrin !5"1 
and !2"1 for anchoring to fibronectin (Huttenlocher and Horwitz, 2011; 
Rainero and Norman, 2013). We therefore wanted to see if the role of TPD54 
was dependant on one type of ECM component or if its effect was more 
generalised. To do so, RPE1 cells were seeded in dishes coated with laminin 
or fibronectin, or no ECM protein and allowed to migrate. Figure 4.2 B-C 
shows that TPD54 depletion affects RPE1 cell migration speed only when 
migrating on laminin or fibronectin. 
Next, we wanted to make sure that the migration speed phenotype was due 
to the loss of TPD54. To do so, we tried to rescue migration speed by re-
expression of TPD54 in TPD54-depleted cells seeded in dishes coated with 
fibronectin. 
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Figure 4.2: TPD54 knockdown affects migration speed of RPE1 cells on different 
substrates. A) Western blot showing the expression level of TPD54 48 h post transfection 
of siRNA 2 for the migration experiments. Clathrin heavy chain is used as a loading control. 
B-D) Migration speed of RPE1 cells plated in dishes coated with (B)fibronectin, (C) laminin 
or (D) uncoated, and transfected with control or TPD54-targeting siRNAs. n=3 for each 
experiement. p values from Student t-test. Dots represent single cells. Bars: mean and 
standard deviation. 
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As seen in figure 4.3, GFP-TPD54 under a CMV promoter did not rescue 
migration speed (Figure 4.3A). Also, cells transfected with a plasmid after 
being exposed to siRNA transfection mix (GFP+ and GFP-TPD54+) migrate   
 
 
Figure 4.3: Migration speed can be rescued by pIRES-EGFP-TPD54. In RPE1 cells seeded 
on dishes coated with fibronectin, migration speed is not rescued by the expression of GFP-
TPD54 either under a CMV (A) or a PGK (B) promoter. The phenotype could be rescued 
by an untagged version of TPD54 (C, normalised speed) expressed in a pIRES-EGFP vector. 
n=3 for each experiment. p values from Tukey post-hoc comparison. * <0.05, **<0.01. 
Dots are single cells and bars are average and standard deviation. 
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significantly slower than cells treated with siRNA but not transfected with a 
plasmid (GFP– and GFP-TPD54–). We hypothesized that since the CMV 
promoter drives high expression, reducing the level of re-expression of TPD54 
might rescue the phenotype. We then expressed GFP-TPD54 from a PGK 
promoter in TPD54 depleted cells seeded in dishes coated with fibronectin 
(Figure 4.3B). Cells transfected with a plasmid showed again a significantly 
lower migration speed when compared to TPD54 KD cells, indicating that the 
level of expression is not responsible for the decrease in migration speed. We 
next wanted to test if expressing a tagged version of TPD54 was preventing us 
from rescuing the migration phenotype. TPD54 and GFP were expressed in 
cells seeded in dishes coated with fibronectin with a bicistronic pIRES-EGFP 
vector, allowing us to express an untagged TPD54 and a transfection reporter 
(GFP) in the same cells (Figure 4.3C). Three repeats were done, each one 
having a different average migration speed but all showing a rescue. Taken 
together, these data show that TPD54 has a role in cell migration and that this 
role is specific, since three different siRNAs cause a similar phenotype and 
that this phenotype can be rescued by re-expressing TPD54. 
We finally wanted to check if we could induce a slower migration speed in 
RPE1 cells seeded in dishes coated with fibronectin by rapidly inactivating 
TPD54 by knocking it sideways. As seen in figure 4.4, we have been unable 
to affect migration speed by knocking TPD54 sideways, suggesting a longer 
depletion is required to affect migration. 
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Figure 4.4: Knocksideways of TPD54 has no effect on RPE1 migration speed on 
fibronectin.  TPD54-depleted cells expressing either GFP-FKBP or GFP-KFBP-TPD54 were 
treated with either rapamycin or ethanol (vehicle) and migration speed was measured. p 
values from Tukey post-hoc comparison. Dots are single cells and bars are average and 
standard deviation. Pre-rapamycin were recorded for 2 hours and post-rapamycin movies 
for ten hours. n=3. 
 
4.3 The role of TPD54 in migration is independent of Rab4 and 
Rab11 
It has been shown that cell migration requires Rab4 and Rab11 
recycling pathways (Caswell and Norman, 2006), and we have demonstrated 
so far that TPD54 is associated with Rab4 and Rab11 (section 3.2) and is 
required for 2D cell migration. The next question to answer is then whether 
or not TPD54 is on the same pathway as Rab4 and/or Rab11 and if so, is this 
the mechanism behind the role of TPD54 in cell migration? We would expect 
that if TPD54 is on the same pathway as Rab4 or Rab11, depleting both 
TPD54 and Rab4/11 would not create a greater phenotype than the depletion 
of either one. Similarly, if TPD54 is on another pathway important for 
migration, a depletion of TPD54 and Rab4/11 would create a worse 
phenotype than the depletion of only one. To assess this, we depleted Rab4 
or Rab11 in RPE1 cells seeded on fibronectin and compared the migration 
speed of these cells with cells depleted of TPD54 (Figure 4.5). The cells were 
treated with siRNAs for 48 h with a combination of siGL2, siRab4, siRab11 
and siTPD54 which all gave a good depletion (Figure 4.5A). To our surprise, 
we found that depletion of either Rab4 (Figure 4.5B) or Rab11 (Figure 4.5C)  
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Figure 4.5: Knockdown of Rab4 and/or Rab11 didn’t affect migration speed as much as 
TPD54 KD. A) Western blot showing the levels of tubulin (loading control), TPD54, Rab4 
and Rab11 after 48 h of KD. Rab11 blot was done on another experiment, in which the 
level of tubulin was checked to make sure the conditions were the same as the experiment 
shown above. Migration speed of RPE1 cells treated with control, TPD54 or Rab4 (B), 
Rab11 (C) or Rab4/11 dKD. p value from Tukey post-hoc comparison. Dots are single cells 
and bars are average and standard deviation. n=3 for each experiment. 
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did not affect migration speed as much as depletion of TPD54 did. We then 
thought that by depleting both TPD54 and the Rab GTPases, we might affect 
migration speed at least as much as a depletion of TPD54, which was not the 
case. Indeed, a combination of Rab4/TPD54 (double knockdown or dKD), or 
Rab11/TPD54 didn’t have a greater phenotype than depletion of TPD54 
alone. It was possible that impairing one recycling pathway (slow or fast) 
results in the other one being upregulated and that there was compensation. 
We therefore depleted both Rab4 and Rab11 and compared the migration 
speed of these cells with TPD54-depleted cells. As shown in figure 4.5D, a 
TPD54 KD affects RPE1 cells migration speed more than a Rab4/11 double 
KD, suggesting that TPD54 could be on Rab4- and/or Rab11 pathways, 
potentially upstream of the GTPases during cell migration, since the 
phenotype is greater than the Rab4/11 dKD phenotype. The severity of this 
TPD54 KD phenotype highlights the importance of TPD54 in cell motility. 
Although no worsening of migration speed was detected during these 
experiments, we noticed that the cell shape was affected by either a Rab11 or  
a TPD54 depletion (Figure 4.6). Control RPE1 cells migrating on fibronectin 
displayed an archetypal shape: quite compact, with a clear tail at the rear end 
and a lamellipodium at the leading edge (Figure 4.6A). Rab4-depleted cells 
did not display a real difference when compared to control cells. Rab11 KD 
cells were very long, with a disproportionate tail that tended to get ‘stuck’ 
behind the cell, the cell cannot retract its tail (Figure 4.6A). As for TPD54 KD 
cells, they were flattened and appeared much larger than control cells, making 
many protrusions with no clear leading edge (Figure 4.6A). Rab4 did not have 
a much different phenotype than control cells. To examine these shapes in 
more detail, we quantified the cell footprint area and compared our different 
conditions (Figure 4.6B-C). This quantification further re-enforced the 
hypothesis that TPD54 might not act on Rab4 or Rab11 pathways, since 
neither cell shape nor migration speed of TPD54 depleted cells is 
phenocopied by a depletion of Rab4 or Rab11.  
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Finally, we wanted to see if we could mimic the TPD54 KD cell size by rapidly 
removing TPD54 from its normal localisation with a knocksideways of TPD54  
 
 
Figure 4.6: TPD54-depleted RPE1 cells have a larger footprint. A) Representative 
micrographs of cells in the different conditions freely migrating on fibronectin-coated 
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dishes. B-C) Cell area comparison between control, Rab4/11 KD, TPD54 KD or TPD54/Rab 
dKD. D) Effect of a GFP-FKBP(-TPD54) knocksideways on RPE1 cells area. p values from 
Tukey post-hoc comparison. n=3 for each experiment. 
(Figure 4.6D). We have been able to see that TPD54-depleted cells have a 
bigger footprint than TPD54-depleted cells re-expressing GFP-FKBP-TPD54 
(we could rescue the cell footprint area). However, taking away TPD54 
quickly had no effect on cell size. 
Taken together, the data suggest that since depletion of Rab4 and/or Rab11 
doesn’t phenocopy depletion of TPD54, the latter might have a role in 2D cell 
migration that is independent of its putative association with Rab4 or Rab11. 
It remains possible that TPD54 has a role in cell motility which is independent 
of membrane traffic (and that this could be in addition to a trafficking-specific 
role in migration). However, we propose the idea that the role of TPD54 in 
trafficking underlies the migration phenotype. 
 
4.4 TPD54 has a role in the recycling of integrins 
 One of the key steps enabling cell migration is the trafficking of 
integrins, allowing assembly and disassembly of cellular adhesions. As 
mentioned in section 4.1, Rab4 and Rab11 are not the only recycling routes 
that integrins can be trafficked on (De Franceschi et al., 2015). Another 
important route is the Rab25-dependant pathway, either salvaging ligand-
bound integrins from the lysosomal pathway (Dozynkiewicz et al., 2012) or 
keeping a pool of integrins at the cell front for a more efficient invasion 
(Caswell et al., 2007). Since it doesn’t seem like TPD54 is entirely on Rab4 or 
Rab11 pathway but still have an important role in cell migration we wanted 
to investigate the possibility of an association with Rab25. To do so, we used 
to co-knocksideways approach to test if Rab25-positive vesicles could also be 
rerouted by a TPD54 knocksideways. As shown in figure 4.7, Rab25 
colocalises with TPD54 on the mitochondria after the addition of rapamycin, 
suggesting an association between TPD54 and Rab25-recycling pathway too. 
Given the role of TPD54 in migration and its association with the recycling 
pathways, we next wanted to test directly this hypothesis by assessing the 
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requirement for TPD54 in the recycling of the integrins. Briefly, in RPE1 cells, 
surface receptors were labelled with biotin and allowed to be internalised. 
Biotin on receptors that stayed at the surface was removed and internalised 
receptors allowed to be recycled for 10, 20 or 30 minutes. Biotin on the 
recycled receptors was removed from the cell surface and the internal content 
of the cell was quantified, measuring the recycling efficiency (Figure 4.8A). 
Figure 4.8B shows that TPD54 has a role in the recycling of integrin !5 since 
its depletion causes a significant decrease in the cells ability to recycle the 
receptors. 
 
Figure 4.7: Rab25 is rerouted to the mitochondria with a mCherry-FKBP-TPD54 
knocksideways. HeLa cells expressing GFP-Rab25, mCherry-FKBP-TPD54 and dark 
MitoTrap were treated with 200 µM rapamycin. Inset: 5X zoom. Scale bar: 10 µm. 
 
If TPD54 is important for integrin traffic, we would be able to see 
colocalisation of TPD54 and integrin !5 in live cells. We used widefield 
microscopy and co-expressed integrin !5-GFP and mCherry-TPD54 to test 
this. We have been able to see both proteins on the same structure, being 
trafficked together over time (Figure 4.9). This is more evidence that TPD54 
has a role in the trafficking of integrins, and that this might be the underlying 
role of the protein in cell motility. 
We also wanted to know if integrins were present on the vesicles removed 
during knocksideways. We have tested a conformation-independent integrin 
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!5 and a conformation-dependant integrin "1, because different routes can 
be taken by the integrins depending on their conformation state (Arjonen et 
al., 2012) . In figure 4.10, we show that this could not be done, either with 
integrin !5-GFP or an antibody recognising the inactive form of integrin "1, 
mAb13. 
 
 
Figure 4.8: Integrin recycling is impaired in TPD54 depleted cells. A) Schematic diagram 
of the recycling assay. B) RPE1 cells were transfected with control of TPD54 targeting 
siRNAs for 48 h. Graph showing the amount of recycled integrin !5 as a function of time. 
Three independent experiments were averaged. Bars show standard deviation. p values 
from Student t-test. * <0.05, **<0.01. 
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Figure 4.9: mCherry-TPD54 and integrin !5-GFP are trafficked together. Time course 
showing that both proteins can be found on the same vesicles in HeLa cells. Arrows 
indicate colocalisation. Scale bar: 1µm. 
 
 
 
Figure 4.10: Knocksideways of TPD54 does not reroute integrin !5"1. TPD54-depleted 
HeLa cells were transfected with dark MitoTrap, mCherry-FKBP-TPD54 and integrin !5-
GFP (upper panel) and treated with 200 µM rapamycin for 20 min before fixation and 
staining with mAb13 (lower panel). Scale bar: 10 µm, inset: 5X zoom. 
 
The trafficking of integrins results in the cell’s ability to remove old focal 
adhesions and form new ones, allowing them to move. TPD54 is important 
for cell migration and for the recycling of integrins. We next wanted to know 
whether or not focal adhesions are altered in TPD54 depleted cells. An 
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immunofluorescence of vinculin was performed on control or TPD54-
depleted RPE1 cells (Figure 4.11). Micrographs were acquired and analysed 
with an automated workflow. The cells area and the size of focal adhesions 
were measured in an unbiased manner (Figure 4.11A). With this technique, 
we have found no significance difference in the density of bigger focal 
adhesion (>500 µm/µm2) (Figure 4.11B), of smaller focal adhesions 
(>100 µm/µm2) (Figure 4.11C) or in the total density of focal adhesions (Figure 
4.11D).  
 
4.5 Discussion 
In this chapter, we saw that TPD54 is important for 2D cell migration, on 
either fibronectin or laminin. This suggests that the effect of TPD54 on 
migration is not limited to very motile cells, like cancer cells, which is the 
model that has been favoured so far for assessing the role of TPDs in cell 
migration (Mukudai et al., 2013; Yu et al., 2017). We have also shown that 
TPD54 does not affect directionality. The cells are not more or less likely to 
change direction while migrating. Studies have suggested that migration 
persistence can be affected by Rab11 or Rab6 (Shafaq-Zadah et al., 2016; 
Theisen et al., 2012; White et al., 2007). The fact that TPD54 KD cells have 
similar directionality ratio as control cells suggests that TPD54 depletion 
doesn’t impair these pathways. The migration speed phenotype can be 
rescued by an untagged TPD54. We have so far been unable to rescue the 
phenotype with GFP-TPD54, suggesting that this tag might alter the protein’s 
integrity or its role in migration. 
During a knocksideways, the rerouted protein is sequestered to the 
mitochondria and unavailable for its normal role, and defects can become 
apparent on a short time scale. In a study conducted by Cheeseman et al. in 
2013, a knocksideways of TACC3, an essential protein for mitotic spindle 
stability, caused a delay in different stages of mitosis within minutes after  
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Figure 4.11: Depletion of TPD54 doesn’t cause an alteration in focal adhesion number. 
A) Representative micrograph of an RPE1 cell stained with anti-vinculin antibody (top 
panel) and the mask generated by our automated workflow for Igor Pro for the analysis of 
focal adhesion number: the cell footprint (middle panel) and the focal adhesions (lower 
panel). Scale bar: 10 µm. B-D) Density of focal adhesions according to their size. p value 
from Student t-test. Dots are single cells and bars are average and standard deviation. n=3. 
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rerouting (Cheeseman et al., 2013). We would then expect a knocksideways 
of TPD54 to impair migration of cell size within a few hours. Although to our 
surprise, rerouting TPD54 to the mitochondria has had no effect on migration 
speed.  
As seen by immunofluorescence, barely any TPD54 is left in the cytosol 
(Figures 4.7 and 4.10) after knocksideways. Therefore, the reason why we 
detected no effect on migration cannot be explained by enough proteins left 
free. This is also re-enforced by the fact that a slower migration speed can be 
observed after only 24 h of treatment with TPD54 siRNA (data not shown), 
which leaves some proteins in the cell (Chapter 3, Figure 3.7). The reason 
why a knocksideways has no effect on migration could be due to an 
experimental time course that is not long enough. In this experiment, 
rapamycin was added to the cells after two hours and cells were recorded for 
ten more hours. We might have seen a decrease in migration speed after a 
longer time. This could be tested, although it would have to be kept in mind 
that the dissociation t1/2 of rapamycin and FKBP is 17.5 h (Hosoi et al., 1999). 
The longer we record, the less dimerization we have. Another reason why no 
change in speed was recorded might be that, on whichever pathway TPD54 
is acting, interfering with one might upregulated another. We can also 
imagine that if TPD54 is indeed on Rab4-, Rab11-, or Rab25-dependent 
pathways, there might also be some Rab-positive but TPD54-negative vesicles 
left, and that these vesicles are able to carry on their migration role. Indeed, 
as seen in figure 4.7, the amount of GFP-Rab25 rerouted to the mitochondria 
is minor when compared to the amount of mCherry-FKBP-TPD54. We could 
also be facing a case where the role of TPD54 in migration is independent 
from its role in membrane trafficking. This is however unlikely, because 
TPD54 can be seen on the same vesicles as integrins, and it is required for 
integrin trafficking. 
For the cell to move, the integrins linking the cell to the ECM must be 
trafficked. We found that a depletion of TPD54 causes a greater effect on 2D 
migration than a depletion of Rab4- or Rab11-dependant recycling pathways. 
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This could be due to the fact that integrins can take multiple different routes 
to go back to the surface once internalised, whether they are at the cell front 
or the tail, whether the integrins are in an active or inactive conformation, or 
depending on the identity of the integrins forming the dimer (De Franceschi 
et al., 2015). This indicates that the role of TPD54 in 2D cell migration might 
come from its association with another pathway. 
The fact that we rerouted Rab25 alongside TPD54 suggests that the protein 
also have a role in invasion. We have been able to collaborate with Dr. P.T. 
Caswell. His team has used breast cancer cell line A2780 stably expressing 
GFP-Rab25. They found that invasion efficiency on a 3D cell-derived matrix 
is significantly decreased in TPD54 depleted cells (Larocque et al., 2016) (see 
poster in appendix 1).  
To check if we indeed affect the recycling of the integrins, we have done an 
assay that did show a defect in recycling which was similar to published 
defects observed for a CLIC3- (Dozynkiewicz et al., 2012) or a GGA3-
depletion (Ratcliffe et al., 2016), re-enforcing the hypothesis that TPD54 
affects migration by having a role in integrin recycling, even though 
knocksideways of TPD54 could not reroute integrins. There might not be 
enough integrins in the rerouted vesicles to be detected by 
immunofluorescence. However, we have not had a migration phenotype with 
knocksideways either. It therefore appears that knocksideways might not be 
the right technique for assessing the role of TPD54 in migration. 
Finally, we have not been able to see an effect on the size or number of focal 
adhesions so far, but we would probably need to look at the dynamics of this 
process. We can hypothesise that the number of adhesion doesn’t change but 
the assembly or disassembly efficiency might be impaired. Movies of 
migrating cells expressing a focal adhesion marker would give us more insight 
on this. 
To conclude, we have found that TPD54 is required for 2D cell migration on 
either fibronectin or laminin and also in the recycling of integrins, probably 
via its association with Rab25. We also hypothesise that this role in integrin 
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trafficking is independent of the Rab4- and Rab11-dependent recycling 
pathway, despite an association with these vesicles. 
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Chapter 5 – TPD54 is required for recycling of dileucine 
motif-containing receptors 
 
 
5.1 Introduction 
TPD54 is associated with transport vesicles, probably on a pathway 
before or after the recycling endosomes, since the protein reroutes vesicles 
containing Rab4, Rab11 or Rab25 to the mitochondria after a knocksideways. 
Furthermore, the TPD52 family has been reported to be associated with 
membrane trafficking components like clathrin (Borner et al., 2006) and 
SNARES (Proux-Gillardeaux et al., 2003), and involved in secretion 
(Messenger et al., 2013) of polarized cells endosomes (Sathasivam et al., 
2001), suggesting a role for TPD54 in trafficking. However, the rerouting of 
the Rab GTPases was partial, arguing that the association is not exclusive. We 
also don’t know what cargo the TPD54-positive vesicles contain. 
We hypothesised in the previous chapter that TPD54 is involved in the 
recycling of the integrins and we have shown that a depletion of TPD54 in 
RPE1 cells results in a defect in integrin !5 trafficking. Both proteins can also 
be imaged on the same vesicle, but we were surprised by the fact that we 
could not reroute integrin !5 or "1 with a TPD54 knocksideways even though 
we could affect their recycling by TPD54 RNAi. 
In this chapter, we aim to determine which cargo is in TPD54-positive vesicles 
and what pathway it acts on. This will help us uncover the role of TPD54 in 
membrane trafficking. 
 
5.2 TPD54 is associated with the dileucine motif 
 What cargo do TPD54-positive vesicles contain? Rab4, Rab11 and 
Rab25 are all recycling-associated GTPases. One of the well characterised 
proteins going through the recycling pathways is the transferrin receptor (TfR) 
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(Sonnichsen et al., 2000; Vandersluijs et al., 1992). TfR binds to iron-bound 
transferrin (Tf) at the cell surface and gets internalised. When the complex 
reaches the lower pH of the early endosomes, iron ions are released and the 
TfR-Tf complex returns to the cell surface and dissociates (Hsu et al., 2012). 
Is TPD54 involved in the recycling of TfR, and if so, would we be able to co-
reroute it with TPD54 knocksideways? To investigate this, HeLa cells were 
treated with control or TPD54-targeting siRNA for 48 h. Cells were then 
incubated with AlexaFluor-488 labelled transferrin (Tf) and internalisation and 
recycling were allowed. Figure 5.1 shows that depletion of TPD54 does not 
affect Tf uptake (0-15 min after internalisation), but has a significant effect on 
its recycling. 
 
Figure 5.1: Depletion of TPD54 significantly affects the recycling of Tf. A) Boxplot 
showing the uptake and recycling of Tf in control and TPD54-depleted HeLa cells. Boxes 
show lower and upper quartile, bar is median value and whiskers show 10th and 90th 
percentile. p value from Student T-test. **<0.01. B) Graph showing the median value of 
internalised Tf in control and TPD54 depleted HeLa cells as a function of time. n=3. 
 
To see if the TfR could be co-rerouted by TPD54 knocksideways, HeLa cells 
were treated with TPD54 siRNA and transfected with dark MitoTrap, 
mCherry-FKBP-TPD54 and mNeonGreen-TfR. The cells were treated with 
rapamycin for 20 minutes and fixed. As seen in figure 5.2, like integrins, the 
TfR does not go to the mitochondria with TPD54 knocksideways.  
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Figure 5.2: TfR is not co-rerouted with a TPD54 KS. Representative micrograph of 
knocksideways of TPD54. TPD54-depleted HeLa cells were transfected with 
mNeonGreen-TfR, mCherry-TPD54 and dark MitoTrap, treated with 200 nM rapamycin 
for 20 min and fixed. Mitochondria were stained with far-red MitoTracker. Scale bar: 
10 µm, inset: 5X zoom. 
 
We now have two different transmembrane proteins, for which recycling is 
well characterised, that do not reroute with TPD54 and yet, a depletion of the 
protein affects their recycling. The question is then: what cargo can be 
rerouted with TPD54 knocksideways?  
To answer this question, we used prototypical cargoes, the CD8-chimeras 
developed by Kozik et al. With no engineered tail, CD8 stays at the surface 
and isn’t internalised. The chimeras contain one of the three most common 
endocytic motifs. CD8-YAAL contains the YXX# motif, where # is a bulky 
hydrophobic amino acid and X is any amino acid. CD8-EAAALL contains the 
[D/E]XXXL[L/I] motif and CD8-FANPAY contains the FXNPXY motif. There is 
also a negative control, CD8-8xA with is a tail of eight alanines (the 
construction base for the three other motifs), and CD8-CIMPR containing the 
tail of cation-independent mannose-6-phosphate receptor (CIMPR) which has 
multiple motifs (Figure 5.3) (Kozik et al., 2010). The three endocytic motifs 
are internalised normally, and CD8-CIMPR goes to the cell surface but is 
mainly trafficked between the TGN and the endosomes (Fielding and Royle, 
2013; Kozik et al., 2010).  
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Figure 5.3: Sequence of the CD8-chimeras. Different endocytic motifs have been added 
to the CD8 receptor by Kozik and colleagues. The motifs have been added after the 
transmembrane domain of CD8, to the C-terminus cytoplasmic end of the protein. Known 
endocytic motifs are coloured. 
 
To see whether or not a receptor containing one of the three main endocytic 
motifs could be rerouted with TPD54, TPD54-depleted HeLa cells were 
transfected with dark MitoTrap, mCherry-FKBP-TPD54 and one of the CD8-
chimeras. Cells were either fixed and stained before treatment or treated with 
200 nM rapamycin for 20 minutes, fixed and stained with a AlexaFluor488-
CD8 antibody. We are therefore looking at total receptor and changes in its 
steady-state distribution. Figure 5.4A and B shows that only CD8-EAAALL and 
CD8-CIMPR (which also contains a dileucine motif) were rerouted to the 
mitochondria alongside TPD54, suggesting that only receptors containing the 
dileucine motif are associated with TPD54, and not receptors with the 
tyrosine-based or FXNPXY motifs. To verify that our result was not simply 
specific to designer cargoes, we testes the ability of the endogenous, dileucine 
motif-containing protein CIMPR, to be rerouted alongside TPD54 with a 
knocksideways and found both on mitochondria (Figure 5.4C). This suggested 
a real association between TPD54 and dileucine motif. 
TPD54 can reroute a cargo containing a dileucine motif, but not a tyrosine-
based motif. Since both are recognised by the same set of adaptor proteins 
and have the same sorting functions (Bonifacino and Traub, 2003), we wanted 
to see if we could track CD8-YAAL and CD8-EAAALL to perhaps, a TPD54 
specific compartment, where the cargoes bearing these motifs could diverge. 
To do so, we transfected cells with either CD8-YAAL or CD8-EAAALL and 
markers of the trafficking pathways. On the confocal microscope, cells were 
  
87 
 
 
  
88 
 
  
89 
 
Figure 5.4: Knocksideways shows that TPD54 is associated with dileucine motif 
exclusively. Representative widefield micrographs of TPD54-depleted cells transfected 
with dark Mitotrap, mCherry-FKBP-TPD54 and CD8-8A, CD8-FANPAY and CD8-YAAL (A) 
or CD8-EAAALL and CD8-CIMPR (B). TPD54 is rerouted by adding 200 nM rapamycin to 
the cells (dark orange bar). C) Knocksideways of TPD54 in TPD54 KD cells expressing 
mCherry-FKBP-TPD54 and dark MitoTrap, fixed and stained with AlexaFluor488-
conjugated anti-CIMPR antibody. Scale bar: 10 µm, inset: 2X zoom. 
 
live-labelled with AlexaFluor-647-conjugated anti-CD8 antibodies and 
imaged for up to two hours depending on the trafficking marker. As seen in 
figure 5.5, CD8-YAAL and CD8-EAAALL both colocalised with markers of 
TGN-late endosomes and Golgi-endoplasmic reticulum respectively, Rab9 
and Rab2 (Figure 5.5A) early endosomes Rab5 and EEA1 (Figure 5.5B), with 
markers of recycling pathways Rab4 and Rab11 (Figure 5.5C), markers of late 
endosomes and lysosomes respectively Rab7 and LAMP1 (Figure 5.5D) but 
not the intra-golgi Rab6 (Figure 5.5E). This argues against the hypothesis that 
dileucine motif-containing receptors are trafficked differently than tyrosine-
base motif-containing receptors. However, we could also have missed a 
compartment on which TPD54 could be, since our colocalisation assay was 
partial, utilising only the best described markers. 
We also wanted to have a quantitative estimate of the colocalisation between 
these receptors and the trafficking markers. To do so, we tracked the CD8-
positive and marker-positive spots in our movies with an automated work- 
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Figure 5.5: CD8-YAAL and CD8-EAAALL both colocalise with Rab5, EEA1, Rab4, Rab11, 
Rab7, LAMP1, Rab9 and Rab2 but not Rab6. HeLa cells were transfected with either CD8-
YAAL or CD8-EAAALL, a GFP- or mNeonGreen-tagged marker of trafficking and live-
labelled with AlexaFluor-647-conjugated anti-CD8 antibodies. Cells were imaged on 
confocal microscope up to two hours post-labelling. A) Colocalisation with Rab9 and 
Rab2, B) with Rab5 and EEA1, C) with Rab4 and Rab11, D) with Rab7 and LAMP1 and E) 
with Rab6. Scale bar in A = 10 µm, inset: 5X zoom. Scale bar in B-E: 1 µm. 
 
flow using the ImageJ plugin ComDet and Igor Pro code to analyse the 
colocalisation between the spots detected (Figure 5.6). We compared 
colocalisation of spots with the likelihood of two spots being randomly at the 
same place. With this method, we have been able to confirm objectively the 
imaging data stating that CD8-YAAL and CD8-EAAALL are trafficked through 
the tested organelles. 
We next wanted to know how TPD54 recognises the dileucine motif. Is the 
protein binding to it directly, or are they in the same vesicle when TPD54 is 
rerouted to the mitochondria? A way to test whether or not TPD54 binds 
directly and immediately to dileucine motif, is by trying to “catch” it with a 
knocksideways at a certain time point after the motif’s internalisation. To do 
so, we transfected TPD54-depleted cells with dark MitoTrap, mCherry-FKBP-
TPD54 and CD8-EAAALL or CD8-CIMPR, surface-labelled the cells with 
AlexaFluor488-conjugated anti-CD8 antibodies, and allowed internalisation 
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of CD8 for 5, 30, 60, 90 or 120 minutes before inducing knocksideways 
(Figure 5.7). As figure 5.7A shows, we can only co-reroute CD8-EAAALL with 
TPD54 knocksideways after at more than 60 minutes. As for CD8-CIMPR, it 
can be co-rerouted after 30 minutes (Figure 5.7B). This argues against the fact 
that TPD54 can bind directly to the dileucine motif, because it would have 
been expected that if this were the case, we would have been able to reroute 
it as soon as it is internalised. 
 
 
Figure 5.6: Quantification of CD8-YAAL or CD8-EAAALL colocalisation with trafficking 
markers. Number of trafficking marker-positive spots colocalising with CD8-YAAL (Y) or 
CD8-EAAALL (LL)-positive spots as a function of time after the start of the recording. Dark 
trace: colocalisation. Pale trace: colocalisation that would only be due to chance. EEA1 
LL: n=3. EEA1 Y: n=3. OCRL1 LL: n=3. OCRL1 Y: n=1. Rab4 LL: n=2. Rab4 Y: n=1. Rab6 
LL: n=4. Rab6 Y: n= 4. Rab7 LL: n=1. Rab7 Y: n=1. Rab9 LL: n=3. Rab9 Y: n=2. Rab11 LL: 
n=2. Rab11 Y: n=2. LAMP1 LL: n=2. LAMP1 Y: n=2. 
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One of the main differences between the dileucine motif and the tyrosine-
based motif is their recognition by AP2. Since it appears that CD8-YAAL and 
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Figure 5.7: CD8-EAAALL can only be rerouted with TPD54 after more than 60 minutes, 
and CD8-CIMPR after more than 30 minutes. Representative widefield micrographs 
showing the colocalisation of CD8-EAAALL (A) or CD8-CIMPR (B) with mCherry-FKBP-
TPD54 after addition of 200 nM rapamycin. 20 minutes post-rapamycin, HeLa cells were 
fixed and stained with AlexFluor488-anti-CD8. Scale bar: 10 µm. Inset: 5X zoom. 
 
CD8-EAAALL are trafficked through the same compartment, but that TPD54 
is only associated with dileucine motif, could the TPDs be another mechanism 
to sort separately the two motifs? It is known that TPD54, TPD53 and TPD52 
can bind to each other via their coiled-coil domain (Byrne et al., 1998; 
Sathasivam et al., 2001). A tempting hypothesis is that the TPDs might be 
subunits of a protein complex, perhaps involved in protein sorting. We 
therefore wanted to know if TPD54 only can reroute the dileucine motif, and 
that the other TPDs might bind another motif. To do so, we did the same co-
knocksideways experiment that we did to determine which CD8-chimera 
TPD54 binds. TPD52-depleted HeLa cells were transfected with dark 
MitoTrap, mCherry-FKBP-TPD52 and the CD8-chimeras. TPD52 was 
knocked sideways, fixed and stained with an anti-CD8 antibody (Figure 5.8). 
The figure shows that like TPD54, TPD52 is only associated to the dileucine 
motif, arguing against the hypothesis. 
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Figure 5.8: TPD52 knocksideways co-reroutes dileucine motif-containing receptors but 
not tyrosine based- or FXNPXY-containing receptors. Representative widefield 
micrographs showing that TPD52 does not co-reroutes CD8-8xA, CD8-FANPAY or CD8-
YAAL (A) but does reroute CD8-EAAALL and CD8-CIMPR (B) to the mitochondria. TPD52-
depleted HeLa cells were transfected with dark MitoTrap, mCherry-FKBP-TPD52 and one 
of the CD8-chimeras. Knocksideways was induced by adding 200 nM rapamycin (dark 
orange bars) to the cells. Scale bar: 10 µm, inset: 7X zoom. 
 
 
Taken together, the data confirm that TPD54 has a role in membrane 
trafficking. It is needed for normal recycling of TfR and is associated with 
receptors containing dileucine motifs (CD8-EAAALL, CIMPR) but not FXNPXY 
or tyrosine-based motifs. 
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5.3 TPD54 is strongly associated with Rab14 
It seems that the tyrosine and dileucine motifs are generally going to the same 
compartments and that TPD54 doesn’t bind them directly. How and where 
does TPD54 becomes associated with dileucine motif? Are we missing the 
sorting compartment on which TPD54 is? So far, we have seen that TPD54 is 
mostly cytosolic when overexpressed, with sometimes a vesicular location, 
potentially around the Golgi apparatus (Chapter 3, Figure 3.2, and Figure 
5.4). However, we don’t clearly know where the TPD54-positive vesicles that 
we reroute to the mitochondria come from. To have a more precise idea on 
the protein’s location, we performed a co-knocksideways experiment with 
dark MitoTrap, mCherry-FKBP-TPD54 and GFP-tagged markers of membrane 
trafficking organelles (Figure 5.9). Figure 5.9A shows the markers that did 
reroute with TPD54, the v-SNARE VAMP2 and the trans Golgi network 
resident TGN46. This suggests that TPD54 is indeed located near the trans 
Golgi network, potentially on transport vesicles. Figure 5.9B shows the 
markers that didn’t reroute alongside TPD54. Indeed, the early endosomal 
EEA1, the cis Golgi network GM130, the early endosomal-retromer 
component SNX5, another retromer component Vps26, the lysosomal LAMP1 
and the more widely distributed OCRL1 do not follow TPD54 to the 
mitochondria. This suggests that TPD54 is on transport vesicles somewhere 
between the recycling endosomes and the Golgi apparatus since VAMP2, 
Rab11, Rab4 and TGN46 could be co-rerouted with TPD54. 
We now have marked a wide range of pathways in order to better understand 
where TPD54 exactly is inside the cell. We also know that TPD54 can 
somehow be associated with CD8-EAAALL or CD8-CIMPR, but not CD8-
FANPAY or CD8-YAAL. We have tried to discriminate CD8-EAAALL and 
CD8-YAAL on the basis of their sorting, but we have seen so far that both go 
to the same compartments. We also know that it is unlikely that TPD54 binds 
to the dileucine motif directly. This all suggests that the motif needs to be in a 
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specific TPD54-positive compartment that we have so far missed with our 
tracking and co-KS assays. We therefore wanted to try to have a better 
understanding of the localisation of TPD54 by knowing more about its binding 
partners. To do so, we performed a GFP-IP in HeLa cells expressing either 
GFP or GFP-TPD54 and CD8-EAAALL or CD8-YAAL and analysed the 
proteins by mass spectrometry. Although the original idea was to confirm that 
we indeed couldn’t see an interaction between dileucine motif and TPD54, 
the dataset generated allowed us to know more about the binding partners of 
TPD54 (see appendix 2 for complete list of interactors).  
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Figure 5.9: Knocksideways of TPD54 co-reroutes TGN46 and VAMP2 exclusively. 
Representative widefield micrographs of TPD54 knocksideways on TGN46 and VAMP2 
(A) or EEA1, SNX5, VPS26, LAMP1 or OCRL1 (B). TPD54-depleted cells were transfected 
with either GFP-FKBP-TPD54 or mCherry-FKBP-TPD54, dark MitoTrap and a fluorescently 
tagged marker of the trafficking pathways, in the case of VAMP2, OCRL1 and SNX5. For 
the other the protein of interest was stained with AlexaFluor 488-conjugated antibody. 
Knocksideways was induced by adding 200 nM rapamycin to the cells. Scale bar: 10 µm, 
inset: 2X zoom. 
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Figure 5.10 highlights the most interesting hits of this analysis. TPD54 
interactors are classified according to the significance of the presence 
difference between the GFP and GFP-TPD54 samples, and according to the 
degree of enrichment in the GFP-TPD54 samples. Out of many interesting 
hits, we found proteins involved in membrane trafficking (Rab5c, Rab7, 
Rab2a, etc) or in cell migration (integrin "1, desmoglein-2). We also found 
TPD53 and TPD52, suggesting that the trio of TPDs might indeed be a 
complex. The protein that mainly caught our attention was the GTPase Rab14. 
Rab14 has been involved in cell migration (Linford et al., 2012), in the 
transport from the Golgi apparatus to the endosomes (Junutula et al., 2004) 
and in the transport of the dileucine motif-containing protein GLUT4 (Brewer 
et al., 2016), therefore making it the perfect candidate marker for the cellular 
localisation of TPD54. 
We next wanted to assess the association of TPD54 with Rab14 in our co-
knocksideways assay. We also added more Rabs to the assay, to give a wider  
picture of the role of TPD54 in Rab GTPases binding. We therefore tried a co-
knocksideways with GFP-Rab1a (ER to cis Golgi), Rab2a (cis-Golgi to ER), 
Rab6 (intra-Golgi and endosomes to Golgi), Rab8a (polarised trafficking and 
protrusion formation) or Rab14 in TPD54-depleted HeLa cells (Figure 5.11). 
We found that Rab1a, Rab2a and Rab14 are co-rerouted to mitochondria 
alongside TPD54 (Figure 5.11A) but that Rab6 and Rab8a are not (Figure 
5.11B). It is also possible to notice that before adding rapamycin, TPD54 
vesicles colocalise strongly with Rab14 vesicles (Figure 5.11B), making an 
interaction between Rab14 and TPD54 even more likely.  This further involves 
TPD54 at the Golgi apparatus and confirms the interactions found by mass 
spectrometry.  
We now have a few Rab GTPases that associate with TPD54: Rab1a, Rab2a, 
Rab4a, Rab11a, Rab14 and Rab25. We wanted to quantify the knocksideways 
level to see if we could determine if rerouting was more efficient with certain 
Rab GTPases. To do so, we compared confocal micrographs for the 
mitochondrial recruitment of the GTPases with the intensity of the Rab 
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GTPases left in the cytosol. Figure 5.12 shows that according to the 
quantification, Rab1a, Rab11a, Rab14 and Rab25 are rerouted to the 
mitochondria. The recruitment to the mitochondria of Rab1a, Rab11a, Rab14  
 
Figure 5.10: Mass spectrometry analysis of TPD54 interactors. Volcano plot showing 
TPD54 interactors according to the significance of their presence in TPD54 samples 
compared to GFP samples and their enrichment in TPD54 samples. Black spots: not 
significant and enriched in GFP samples. Red: not significant but enriched more than two 
fold in TPD54 samples. Violet: significant and less than two fold enriched in TPD54 
samples. Pink: significant and more than two fold enriched in TPD54 samples. n=4. 
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Figure 5.11: Knocksideways of TPD54 reroutes Rab1a, Rab2a, Rab14 but not Rab6 or 
Rab8a to the mitochondria. Representative confocal micrographs of TPD54-depleted HeLa 
cells expressing dark MitoTrap, mCherry-FKBP-TPD54 and either GFP-Rab1a, GFP-Rab2a, 
GFP-Rab14 (A), GFP-Rab6 or GFP-Rab8a (B). Mitochondria are stained with MitoTracker. 
Kkocksideways was induced by adding 200 nM rapamycin to the cells (dark orange band). 
Scale bar: 10 µm. Inset: 7X zoom. 
 
 
and Rab25 are the most dramatic in every cell imaged. It also shows that only 
Rab1a, Rab11a, Rab14 and Rab25 are significantly more present on the 
mitochondria than in the cytosol, suggesting that only these GTPases are truly 
rerouted with TPD54, therefore are associated to it.  
These knocksideways experiments have also allowed us to localise TPD54 at 
steady state. Indeed, by looking at colocalisation with the different Rab 
GTPases before any rapamycin treatment (Figure 5.13), we have been able to 
notice that some colocalisation can be seen with all Rabs but Rab6 and Rab8, 
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the most striking one being with Rab14, further reinforcing our hypothesis of 
direct and functional interaction.  
 
 
Figure 5.12: Knocksideways quantification. Log2 transformed ratios of post- over pre-
rapamycin Rab GTPases or GFP mitochondrial recruitment. n=1. Bars: mean and standard 
deviation. Doted line: GFP mean. Shaded area: GFP standard deviation. p values from 
Tukey post-hoc comparison. *<0.05, ***<0.001. 
 
 
5.4 Discussion 
 In this chapter, we were able to confirm that TPD54 is involved in 
membrane trafficking by its association with CD8-EAAALL trafficking vesicles 
and by uncovering three new associations with Rab14, Rab1a and potentially 
Rab2a. We now have a few Rab GTPases associated with TPD54, and if we 
combine the other associations found with the knocksideways technique, we 
can have a good idea of the cellular localisation of TPD54 (Figure 5.14). 
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Figure 5.13 Colocalisation of TPD54 and Rab GTPases. Representative confocal 
micrographs showing the colocalisation of mCherry-FKBP-TPD54 and GFP-Rab1a, 2, 4, 
5a, 6, 7, 8, 9, 11, 14 and 25 in HeLa cells at steady-state. Scale bar: 10 µm. Inset: 5X zoom. 
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Figure 5.14: Where is TPD54? Cartoon of the membrane trafficking pathways with the 
markers tested for their association with TPD54. Markers highlighted in red did not co-
reroute, and in markers in green rerouted. Markers in orange gave mixed results. Arrows 
indicate sense of traffic. 
 
We also showed that TPD54 has a role in the recycling of the transferrin 
receptor, but not its internalisation. However, as for integrin !5 and "1, TfR 
could not be seen at the mitochondria with TPD54 after a knocksideways. 
This could mean that TPD54-positive vesicles do not contain enough of these 
two types of cargo to be seen by knocksideways. This would also explain why 
we can see some colocalisation with Rab5, Rab7 and Rab9 at steady-state. 
We can see both proteins on some structures, but not enough to perceive with 
the KS. It could also be TPD54-positive vesicles are an artefact of the 
technique, that vesicles are formed artificially and that they contain only 
membrane residents but no cargo. However, this is not the case because we 
have been able to reroute two types of cargoes: the CD8-chimeras containing 
a dileucine motif (EAAALL and CIMPR) and CIMPR itself which has to be 
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trafficked from the Golgi apparatus to the endosomes and back again (Arighi 
et al., 2004; Meyer et al., 2000; Puertollano et al., 2001). 
We also tried to distinguish CD8-YAAL from CD8-EAAALL in order to 
understand how TPD54 can only be associated with one but not the other. 
We hypothesised that TPD54 might bind directly to the dileucine motif. Using 
two different ways of detection, we are now confident that this is not the case. 
We tried to co-immunoprecipitate either mCherry-CD8-EAAALL or mCherry-
CD8-YAAL with GFP-TPD54. We have detected bands corresponding to 
mCherry-CD8 in both cases, although because the same band was also 
detected when co-immunoprecipitating mCherry-CD8-EAAALL with GFP 
only, we concluded that mCherry binds the GFP-Trap used to do the 
immunoprecipitation. This has later been confirmed (data not shown). 
Another argument in favour of this was the substantial increase of signal in 
our positive control, GFP-FKBP-TPD54 + rapamycin + mCherry-FRB-CD8.  
The other way of confirming this negative result was to send the 
immunoprecipitations for mass spectrometry analysis. In the list of many 
interactors for TPD54, no CD8 peptide was found, arguing against the 
hypothesis that TPD54 recognise directly the dileucine motif by binding to it. 
 
The other experiment we used to confirm this hypothesis is the ‘timed’ 
knocksideways. We wanted to know if we could co-reroute CD8-EAAALL to 
the mitochondria with TPD54 as soon as the receptor is internalised, or if it 
needed to be transported to a certain compartment before it associates with 
TPD54. We found that the latter is true. TPD54 is only associated with 
dileucine motifs after more than 60 minutes post-internalisation, in the case 
of CD8-EAAALL. This not only suggests that in order to be associated with 
TPD54, CD8-EAAALL needs to be in the right compartment but also that this 
TPD54-positive compartment is likely to be on the Golgi anterograde 
pathway. Furin, a molecule that is trafficked on the retrograde pathway, takes 
about 45 minutes to reach the trans Golgi network from the plasma membrane 
and through late endosomes in a Rab9-dependent manner (Chia et al., 2013; 
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Mallet and Maxfield, 1999). CD8-EAAALL colocalises with the late 
endosomal Rab7a, Rab9a but is also recycled to the plasma membrane. This 
suggests that it is internalised, goes to the late endosomes, and then back to 
the plasma membrane, most probably through the Golgi apparatus. The fact 
that we see an association with TPD54 after more than 60 minutes suggests 
that TPD54 is on this Golgi recycling pathway.  
We haven’t been able so far, to dissociate CD8-YAAL and CD8-EAAALL. We 
have quantified their colocalisation with different trafficking markers such as 
the endosomal OCRL1, the early endosomal EEA1, the late endosomal Rab7a, 
the lysosomal LAMP1 and the recycling endosomes-associated Rab4a and 
Rab11a. Both CD8 receptors appeared to localise with them all to a similar 
extent. This then suggests that the compartment that could differentially sort 
the two motifs, on which TPD54 probably is, has not been identified yet. 
The localisation of TPD54 has also been examined more closely (Figure 5.14). 
According to our co-knocksideways experiments, TPD54 is likely to be on 
transport vesicles (VAMP2) located on an anterograde, post-Golgi pathway 
(Rab14, TGN46), potentially going through the recycling endosomes 
(Rab11a/Rab25). The fact that Rab1a, and potentially Rab2a, can be co-
rerouted with TPD54 is puzzling. We haven’t seen rerouting of GM130 
(marker of cis-Golgi network), but have seen rerouting of TGN46 (marker of 
trans-Golgi network). This was found by staining for endogenous proteins with 
antibodies, rather than overexpression. We did overexpress Rab1a and Rab2a, 
therefore we might only be seeing an association because of a protein excess.  
Another way of looking at the association between TPD54 and the different 
Rab GTPases, would be that instead of being on a fixed organelle, TPD54 
might recognise one or more Rab GTPases through a conserved motif on 
them. There might be one main Rab, probably Rab14, given the mass 
spectrometry analysis, and TPD54 binds to a similar sequence on others. 
Rab2a, Rab4a, Rab11a (and Rab25) and Rab14 are all members of a same 
Rab sub-family, meaning that they are more likely to be similar, having 
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evolved together (Klopper et al., 2012). This similarity might be the reason 
why we can co-reroute them all at least partially, with TPD54.  
This rises the validity of our knocksideways quantification. We have been able 
to see in chapter 3 that TPD54 is associated with Rab4a. In the same way, 
figure 5.11A clearly shows that Rab2a is associated with TPD54 as well. 
However, these two Rab GTPases failed to pass the significance test in our 
quantification. This could again be due to overexpression. The association is 
perhaps only triggered by an excess of Rab4 or Rab2 and since they share 
similarities with Rab11a, Rab25 and Rab14, TPD54’s binding sequence could 
be mildly conserved. 
Finally, we have also been able to acquire a list of interactors for TPD54. 
Besides Rab14, TPD53 and TPD52 caught our attention. This confirms that 
the TPDs are indeed able to bind to each other, but also that the TPDs are 
likely to be part of a complex constitutively. This experiment also confirms 
that, at least for its role in membrane trafficking, GFP-TPD54 is functional. 
We have been able to co-immunoprecipitate known interactors and new ones 
fitting well in what we already know about its biology. Amongst these new 
interactors are proteins involved in cell motility (desmoglein-2, integrin "1) 
and trafficking (TPDs, Rab14, Rab5c, Rab2a, Rab7a, TERA), but also a few 
nucleic acids-associated proteins (H4, RS14, RS4X, HNRH1, SYEP, RS10), 
which are likely to be contamination. 
Integrin "1 was interesting, because although we haven’t been able to knock 
it sideways, this shows that TPD54 is likely to be binding it and argues in 
favour that the role of TPD54 in cell migration is indeed through its trafficking 
role and the recycling of integrins. 
Desmogleins are the main components for desmosomes, together with 
desmocollins. Desmososmes are important for maintenance of the integrity of 
an epithelium, by linking intermediate filaments of one cell to the filaments 
of a neighbouring cell. The disassembly/reassembly of desmoglein polymers 
is therefore important for the cells ability to migrate, after a rupture of the 
epithelium, for example (Cadwell et al., 2016). Internalisation of desmogleins 
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is done in a Kif5B- and microtubules-dependent manner (Nekrasova et al., 
2013) and in a clathrin-independent way (Delva et al., 2008). TPD54, and 
potentially Rab14 could therefore be a mechanism to bring newly synthesized 
desmoglein-2 molecules to the surface, into desmosomes. 
ACSL3 (long-chain acyl-CoA synthetase 3) is mainly known for its role in lipid 
metabolism and lipid droplets (Poppelreuther et al., 2012), like TPD53 and 
TPD52 (Kamili et al., 2015). It has also been shown to be important for Golgi 
export to the plasma membrane of the tyrosine kinase Lyn (Obata et al., 2010). 
TPD54 could therefore, alongside TPD52 and TPD53, have a role in lipid 
droplet metabolism, and participate in the transport of the kinase Lyn through 
the Golgi apparatus. 
The interactor with the highest level of significance is GDE (glycogen 
debranching enzyme). Linking TPD54 with GDE is a bit challenging, nothing 
has been found so far about TPD54 being involved in glycogen metabolism. 
However, glycogen is a form of glucose storage in liver cells and muscles. The 
additional glucose will be glycolysed to form lipids, and these lipids can be 
translocated to the mitochondria by proteins of the ACSL family, including 
ACSL3 (Sahini and Borlak, 2014).  
Our knocksideways experiments showed that Rab5a cannot be rerouted with 
TPD54, but the mass spectrometry analysis revealed that there might be a 
binding between Rab5c and TPD54. Although Rab5a, b and c are expressed 
in all tissues (Gurkan et al., 2005), the three isoforms have been shown to 
have different functions, rather than being redundant. For example, Rab5a is 
involved in internalisation of EGFR, and depletion of Rab5c has no effect on 
the trafficking of this receptor (Chen et al., 2009). It has also been shown that 
Rab5c, but not Rab5a or Rab5b, is associated with the activation of Rac1 and 
promotes cell motility (Chen et al., 2014). It would therefore be possible that 
Rab5c, but not Rab5a is associated with TPD54. It is also worth noting that 
TPD52 has been shown to bind Rab5c in a yeast two-hybrid screening 
(Shahheydari et al., 2014). 
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On the other hand, having Rab7a in our analysis is surprising. We couldn’t 
reroute it to the mitochondria with TPD54. However, it was the same situation 
for integrin "1. This might suggest that the knocksideways technique might 
give false-negatives. 
In this chapter, we have been able to show that TPD54 is indeed involved in 
membrane trafficking. It is associated with Rab1, 11, 14 and 25, and receptors 
containing a dileucine motif (CD8-EAAALL, CD8-CIMPR, CIMPR) but not a 
NPXY or a tyrosine-based motif. We have also been able to identify many 
TPD54 interactors, such as Rab14, Rab2a and Rab5c confirming its role in 
membrane trafficking and such as desmoglein-2 and integrin "1, confirming 
its role in cell motility. 
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Chapter 6 – General discussion 
 
 
The aim of this thesis was to provide mechanistic insights into the role of the 
Tumor protein D52 family member TPD54, in two fundamental cellular 
processes, cell migration and membrane traffic. By doing so, we would be 
able to understand why a gene duplication of TPD54 in cancer is likely to 
lead to a poor prognosis.  
In the Introduction I described how TPD54 probably has a role in membrane 
trafficking since the Tumor protein D52 family members are found with CCSs, 
can act as a SNARE (at least in vitro), and is required for the secretion of 
digestive enzymes (Kaur et al., 2014; Messenger et al., 2013; Proux-
Gillardeaux et al., 2003). The fact that the sequence of the TPD52 family 
members is similar and that TPD52, 53 and 54 can interact with each other, 
we had good reason to believe that TPD54 might indeed have a role in 
membrane traffic (Sathasivam et al., 2001).  
It was also clear that since one of the main effects of overexpression of the 
TPDs in cancer is altered migration/adhesion/invasion, TPD54 must also have 
a role in these processes (Ito et al., 2017; Mukudai et al., 2013).  
We have found using the knocksideways technique that TPD54 is strongly 
associated with small vesicles and that these vesicles contain recycling Rab 
GTPases (Rab4, Rab11 and Rab25), as well as other Rabs in the supergroup 
(Rab14 and Rab2) and Rab1 (summarized in Table 6.1). These associations 
were also seen by co-IP and mass spectrometry (Rab2, Rab14) and a BioID 
experiment (Rab11, Rab25) conducted in the laboratory of our collaborator 
Dr P. Caswell (Manchester). We also saw by mass spectrometry that Rab7 
might be an interactor of TPD54, although this was not observed by KS. We 
also found Rab5c as a potential interactor by MS, however we only assessed 
Rab5a using KS. Rab5c is different enough from Rab5a for these two proteins 
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not to be redundant (Chen et al., 2009; Chen et al., 2014). It will be worth 
investigating Rab5c by KS in the future. 
 
Table 6.1 Summary of the Rab GTPases associations with TPD54. Y: yes, N: no, NA: not 
available 
Protein Steady-state colocalisation Knocksideways IP/MS BioID 
Rab1a Y Y N NA 
Rab2a Y N? Y NA 
Rab4a Y N N N 
Rab5a Y N N NA 
Rab5c NA NA Y NA 
Rab6 N N N NA 
Rab7a Y N Y NA 
Rab8a N N N NA 
Rab9a Y N N NA 
Rab11a Y Y N Y 
Rab14 Y Y Y NA 
Rab25 Y Y NA Y 
 
The discrepancies we see between the Rab GTPases associated with TPD54 
by co-IP/MS and by KS might be explained the fact that not every Rab is 
expressed in HeLa cells, the model used for the mass spectrometry assay. Also, 
in the KS experiment, we overexpressed TPD54 and the Rab GTPases. The 
abnormally high amount of proteins might force interactions. However, these 
hypotheses do not explain why we saw an association with Rab7a by mass 
spectrometry and not by KS. An explanation for this could be that the vesicles 
we reroute to the mitochondria with a KS are only the very small vesicles and 
that Rab7-positive late endosomes are too big to be rerouted. However, there 
has been an example where a group was able to reroute large parts of the 
Golgi apparatus to the mitochondria using KS (Dunlop et al., 2017). We have 
also seen colocalisation of all the Rabs (except Rab6 and Rab8) with TPD54. 
This will however need to be quantified more closely with the particle analysis 
ComDet plugin, to see the extent of the colocalisation. 
We think it is unlikely that if TPD54 binds to Rab GTPases, it binds such a 
large number and a large variety of them. First, these Rabs are all scattered in 
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the membrane trafficking pathway, from the ER to the plasma membrane. 
Second, they are evolutionarily distant in the Rab GTPases tree (Rab1 and 
Rab5 being quite distant, as well as Rab4 and Rab7) (Figure 6.1) (Klopper et 
al., 2012). Few proteins are able to bind such a wide diversity of Rabs. The 
GDIs chaperone them from the acceptor membrane to the donor membrane 
are example of proteins having this ability, although there are only two known 
GDI in humans, GDI1 and GDI2 (Goody et al., 2017; Pfeffer, 2017), meaning 
that this is not a role that many different types of proteins can have. Also, it 
would be expected that if TPD54 is a new GDI-like protein, we would not see 
it reroute vesicles to the mitochondria, since the complex GDI-Rab is 
cytosolic (Wandinger-Ness and Zerial, 2014). Another hypothesis is that 
TPD54 binds one main Rab (maybe Rab14, given the intensity of Rab14 in 
the mass spectrometry experiment), and that it binds also other similar Rabs 
(2, 4, 11, 25) more weakly. If this is the case, the Rabs from other supergroups 
are false-positives due to overexpression or suboptimal washes during the 
immunoprecipitation leading to the mass spectrometry analysis. The Rab5c 
interaction argues against this. Rab5c has also been found to interact with 
TPD52 by another group (Shahheydari et al., 2014), which argues that this 
interaction is likely to be real.  
We think the main Rab GTPase interacting with TPD54 might be the post 
Golgi Rab14 (Junutula et al., 2004). Not only was it a strong hit in the mass 
spectrometry experiment, but Rab14 is also on the pathway that agrees the 
most with our other experiments. We have concluded that TPD54 is 
somewhere between the trans-Golgi network and the endosomes, since we 
could reroute TGN46, but not GM130, and Rab11/25 with a KS. Also, the 
CD8-chimera containing a dileucine motif was only rerouted with TPD54 
after more than 60 minutes post-internalisation, which agrees with the idea 
that TPD54 is on the post-Golgi recycling pathway. If TPD54 were simply on 
the recycling route, the dileucine motif, and probably TfR, would have been 
rerouted with TPD54, at some point between 30 and 60 minutes port-
internalisation. 
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Figure 6.1: Phylogenetic tree of the Rab GTPases subfamilies, from Klopper et al., 2012. 
Each Rabs inside a group have evolved more closely and therefore are more likely to have 
similar features and sequence. Rab25, which was also called Rab11c, is in the Rab11 
branch. 
 
We therefore hypothesise that TPD54 is on the Rab14-positive vesicles 
regulating the recycling of receptors with a dileucine motif to the plasma 
membrane after the Golgi apparatus. We don’t know yet the precise role of 
TPD54 with the Rab GTPases. We think TPD54 might be an effector because 
of the size of the vesicles we reroute with a KS. We can imagine that if TPD54 
were a GDI, as mentioned earlier, no vesicle would be rerouted. Similarly, if 
TPD54 were a GEF, we would capture bigger vesicles, such as Golgi 
fragments, and that if TPD54 were a GAP, we would also capture bigger 
endosomal vesicles, or tubular vesicles from the recycling endosome. Instead, 
we have small and regular vesicles, such as transport vesicles. TPD54 might 
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therefore be an effector regulating the translocation of transport vesicles. To 
confirm this hypothesis, we would need to do a better quantification of the 
size and shape of these vesicles seen by electron microscopy, as well as 
verifying the affinity of TPD54 for a GDP- or GTP-bound Rab GTPase. Proux-
Gillardeaux et al. have shown that TPD53 might be a SNARE, we can 
therefore hypothesize that TPD54 is an affeector by being a SNARE as well. 
We could test this by monitoring fusion of TPD54-positive liposomes in vitro. 
 
If TPD54 is indeed on the post-Golgi recycling pathway, this might explain 
why depletion of TPD54 slows migration and impairs invasion. Integrins are 
known to transit through the Golgi apparatus, but the way out to the plasma 
membrane after this is still unclear. We hypothesise that Rab14 and TPD54 
regulate this pathway, since we monitored a defect in integrin recycling, and 
found an interaction between TPD54 and integrin "1 by mass spectrometry. 
To confirm this hypothesis, we will assess the anterograde transport of GFP-
tagged VSVG (vesicular stomatitis virus G) particle. This will allow us to see 
if the particle is trafficked normally from the ER to the Golgi, and from the 
Golgi to the PM, in TPD54 KD cells. To assess transport on the retrograde 
pathway, we will use Shiga toxin, since it traffics from the PM to endosomes, 
endosomes to Golgi in a retromer-dependant manner, and Golgi to ER 
(Johannes and Roemer, 2010). 
In the future, we will need to understand the structure of TPD54 and the role 
of its interaction with TPD52 and TPD53. We have been able to confirm that 
TPD54 interacts with the two others, and we can hypothesise that the three 
main TPDs are perhaps part of a complex. Predicted models of the structure 
of TPD54 are available (see appendix 3), but a crystal structure would be very 
revealing. This would also allow us to better explore the sequence of TPD54 
in order to make mutants inhibiting the functions of the protein. 
This study has definitely allowed us to better understand the function of 
TPD54, by having more mechanistic insights into its cellular roles, and how 
this promotes cancer and lead to a poor prognosis. 
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Appendix 2 
 
 
Table A1: Mass spectrometry analysis results 
 
Protein name 
Short 
name 
p value 
TPD54/ 
GFP ratio 
Tumor protein D54 OS=Homo sapiens GN=TPD52L2 PE=1 SV=2 - [TPD54_HUMAN] TPD54 0.002350471 82.49002394 
Tumor protein D52 OS=Homo sapiens GN=TPD52 PE=1 SV=2 - [TPD52_HUMAN] TPD52 0.03936578 49.67704121 
Glycogen debranching enzyme OS=Homo sapiens GN=AGL PE=1 SV=3 - [GDE_HUMAN] GDE 1.10E-07 4.175101322 
Tumor protein D53 OS=Homo sapiens GN=TPD52L1 PE=1 SV=1 - [TPD53_HUMAN] TPD53 0.003949604 9.464534208 
Ras-related protein Rab-14 OS=Homo sapiens GN=RAB14 PE=1 SV=4 - [RAB14_HUMAN] RAB14 0.000511816 6.601834833 
Long-chain-fatty-acid--CoA ligase 3 OS=Homo sapiens GN=ACSL3 PE=1 SV=3 - [ACSL3_HUMAN] ACSL3 0.005496156 7.753670482 
Ras-related protein Rab-2A OS=Homo sapiens GN=RAB2A PE=1 SV=1 - [RAB2A_HUMAN] RAB2A 0.044824451 8.724958424 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 OS=Homo sapiens GN=GNB1 PE=1 
SV=3 - [GBB1_HUMAN] GBB1 0.011194352 4.421704646 
Bifunctional glutamate/proline--tRNA ligase OS=Homo sapiens GN=EPRS PE=1 SV=5 - 
[SYEP_HUMAN] SYEP 0.007917716 3.114887967 
Ras-related protein Rab-5C OS=Homo sapiens GN=RAB5C PE=1 SV=2 - [RAB5C_HUMAN] RAB5C 0.019812876 3.370600309 
Alkaline phosphatase, tissue-nonspecific isozyme OS=Homo sapiens GN=ALPL PE=1 SV=4 - 
[PPBT_HUMAN] PPBT 0.002567993 2.182413263 
40S ribosomal protein S4, X isoform OS=Homo sapiens GN=RPS4X PE=1 SV=2 - [RS4X_HUMAN] RS4X 0.033696804 3.784292736 
Ras GTPase-activating protein-binding protein 1 OS=Homo sapiens GN=G3BP1 PE=1 SV=1 - 
[G3BP1_HUMAN] G3BP1 0.025438899 3.422136539 
Desmoglein-2 OS=Homo sapiens GN=DSG2 PE=1 SV=2 - [DSG2_HUMAN] DSG2 0.015102814 2.842562495 
Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 - [H4_HUMAN] H4 0.012471654 2.464547853 
Prohibitin-2 OS=Homo sapiens GN=PHB2 PE=1 SV=2 - [PHB2_HUMAN] PHB2 0.033682968 3.03687628 
Ras-related protein Rab-7a OS=Homo sapiens GN=RAB7A PE=1 SV=1 - [RAB7A_HUMAN] RAB7A 0.013321094 2.362921029 
40S ribosomal protein S10 OS=Homo sapiens GN=RPS10 PE=1 SV=1 - [RS10_HUMAN] RS10 0.021373905 2.621979968 
Heterogeneous nuclear ribonucleoprotein H OS=Homo sapiens GN=HNRNPH1 PE=1 SV=4 - 
[HNRH1_HUMAN] HNRH1 0.016850408 2.445434717 
Membrane-associated progesterone receptor component 2 OS=Homo sapiens GN=PGRMC2 PE=1 
SV=1 - [PGRC2_HUMAN] PGRC2 0.03096462 2.762257982 
Polyadenylate-binding protein 1 OS=Homo sapiens GN=PABPC1 PE=1 SV=2 - [PABP1_HUMAN] PABP1 0.004484757 1.565630998 
26S proteasome non-ATPase regulatory subunit 11 OS=Homo sapiens GN=PSMD11 PE=1 SV=3 - 
[PSD11_HUMAN] PSD11 0.020622572 1.748408023 
14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1 SV=1 - [1433E_HUMAN] 1433E 0.027397923 1.825632693 
Neutral amino acid transporter B(0) OS=Homo sapiens GN=SLC1A5 PE=1 SV=2 - [AAAT_HUMAN] AAAT 0.026642947 1.779173127 
40S ribosomal protein S14 OS=Homo sapiens GN=RPS14 PE=1 SV=3 - [RS14_HUMAN] RS14 0.043950245 1.847696312 
Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 PE=1 SV=2 - [HSPB1_HUMAN] HSPB1 0.028732263 1.571890908 
Transitional endoplasmic reticulum ATPase OS=Homo sapiens GN=VCP PE=1 SV=4 - 
[TERA_HUMAN] TERA 0.02772511 1.442864052 
Plectin OS=Homo sapiens GN=PLEC PE=1 SV=3 - [PLEC_HUMAN] PLEC 0.25946775 26.15472778 
HLA class I histocompatibility antigen, B-8 alpha chain OS=Homo sapiens GN=HLA-B PE=1 SV=1 - 
[1B08_HUMAN] 1B08 0.1141289 12.07010258 
Nuclease-sensitive element-binding protein 1 OS=Homo sapiens GN=YBX1 PE=1 SV=3 - 
[YBOX1_HUMAN] YBOX1 0.055954635 8.417912 
Poly [ADP-ribose] polymerase 1 OS=Homo sapiens GN=PARP1 PE=1 SV=4 - [PARP1_HUMAN] PARP1 0.065113306 5.984487576 
Filamin-B OS=Homo sapiens GN=FLNB PE=1 SV=2 - [FLNB_HUMAN] FLNB 0.1021385 6.113356402 
Brain acid soluble protein 1 OS=Homo sapiens GN=BASP1 PE=1 SV=2 - [BASP1_HUMAN] BASP1 0.1672032 7.311548721 
Transferrin receptor protein 1 OS=Homo sapiens GN=TFRC PE=1 SV=2 - [TFR1_HUMAN] TFR1 0.061318159 3.700931791 
Cytoplasmic dynein 1 heavy chain 1 OS=Homo sapiens GN=DYNC1H1 PE=1 SV=5 - 
[DYHC1_HUMAN] DYHC1 0.17659879 5.795802399 
DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 SV=3 - 
[PRKDC_HUMAN] PRKDC 0.088848867 4.073574297 
Polypeptide N-acetylgalactosaminyltransferase 2 OS=Homo sapiens GN=GALNT2 PE=1 SV=1 - 
[GALT2_HUMAN] GALT2 0.078431308 3.74449666 
Keratin, type I cytoskeletal 13 OS=Homo sapiens GN=KRT13 PE=1 SV=4 - [K1C13_HUMAN] K1C13 0.16956718 4.862172906 
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Histone H2A.Z OS=Homo sapiens GN=H2AFZ PE=1 SV=2 - [H2AZ_HUMAN] H2AZ 0.19541398 5.187887248 
Keratin, type I cytoskeletal 19 OS=Homo sapiens GN=KRT19 PE=1 SV=4 - [K1C19_HUMAN] K1C19 0.24062382 5.845583475 
Poly [ADP-ribose] polymerase 14 OS=Homo sapiens GN=PARP14 PE=1 SV=3 - [PAR14_HUMAN] PAR14 0.19686858 5.09784888 
Aspartyl/asparaginyl beta-hydroxylase OS=Homo sapiens GN=ASPH PE=1 SV=3 - [ASPH_HUMAN] ASPH 0.18400952 4.691269854 
Insulin-like growth factor 2 mRNA-binding protein 3 OS=Homo sapiens GN=IGF2BP3 PE=1 SV=2 - 
[IF2B3_HUMAN] IF2B3 0.065951131 2.913660181 
Polyadenylate-binding protein 4 OS=Homo sapiens GN=PABPC4 PE=1 SV=1 - [PABP4_HUMAN] PABP4 0.19341166 4.750573774 
Splicing factor, proline- and glutamine-rich OS=Homo sapiens GN=SFPQ PE=1 SV=2 - 
[SFPQ_HUMAN] SFPQ 0.18264732 4.545313618 
Voltage-dependent anion-selective channel protein 1 OS=Homo sapiens GN=VDAC1 PE=1 SV=2 - 
[VDAC1_HUMAN] VDAC1 0.1636197 4.170168331 
Myoferlin OS=Homo sapiens GN=MYOF PE=1 SV=1 - [MYOF_HUMAN] MYOF 0.14887498 3.910550303 
40S ribosomal protein S8 OS=Homo sapiens GN=RPS8 PE=1 SV=2 - [RS8_HUMAN] RS8 0.076813474 2.888301234 
Tubulin beta-6 chain OS=Homo sapiens GN=TUBB6 PE=1 SV=1 - [TBB6_HUMAN] TBB6 0.19394292 4.346081482 
Vesicular integral-membrane protein VIP36 OS=Homo sapiens GN=LMAN2 PE=1 SV=1 - 
[LMAN2_HUMAN] LMAN2 0.069520503 2.574099676 
Integrin beta-1 OS=Homo sapiens GN=ITGB1 PE=1 SV=2 - [ITB1_HUMAN] ITB1 0.081756085 2.704716845 
40S ribosomal protein S3a OS=Homo sapiens GN=RPS3A PE=1 SV=2 - [RS3A_HUMAN] RS3A 0.079504572 2.599902303 
HLA class I histocompatibility antigen, A-69 alpha chain OS=Homo sapiens GN=HLA-A PE=1 SV=2 - 
[1A69_HUMAN] 1A69 0.39696652 7.104442458 
Signal recognition particle receptor subunit beta OS=Homo sapiens GN=SRPRB PE=1 SV=3 - 
[SRPRB_HUMAN] SRPRB 0.088498011 2.620210258 
60S ribosomal protein L23 OS=Homo sapiens GN=RPL23 PE=1 SV=1 - [RL23_HUMAN] RL23 0.093564942 2.598104484 
ATP synthase subunit O, mitochondrial OS=Homo sapiens GN=ATP5O PE=1 SV=1 - 
[ATPO_HUMAN] ATPO 0.065734923 2.261096805 
Erythrocyte band 7 integral membrane protein OS=Homo sapiens GN=STOM PE=1 SV=3 - 
[STOM_HUMAN] STOM 0.11031449 2.749562864 
60S ribosomal protein L18a OS=Homo sapiens GN=RPL18A PE=1 SV=2 - [RL18A_HUMAN] RL18A 0.054852035 2.076347087 
Keratin, type II cytoskeletal 8 OS=Homo sapiens GN=KRT8 PE=1 SV=7 - [K2C8_HUMAN] K2C8 0.11560359 2.780149752 
Histone H2A type 1-B/E OS=Homo sapiens GN=HIST1H2AB PE=1 SV=2 - [H2A1B_HUMAN] H2A1B 0.38810951 6.102757506 
HLA class I histocompatibility antigen, B-55 alpha chain OS=Homo sapiens GN=HLA-B PE=1 SV=1 - 
[1B55_HUMAN] 1B55 0.18853654 3.428412236 
Talin-1 OS=Homo sapiens GN=TLN1 PE=1 SV=3 - [TLN1_HUMAN] TLN1 0.14981109 3.008666782 
Cation-independent mannose-6-phosphate receptor OS=Homo sapiens GN=IGF2R PE=1 SV=3 - 
[MPRI_HUMAN] MPRI 0.14658721 2.947713797 
Extended synaptotagmin-1 OS=Homo sapiens GN=ESYT1 PE=1 SV=1 - [ESYT1_HUMAN] ESYT1 0.16446556 3.118307174 
Poly [ADP-ribose] polymerase 2 OS=Homo sapiens GN=PARP2 PE=1 SV=2 - [PARP2_HUMAN] PARP2 0.22163862 3.713459686 
DNA ligase 3 OS=Homo sapiens GN=LIG3 PE=1 SV=2 - [DNLI3_HUMAN] DNLI3 0.2448398 3.953697071 
Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 - [TKT_HUMAN] TKT 0.10105 2.424671102 
Beta-1,4-galactosyltransferase 1 OS=Homo sapiens GN=B4GALT1 PE=1 SV=5 - [B4GT1_HUMAN] B4GT1 0.16246757 3.046235093 
Guanine nucleotide-binding protein G(i) subunit alpha-2 OS=Homo sapiens GN=GNAI2 PE=1 SV=3 
- [GNAI2_HUMAN] GNAI2 0.12959205 2.690956841 
Tubulin alpha-1A chain OS=Homo sapiens GN=TUBA1A PE=1 SV=1 - [TBA1A_HUMAN] TBA1A 0.38980216 5.816118547 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 OS=Homo sapiens 
GN=RPN2 PE=1 SV=3 - [RPN2_HUMAN] RPN2 0.099675447 2.365084759 
Unconventional myosin-Ic OS=Homo sapiens GN=MYO1C PE=1 SV=4 - [MYO1C_HUMAN] MYO1C 0.23421551 3.695207881 
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 OS=Homo sapiens GN=PLOD1 PE=1 SV=2 - 
[PLOD1_HUMAN] PLOD1 0.13697949 2.593530586 
Heat shock protein 105 kDa OS=Homo sapiens GN=HSPH1 PE=1 SV=1 - [HS105_HUMAN] HS105 0.094613709 2.182140626 
Nuclear pore complex protein Nup155 OS=Homo sapiens GN=NUP155 PE=1 SV=1 - 
[NU155_HUMAN] NU155 0.18787965 2.996575556 
RNA-binding protein 14 OS=Homo sapiens GN=RBM14 PE=1 SV=2 - [RBM14_HUMAN] RBM14 0.23427267 3.403994285 
Multifunctional protein ADE2 OS=Homo sapiens GN=PAICS PE=1 SV=3 - [PUR6_HUMAN] PUR6 0.12459617 2.371814301 
60S ribosomal protein L7 OS=Homo sapiens GN=RPL7 PE=1 SV=1 - [RL7_HUMAN] RL7 0.097506054 2.092342723 
DNA ligase 4 OS=Homo sapiens GN=LIG4 PE=1 SV=2 - [DNLI4_HUMAN] DNLI4 0.1836274 2.842935502 
Leucine-rich PPR motif-containing protein, mitochondrial OS=Homo sapiens GN=LRPPRC PE=1 SV=3 
- [LPPRC_HUMAN] LPPRC 0.19923094 2.961814125 
Moesin OS=Homo sapiens GN=MSN PE=1 SV=3 - [MOES_HUMAN] MOES 0.10847267 2.12636027 
Ataxin-10 OS=Homo sapiens GN=ATXN10 PE=1 SV=1 - [ATX10_HUMAN] ATX10 0.18887103 2.825951291 
Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4 - [VIME_HUMAN] VIME 0.14055224 2.397165897 
ADP/ATP translocase 2 OS=Homo sapiens GN=SLC25A5 PE=1 SV=7 - [ADT2_HUMAN] ADT2 0.18112044 2.639372542 
Cytoplasmic dynein 1 intermediate chain 2 OS=Homo sapiens GN=DYNC1I2 PE=1 SV=3 - 
[DC1I2_HUMAN] DC1I2 0.14469066 2.331908482 
40S ribosomal protein S18 OS=Homo sapiens GN=RPS18 PE=1 SV=3 - [RS18_HUMAN] RS18 0.11440125 2.073138127 
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Eukaryotic translation initiation factor 3 subunit L OS=Homo sapiens GN=EIF3L PE=1 SV=1 - 
[EIF3L_HUMAN] EIF3L 0.15977046 2.450446989 
Lamina-associated polypeptide 2, isoform alpha OS=Homo sapiens GN=TMPO PE=1 SV=2 - 
[LAP2A_HUMAN] LAP2A 0.12638932 2.129748925 
Dolichol-phosphate mannosyltransferase subunit 1 OS=Homo sapiens GN=DPM1 PE=1 SV=1 - 
[DPM1_HUMAN] DPM1 0.17913562 2.561190657 
X-ray repair cross-complementing protein 6 OS=Homo sapiens GN=XRCC6 PE=1 SV=2 - 
[XRCC6_HUMAN] XRCC6 0.1739604 2.512990984 
Putative ATP-dependent RNA helicase DHX30 OS=Homo sapiens GN=DHX30 PE=1 SV=1 - 
[DHX30_HUMAN] DHX30 0.18428223 2.564897797 
Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 - [TBA1B_HUMAN] TBA1B 0.17285772 2.440874413 
Histone H2A type 2-C OS=Homo sapiens GN=HIST2H2AC PE=1 SV=4 - [H2A2C_HUMAN] H2A2C 0.40735894 4.75792145 
NADH-cytochrome b5 reductase 3 OS=Homo sapiens GN=CYB5R3 PE=1 SV=3 - [NB5R3_HUMAN] NB5R3 0.14771023 2.187484757 
Galectin-7 OS=Homo sapiens GN=LGALS7 PE=1 SV=2 - [LEG7_HUMAN] LEG7 0.15789968 2.250087713 
Voltage-dependent anion-selective channel protein 2 OS=Homo sapiens GN=VDAC2 PE=1 SV=2 - 
[VDAC2_HUMAN] VDAC2 0.15515476 2.228568125 
Non-homologous end-joining factor 1 OS=Homo sapiens GN=NHEJ1 PE=1 SV=1 - [NHEJ1_HUMAN] NHEJ1 0.15742458 2.240318416 
Cyclic GMP-AMP synthase OS=Homo sapiens GN=MB21D1 PE=1 SV=2 - [CGAS_HUMAN] CGAS 0.25774878 3.046655095 
Histone H2B type 1-K OS=Homo sapiens GN=HIST1H2BK PE=1 SV=3 - [H2B1K_HUMAN] H2B1K 0.17434146 2.355720948 
DNA repair protein XRCC4 OS=Homo sapiens GN=XRCC4 PE=1 SV=2 - [XRCC4_HUMAN] XRCC4 0.21448527 2.656043451 
Ras-related protein Rab-11B OS=Homo sapiens GN=RAB11B PE=1 SV=4 - [RB11B_HUMAN] RB11B 0.21321292 2.633028109 
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial OS=Homo sapiens 
GN=SDHA PE=1 SV=2 - [SDHA_HUMAN] SDHA 0.23869087 2.811142785 
Eukaryotic initiation factor 4A-I OS=Homo sapiens GN=EIF4A1 PE=1 SV=1 - [IF4A1_HUMAN] IF4A1 0.15247563 2.132269393 
Probable ATP-dependent RNA helicase DDX5 OS=Homo sapiens GN=DDX5 PE=1 SV=1 - 
[DDX5_HUMAN] DDX5 0.20728475 2.543949504 
Ras-related protein Rab-32 OS=Homo sapiens GN=RAB32 PE=1 SV=3 - [RAB32_HUMAN] RAB32 0.14919734 2.099028566 
Staphylococcal nuclease domain-containing protein 1 OS=Homo sapiens GN=SND1 PE=1 SV=1 - 
[SND1_HUMAN] SND1 0.18414062 2.356845868 
60S ribosomal protein L7a OS=Homo sapiens GN=RPL7A PE=1 SV=2 - [RL7A_HUMAN] RL7A 0.14125836 2.018134212 
FACT complex subunit SSRP1 OS=Homo sapiens GN=SSRP1 PE=1 SV=1 - [SSRP1_HUMAN] SSRP1 0.19616824 2.37960321 
Septin-2 OS=Homo sapiens GN=SEPT2 PE=1 SV=1 - [SEPT2_HUMAN] Sep-02 0.23852962 2.672729043 
Fragile X mental retardation syndrome-related protein 2 OS=Homo sapiens GN=FXR2 PE=1 SV=2 - 
[FXR2_HUMAN] FXR2 0.19217999 2.281476306 
Keratin, type II cytoskeletal 7 OS=Homo sapiens GN=KRT7 PE=1 SV=5 - [K2C7_HUMAN] K2C7 0.22421588 2.508872318 
Structural maintenance of chromosomes protein 4 OS=Homo sapiens GN=SMC4 PE=1 SV=2 - 
[SMC4_HUMAN] SMC4 0.22913145 2.50425846 
Ras-related protein Rab-1B OS=Homo sapiens GN=RAB1B PE=1 SV=1 - [RAB1B_HUMAN] RAB1B 0.17044061 2.083286134 
Replication protein A 70 kDa DNA-binding subunit OS=Homo sapiens GN=RPA1 PE=1 SV=2 - 
[RFA1_HUMAN] RFA1 0.23760839 2.528431096 
Zinc finger CCCH-type antiviral protein 1 OS=Homo sapiens GN=ZC3HAV1 PE=1 SV=3 - 
[ZCCHV_HUMAN] ZCCHV 0.18461563 2.149109899 
Matrin-3 OS=Homo sapiens GN=MATR3 PE=1 SV=2 - [MATR3_HUMAN] MATR3 0.17046715 2.036676007 
Polypyrimidine tract-binding protein 1 OS=Homo sapiens GN=PTBP1 PE=1 SV=1 - [PTBP1_HUMAN] PTBP1 0.21080521 2.308123727 
Bifunctional polynucleotide phosphatase/kinase OS=Homo sapiens GN=PNKP PE=1 SV=1 - 
[PNKP_HUMAN] PNKP 0.19775239 2.195299565 
LEM domain-containing protein 2 OS=Homo sapiens GN=LEMD2 PE=1 SV=1 - [LEMD2_HUMAN] LEMD2 0.22239576 2.342138884 
FACT complex subunit SPT16 OS=Homo sapiens GN=SUPT16H PE=1 SV=1 - [SP16H_HUMAN] SP16H 0.24544333 2.471438605 
CD44 antigen OS=Homo sapiens GN=CD44 PE=1 SV=3 - [CD44_HUMAN] CD44 0.23098099 2.358525366 
Poly [ADP-ribose] polymerase 9 OS=Homo sapiens GN=PARP9 PE=1 SV=2 - [PARP9_HUMAN] PARP9 0.29851848 2.850214236 
40S ribosomal protein S16 OS=Homo sapiens GN=RPS16 PE=1 SV=2 - [RS16_HUMAN] RS16 0.25497058 2.50122375 
Regulator of nonsense transcripts 1 OS=Homo sapiens GN=UPF1 PE=1 SV=2 - [RENT1_HUMAN] RENT1 0.22090638 2.23517389 
Keratin, type II cytoskeletal 3 OS=Homo sapiens GN=KRT3 PE=1 SV=3 - [K2C3_HUMAN] K2C3 0.39299169 3.576980673 
Transforming protein RhoA OS=Homo sapiens GN=RHOA PE=1 SV=1 - [RHOA_HUMAN] RHOA 0.19688652 2.054880024 
Non-POU domain-containing octamer-binding protein OS=Homo sapiens GN=NONO PE=1 SV=4 - 
[NONO_HUMAN] NONO 0.21491581 2.169691626 
Transcription intermediary factor 1-beta OS=Homo sapiens GN=TRIM28 PE=1 SV=5 - 
[TIF1B_HUMAN] TIF1B 0.2312476 2.215016554 
Inositol 1,4,5-trisphosphate receptor type 1 OS=Homo sapiens GN=ITPR1 PE=1 SV=3 - 
[ITPR1_HUMAN] ITPR1 0.25832596 2.379215809 
Importin-5 OS=Homo sapiens GN=IPO5 PE=1 SV=4 - [IPO5_HUMAN] IPO5 0.28307927 2.461291276 
Fragile X mental retardation syndrome-related protein 1 OS=Homo sapiens GN=FXR1 PE=1 SV=3 - 
[FXR1_HUMAN] FXR1 0.23490599 2.11544379 
SUN domain-containing protein 2 OS=Homo sapiens GN=SUN2 PE=1 SV=3 - [SUN2_HUMAN] SUN2 0.26255742 2.274192396 
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E3 ubiquitin-protein ligase DTX3L OS=Homo sapiens GN=DTX3L PE=1 SV=1 - [DTX3L_HUMAN] DTX3L 0.343575 2.833296889 
Insulin-like growth factor 2 mRNA-binding protein 1 OS=Homo sapiens GN=IGF2BP1 PE=1 SV=2 - 
[IF2B1_HUMAN] IF2B1 0.27352715 2.334237642 
CAD protein OS=Homo sapiens GN=CAD PE=1 SV=3 - [PYR1_HUMAN] PYR1 0.27306288 2.308519343 
ATP-dependent RNA helicase DDX3X OS=Homo sapiens GN=DDX3X PE=1 SV=3 - 
[DDX3X_HUMAN] DDX3X 0.2303322 2.007139056 
Plastin-3 OS=Homo sapiens GN=PLS3 PE=1 SV=4 - [PLST_HUMAN] PLST 0.28083777 2.297387851 
CD109 antigen OS=Homo sapiens GN=CD109 PE=1 SV=2 - [CD109_HUMAN] CD109 0.28111032 2.27685956 
Eukaryotic translation initiation factor 3 subunit A OS=Homo sapiens GN=EIF3A PE=1 SV=1 - 
[EIF3A_HUMAN] EIF3A 0.25509477 2.095531252 
Histone H2A type 1-A OS=Homo sapiens GN=HIST1H2AA PE=1 SV=3 - [H2A1A_HUMAN] H2A1A 0.37517393 2.83189971 
Ubiquitin-like modifier-activating enzyme 1 OS=Homo sapiens GN=UBA1 PE=1 SV=3 - 
[UBA1_HUMAN] UBA1 0.29258391 2.233742672 
Spectrin beta chain, non-erythrocytic 1 OS=Homo sapiens GN=SPTBN1 PE=1 SV=2 - 
[SPTB2_HUMAN] SPTB2 0.2727395 2.076621429 
Histone H3.3C OS=Homo sapiens GN=H3F3C PE=1 SV=3 - [H3C_HUMAN] H3C 0.27662194 2.096388775 
26S proteasome non-ATPase regulatory subunit 2 OS=Homo sapiens GN=PSMD2 PE=1 SV=3 - 
[PSMD2_HUMAN] PSMD2 0.29461092 2.131733619 
40S ribosomal protein S3 OS=Homo sapiens GN=RPS3 PE=1 SV=2 - [RS3_HUMAN] RS3 0.27514946 2.009751261 
Keratin, type II cytoskeletal 80 OS=Homo sapiens GN=KRT80 PE=1 SV=2 - [K2C80_HUMAN] K2C80 0.34663033 2.428337804 
Serine-threonine kinase receptor-associated protein OS=Homo sapiens GN=STRAP PE=1 SV=1 - 
[STRAP_HUMAN] STRAP 0.34889659 2.358988219 
Arginine--tRNA ligase, cytoplasmic OS=Homo sapiens GN=RARS PE=1 SV=2 - [SYRC_HUMAN] SYRC 0.38483357 2.557301634 
3-hydroxyacyl-CoA dehydrogenase type-2 OS=Homo sapiens GN=HSD17B10 PE=1 SV=3 - 
[HCD2_HUMAN] HCD2 0.32928371 2.183735519 
Ras-related protein Rab-1A OS=Homo sapiens GN=RAB1A PE=1 SV=3 - [RAB1A_HUMAN] RAB1A 0.36459032 2.395851961 
Keratin, type II cytoskeletal 78 OS=Homo sapiens GN=KRT78 PE=2 SV=2 - [K2C78_HUMAN] K2C78 0.36150655 2.254085907 
Neuroblast differentiation-associated protein AHNAK OS=Homo sapiens GN=AHNAK PE=1 SV=2 - 
[AHNK_HUMAN] AHNK 0.33166608 2.004544168 
Keratin, type II cuticular Hb4 OS=Homo sapiens GN=KRT84 PE=2 SV=2 - [KRT84_HUMAN] KRT84 0.40118995 2.380367531 
Histone H2AX OS=Homo sapiens GN=H2AFX PE=1 SV=2 - [H2AX_HUMAN] H2AX 0.37145334 2.124654816 
Epiplakin OS=Homo sapiens GN=EPPK1 PE=1 SV=2 - [EPIPL_HUMAN] EPIPL 0.38591927 2.197977371 
Stomatin-like protein 2, mitochondrial OS=Homo sapiens GN=STOML2 PE=1 SV=1 - 
[STML2_HUMAN] STML2 0.053044844 1.838392168 
Ras-related protein Rab-6A OS=Homo sapiens GN=RAB6A PE=1 SV=3 - [RAB6A_HUMAN] RAB6A 0.073765449 1.974714497 
Neutral alpha-glucosidase AB OS=Homo sapiens GN=GANAB PE=1 SV=3 - [GANAB_HUMAN] GANAB 0.082215674 1.842723471 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 OS=Homo sapiens 
GN=RPN1 PE=1 SV=1 - [RPN1_HUMAN] RPN1 0.099239729 1.987508464 
RuvB-like 1 OS=Homo sapiens GN=RUVBL1 PE=1 SV=1 - [RUVB1_HUMAN] RUVB1 0.11231224 1.952132695 
Stress-70 protein, mitochondrial OS=Homo sapiens GN=HSPA9 PE=1 SV=2 - [GRP75_HUMAN] GRP75 0.052581601 1.422412593 
Cell surface glycoprotein MUC18 OS=Homo sapiens GN=MCAM PE=1 SV=2 - [MUC18_HUMAN] MUC18 0.10686149 1.812943876 
Ras-related protein Rap-1b-like protein OS=Homo sapiens PE=2 SV=1 - [RP1BL_HUMAN] RP1BL 0.13050595 1.922200217 
Extended synaptotagmin-2 OS=Homo sapiens GN=ESYT2 PE=1 SV=1 - [ESYT2_HUMAN] ESYT2 0.11522271 1.776066235 
40S ribosomal protein S5 OS=Homo sapiens GN=RPS5 PE=1 SV=4 - [RS5_HUMAN] RS5 0.10152532 1.674739046 
Glycogen [starch] synthase, muscle OS=Homo sapiens GN=GYS1 PE=1 SV=2 - [GYS1_HUMAN] GYS1 0.13271855 1.855076489 
La-related protein 1 OS=Homo sapiens GN=LARP1 PE=1 SV=2 - [LARP1_HUMAN] LARP1 0.16587155 1.978397737 
Sodium/potassium-transporting ATPase subunit alpha-1 OS=Homo sapiens GN=ATP1A1 PE=1 SV=1 - 
[AT1A1_HUMAN] AT1A1 0.14374468 1.812926835 
Heterogeneous nuclear ribonucleoproteins C1/C2 OS=Homo sapiens GN=HNRNPC PE=1 SV=4 - 
[HNRPC_HUMAN] HNRPC 0.1107426 1.57807841 
Protein DEK OS=Homo sapiens GN=DEK PE=1 SV=1 - [DEK_HUMAN] DEK 0.16860195 1.940549549 
ATP-dependent RNA helicase DDX1 OS=Homo sapiens GN=DDX1 PE=1 SV=2 - [DDX1_HUMAN] DDX1 0.15908252 1.872398064 
60S ribosomal protein L13a OS=Homo sapiens GN=RPL13A PE=1 SV=2 - [RL13A_HUMAN] RL13A 0.12017693 1.595400989 
Calnexin OS=Homo sapiens GN=CANX PE=1 SV=2 - [CALX_HUMAN] CALX 0.16337121 1.864612646 
Nuclear fragile X mental retardation-interacting protein 2 OS=Homo sapiens GN=NUFIP2 PE=1 SV=1 
- [NUFP2_HUMAN] NUFP2 0.17211224 1.905697736 
Interleukin enhancer-binding factor 2 OS=Homo sapiens GN=ILF2 PE=1 SV=2 - [ILF2_HUMAN] ILF2 0.098022483 1.433488513 
Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 - [HSP7C_HUMAN] HSP7C 0.12512793 1.574343702 
Ubiquitin carboxyl-terminal hydrolase 5 OS=Homo sapiens GN=USP5 PE=1 SV=2 - [UBP5_HUMAN] UBP5 0.076771058 1.273948699 
60S acidic ribosomal protein P0 OS=Homo sapiens GN=RPLP0 PE=1 SV=1 - [RLA0_HUMAN] RLA0 0.11370493 1.487470747 
Calcium-binding mitochondrial carrier protein Aralar2 OS=Homo sapiens GN=SLC25A13 PE=1 SV=2 
- [CMC2_HUMAN] CMC2 0.18802901 1.914991385 
40S ribosomal protein S17-like OS=Homo sapiens GN=RPS17L PE=1 SV=1 - [RS17L_HUMAN] RS17L 0.1475994 1.665816023 
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Voltage-dependent anion-selective channel protein 3 OS=Homo sapiens GN=VDAC3 PE=1 SV=1 - 
[VDAC3_HUMAN] VDAC3 0.10105734 1.373965117 
Plasminogen activator inhibitor 1 RNA-binding protein OS=Homo sapiens GN=SERBP1 PE=1 SV=2 - 
[PAIRB_HUMAN] PAIRB 0.17954947 1.833604943 
Integrin alpha-V OS=Homo sapiens GN=ITGAV PE=1 SV=2 - [ITAV_HUMAN] ITAV 0.18619382 1.872687529 
26S proteasome non-ATPase regulatory subunit 5 OS=Homo sapiens GN=PSMD5 PE=1 SV=3 - 
[PSMD5_HUMAN] PSMD5 0.18760984 1.877568983 
Core histone macro-H2A.1 OS=Homo sapiens GN=H2AFY PE=1 SV=4 - [H2AY_HUMAN] H2AY 0.20594357 1.978593451 
60S ribosomal protein L3 OS=Homo sapiens GN=RPL3 PE=1 SV=2 - [RL3_HUMAN] RL3 0.18883133 1.858453076 
ATP synthase subunit beta, mitochondrial OS=Homo sapiens GN=ATP5B PE=1 SV=3 - 
[ATPB_HUMAN] ATPB 0.13043034 1.513570923 
Coatomer subunit alpha OS=Homo sapiens GN=COPA PE=1 SV=2 - [COPA_HUMAN] COPA 0.21122155 1.971830475 
Alkyldihydroxyacetonephosphate synthase, peroxisomal OS=Homo sapiens GN=AGPS PE=1 SV=1 - 
[ADAS_HUMAN] ADAS 0.085902445 1.229849201 
Signal transducer and activator of transcription 1-alpha/beta OS=Homo sapiens GN=STAT1 PE=1 SV=2 
- [STAT1_HUMAN] STAT1 0.19401388 1.838775709 
Replication protein A 32 kDa subunit OS=Homo sapiens GN=RPA2 PE=1 SV=1 - [RFA2_HUMAN] RFA2 0.18600518 1.791113175 
40S ribosomal protein S13 OS=Homo sapiens GN=RPS13 PE=1 SV=2 - [RS13_HUMAN] RS13 0.18409602 1.778555325 
ATP synthase subunit gamma, mitochondrial OS=Homo sapiens GN=ATP5C1 PE=1 SV=1 - 
[ATPG_HUMAN] ATPG 0.21382754 1.926239161 
60S ribosomal protein L14 OS=Homo sapiens GN=RPL14 PE=1 SV=4 - [RL14_HUMAN] RL14 0.14056642 1.50497021 
40S ribosomal protein S6 OS=Homo sapiens GN=RPS6 PE=1 SV=1 - [RS6_HUMAN] RS6 0.20828329 1.860927421 
ATP synthase subunit alpha, mitochondrial OS=Homo sapiens GN=ATP5A1 PE=1 SV=1 - 
[ATPA_HUMAN] ATPA 0.11126517 1.323526295 
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-12 OS=Homo sapiens 
GN=GNG12 PE=1 SV=3 - [GBG12_HUMAN] GBG12 0.19964318 1.793716289 
Eukaryotic translation initiation factor 2 subunit 3 OS=Homo sapiens GN=EIF2S3 PE=1 SV=3 - 
[IF2G_HUMAN] IF2G 0.18612757 1.706244074 
Eukaryotic translation initiation factor 4 gamma 1 OS=Homo sapiens GN=EIF4G1 PE=1 SV=4 - 
[IF4G1_HUMAN] IF4G1 0.19971734 1.774146821 
Ras-related protein Rab-3D OS=Homo sapiens GN=RAB3D PE=1 SV=1 - [RAB3D_HUMAN] RAB3D 0.22614209 1.914315023 
X-ray repair cross-complementing protein 5 OS=Homo sapiens GN=XRCC5 PE=1 SV=3 - 
[XRCC5_HUMAN] XRCC5 0.2103136 1.821306667 
Unconventional myosin-Ib OS=Homo sapiens GN=MYO1B PE=1 SV=3 - [MYO1B_HUMAN] MYO1B 0.18232757 1.66409835 
NAD(P) transhydrogenase, mitochondrial OS=Homo sapiens GN=NNT PE=1 SV=3 - 
[NNTM_HUMAN] NNTM 0.20132735 1.761389399 
CD59 glycoprotein OS=Homo sapiens GN=CD59 PE=1 SV=1 - [CD59_HUMAN] CD59 0.18718776 1.677144411 
Exportin-2 OS=Homo sapiens GN=CSE1L PE=1 SV=3 - [XPO2_HUMAN] XPO2 0.13390695 1.374556139 
Catechol O-methyltransferase OS=Homo sapiens GN=COMT PE=1 SV=2 - [COMT_HUMAN] COMT 0.24348064 1.938957446 
TAR DNA-binding protein 43 OS=Homo sapiens GN=TARDBP PE=1 SV=1 - [TADBP_HUMAN] TADBP 0.23776747 1.892216046 
Prolyl 3-hydroxylase 3 OS=Homo sapiens GN=LEPREL2 PE=1 SV=1 - [P3H3_HUMAN] P3H3 0.19906832 1.683777736 
Glycerol-3-phosphate dehydrogenase, mitochondrial OS=Homo sapiens GN=GPD2 PE=1 SV=3 - 
[GPDM_HUMAN] GPDM 0.23544073 1.865795997 
Ras GTPase-activating protein-binding protein 2 OS=Homo sapiens GN=G3BP2 PE=1 SV=2 - 
[G3BP2_HUMAN] G3BP2 0.23502921 1.861631575 
YTH domain-containing family protein 2 OS=Homo sapiens GN=YTHDF2 PE=1 SV=2 - 
[YTHD2_HUMAN] YTHD2 0.20056185 1.671121531 
78 kDa glucose-regulated protein OS=Homo sapiens GN=HSPA5 PE=1 SV=2 - [GRP78_HUMAN] GRP78 0.2257794 1.7976586 
Major vault protein OS=Homo sapiens GN=MVP PE=1 SV=4 - [MVP_HUMAN] MVP 0.20431888 1.667290741 
Constitutive coactivator of PPAR-gamma-like protein 1 OS=Homo sapiens GN=FAM120A PE=1 SV=2 
- [F120A_HUMAN] F120A 0.24922194 1.892209732 
Reticulon-4 OS=Homo sapiens GN=RTN4 PE=1 SV=2 - [RTN4_HUMAN] RTN4 0.18200113 1.509545944 
4F2 cell-surface antigen heavy chain OS=Homo sapiens GN=SLC3A2 PE=1 SV=3 - [4F2_HUMAN] 4F2 0.19812399 1.584926209 
Phosphoglycerate mutase 1 OS=Homo sapiens GN=PGAM1 PE=1 SV=2 - [PGAM1_HUMAN] PGAM1 0.1956342 1.540499693 
Inverted formin-2 OS=Homo sapiens GN=INF2 PE=1 SV=2 - [INF2_HUMAN] INF2 0.20710793 1.595510491 
Exportin-1 OS=Homo sapiens GN=XPO1 PE=1 SV=1 - [XPO1_HUMAN] XPO1 0.22497651 1.68024423 
60S ribosomal protein L5 OS=Homo sapiens GN=RPL5 PE=1 SV=3 - [RL5_HUMAN] RL5 0.27387699 1.932268519 
Putative helicase MOV-10 OS=Homo sapiens GN=MOV10 PE=1 SV=2 - [MOV10_HUMAN] MOV10 0.21280688 1.60095925 
Histone H2A type 1-H OS=Homo sapiens GN=HIST1H2AH PE=1 SV=3 - [H2A1H_HUMAN] H2A1H 0.26999778 1.883686865 
Cytosolic phospholipase A2 OS=Homo sapiens GN=PLA2G4A PE=1 SV=2 - [PA24A_HUMAN] PA24A 0.19501606 1.499129917 
Importin-7 OS=Homo sapiens GN=IPO7 PE=1 SV=1 - [IPO7_HUMAN] IPO7 0.29176247 1.983061334 
Protein disulfide-isomerase OS=Homo sapiens GN=P4HB PE=1 SV=3 - [PDIA1_HUMAN] PDIA1 0.18899794 1.463974123 
Histone H1t OS=Homo sapiens GN=HIST1H1T PE=2 SV=4 - [H1T_HUMAN] H1T 0.20508642 1.520172697 
Poly(rC)-binding protein 2 OS=Homo sapiens GN=PCBP2 PE=1 SV=1 - [PCBP2_HUMAN] PCBP2 0.24579896 1.711636691 
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Vesicle-associated membrane protein-associated protein B/C OS=Homo sapiens GN=VAPB PE=1 
SV=3 - [VAPB_HUMAN] VAPB 0.22079355 1.545708608 
40S ribosomal protein S15a OS=Homo sapiens GN=RPS15A PE=1 SV=2 - [RS15A_HUMAN] RS15A 0.27632308 1.809186363 
Adenylyl cyclase-associated protein 1 OS=Homo sapiens GN=CAP1 PE=1 SV=5 - [CAP1_HUMAN] CAP1 0.25814998 1.711266837 
Glypican-1 OS=Homo sapiens GN=GPC1 PE=1 SV=2 - [GPC1_HUMAN] GPC1 0.22656547 1.549936895 
Caprin-1 OS=Homo sapiens GN=CAPRIN1 PE=1 SV=2 - [CAPR1_HUMAN] CAPR1 0.2329018 1.578041607 
Sideroflexin-1 OS=Homo sapiens GN=SFXN1 PE=1 SV=4 - [SFXN1_HUMAN] SFXN1 0.28264982 1.818921425 
Ribosome-binding protein 1 OS=Homo sapiens GN=RRBP1 PE=1 SV=4 - [RRBP1_HUMAN] RRBP1 0.30706608 1.930093334 
F-box only protein 3 OS=Homo sapiens GN=FBXO3 PE=1 SV=3 - [FBX3_HUMAN] FBX3 0.27449262 1.761151614 
Leucine-rich repeat-containing protein 59 OS=Homo sapiens GN=LRRC59 PE=1 SV=1 - 
[LRC59_HUMAN] LRC59 0.29507738 1.811263655 
Vesicle-associated membrane protein 3 OS=Homo sapiens GN=VAMP3 PE=1 SV=3 - 
[VAMP3_HUMAN] VAMP3 0.25688794 1.601485195 
ATP-dependent RNA helicase A OS=Homo sapiens GN=DHX9 PE=1 SV=4 - [DHX9_HUMAN] DHX9 0.20030099 1.353544179 
Basigin OS=Homo sapiens GN=BSG PE=1 SV=2 - [BASI_HUMAN] BASI 0.31874436 1.896294126 
ATP synthase subunit g, mitochondrial OS=Homo sapiens GN=ATP5L PE=1 SV=3 - [ATP5L_HUMAN] ATP5L 0.14977287 1.141625568 
Putative RNA-binding protein Luc7-like 2 OS=Homo sapiens GN=LUC7L2 PE=1 SV=2 - 
[LC7L2_HUMAN] LC7L2 0.22524558 1.435991791 
60S ribosomal protein L34 OS=Homo sapiens GN=RPL34 PE=1 SV=3 - [RL34_HUMAN] RL34 0.16966331 1.202702154 
Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 - [NUCL_HUMAN] NUCL 0.21442354 1.379977192 
Chromodomain-helicase-DNA-binding protein 1-like OS=Homo sapiens GN=CHD1L PE=1 SV=2 - 
[CHD1L_HUMAN] CHD1L 0.32244527 1.867658854 
Ras-related protein Rab-18 OS=Homo sapiens GN=RAB18 PE=1 SV=1 - [RAB18_HUMAN] RAB18 0.17381731 1.207565766 
Transmembrane emp24 domain-containing protein 10 OS=Homo sapiens GN=TMED10 PE=1 SV=2 - 
[TMEDA_HUMAN] TMEDA 0.28179923 1.653243317 
Adenosylhomocysteinase OS=Homo sapiens GN=AHCY PE=1 SV=4 - [SAHH_HUMAN] SAHH 0.25297344 1.508388987 
Integrin alpha-6 OS=Homo sapiens GN=ITGA6 PE=1 SV=5 - [ITA6_HUMAN] ITA6 0.34726343 1.943199256 
Nodal modulator 3 OS=Homo sapiens GN=NOMO3 PE=2 SV=2 - [NOMO3_HUMAN] NOMO3 0.26104304 1.530151013 
Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - [ACTB_HUMAN] ACTB 0.23447536 1.412414694 
Prohibitin OS=Homo sapiens GN=PHB PE=1 SV=1 - [PHB_HUMAN] PHB 0.20359652 1.277437685 
60S ribosomal protein L6 OS=Homo sapiens GN=RPL6 PE=1 SV=3 - [RL6_HUMAN] RL6 0.29065472 1.630348438 
Integrin alpha-5 OS=Homo sapiens GN=ITGA5 PE=1 SV=2 - [ITA5_HUMAN] ITA5 0.26785669 1.528683975 
Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2 - [K1C17_HUMAN] K1C17 0.28784558 1.598512318 
Y-box-binding protein 3 OS=Homo sapiens GN=YBX3 PE=1 SV=4 - [YBOX3_HUMAN] YBOX3 0.34640828 1.872216321 
Interferon-induced 35 kDa protein OS=Homo sapiens GN=IFI35 PE=1 SV=5 - [IN35_HUMAN] IN35 0.35275403 1.893373995 
Probable ATP-dependent RNA helicase DDX17 OS=Homo sapiens GN=DDX17 PE=1 SV=2 - 
[DDX17_HUMAN] DDX17 0.33844978 1.817760759 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1 OS=Homo sapiens 
GN=DAD1 PE=1 SV=3 - [DAD1_HUMAN] DAD1 0.26474008 1.451709 
Lamin-B1 OS=Homo sapiens GN=LMNB1 PE=1 SV=2 - [LMNB1_HUMAN] LMNB1 0.33248031 1.750707724 
Programmed cell death protein 6 OS=Homo sapiens GN=PDCD6 PE=1 SV=1 - [PDCD6_HUMAN] PDCD6 0.26656157 1.455901214 
Protein-glutamine gamma-glutamyltransferase E OS=Homo sapiens GN=TGM3 PE=1 SV=4 - 
[TGM3_HUMAN] TGM3 0.34885338 1.823067584 
Far upstream element-binding protein 2 OS=Homo sapiens GN=KHSRP PE=1 SV=4 - 
[FUBP2_HUMAN] FUBP2 0.30905116 1.622116249 
60S ribosomal protein L26 OS=Homo sapiens GN=RPL26 PE=1 SV=1 - [RL26_HUMAN] RL26 0.1960796 1.158175096 
Heat shock 70 kDa protein 4L OS=Homo sapiens GN=HSPA4L PE=1 SV=3 - [HS74L_HUMAN] HS74L 0.31450826 1.627163917 
Histone-binding protein RBBP4 OS=Homo sapiens GN=RBBP4 PE=1 SV=3 - [RBBP4_HUMAN] RBBP4 0.28347674 1.48811402 
T-complex protein 1 subunit eta OS=Homo sapiens GN=CCT7 PE=1 SV=2 - [TCPH_HUMAN] TCPH 0.24502735 1.333169697 
Fragile X mental retardation protein 1 OS=Homo sapiens GN=FMR1 PE=1 SV=1 - [FMR1_HUMAN] FMR1 0.35374239 1.791778393 
Dihydrolipoyl dehydrogenase, mitochondrial OS=Homo sapiens GN=DLD PE=1 SV=2 - 
[DLDH_HUMAN] DLDH 0.32233933 1.638952918 
Threonine--tRNA ligase, cytoplasmic OS=Homo sapiens GN=TARS PE=1 SV=3 - [SYTC_HUMAN] SYTC 0.33285567 1.678965871 
Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens GN=HNRNPU PE=1 SV=6 - 
[HNRPU_HUMAN] HNRPU 0.35369116 1.774953703 
60S ribosomal protein L4 OS=Homo sapiens GN=RPL4 PE=1 SV=5 - [RL4_HUMAN] RL4 0.32141918 1.613564465 
Surfeit locus protein 4 OS=Homo sapiens GN=SURF4 PE=1 SV=3 - [SURF4_HUMAN] SURF4 0.28882694 1.471864257 
Ras-related protein Rab-8A OS=Homo sapiens GN=RAB8A PE=1 SV=1 - [RAB8A_HUMAN] RAB8A 0.27933252 1.427756766 
Proteasome activator complex subunit 2 OS=Homo sapiens GN=PSME2 PE=1 SV=4 - 
[PSME2_HUMAN] PSME2 0.34178808 1.687139986 
Nuclear mitotic apparatus protein 1 OS=Homo sapiens GN=NUMA1 PE=1 SV=2 - 
[NUMA1_HUMAN] NUMA1 0.31525931 1.561664072 
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial OS=Homo sapiens GN=ACADVL 
PE=1 SV=1 - [ACADV_HUMAN] ACADV 0.3577764 1.743511618 
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RuvB-like 2 OS=Homo sapiens GN=RUVBL2 PE=1 SV=3 - [RUVB2_HUMAN] RUVB2 0.30422348 1.505173757 
Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 1 OS=Homo sapiens GN=GFPT1 
PE=1 SV=3 - [GFPT1_HUMAN] GFPT1 0.30292016 1.49150097 
60S ribosomal protein L15 OS=Homo sapiens GN=RPL15 PE=1 SV=2 - [RL15_HUMAN] RL15 0.26528853 1.339762402 
Proteolipid protein 2 OS=Homo sapiens GN=PLP2 PE=1 SV=1 - [PLP2_HUMAN] PLP2 0.31502661 1.519524023 
Importin subunit beta-1 OS=Homo sapiens GN=KPNB1 PE=1 SV=2 - [IMB1_HUMAN] IMB1 0.32649279 1.553649583 
Prenylcysteine oxidase 1 OS=Homo sapiens GN=PCYOX1 PE=1 SV=3 - [PCYOX_HUMAN] PCYOX 0.36520752 1.726209866 
Trifunctional enzyme subunit beta, mitochondrial OS=Homo sapiens GN=HADHB PE=1 SV=3 - 
[ECHB_HUMAN] ECHB 0.28889942 1.393326505 
Heat shock 70 kDa protein 1A/1B OS=Homo sapiens GN=HSPA1A PE=1 SV=5 - [HSP71_HUMAN] HSP71 0.28462824 1.376258325 
Golgi-associated plant pathogenesis-related protein 1 OS=Homo sapiens GN=GLIPR2 PE=1 SV=3 - 
[GAPR1_HUMAN] GAPR1 0.32701349 1.545735181 
T-cell surface glycoprotein CD8 alpha chain OS=Homo sapiens GN=CD8A PE=1 SV=1 - 
[CD8A_HUMAN] CD8A 0.25629026 1.264925815 
Importin subunit alpha-1 OS=Homo sapiens GN=KPNA2 PE=1 SV=1 - [IMA1_HUMAN] IMA1 0.4109574 1.934064613 
2'-5'-oligoadenylate synthase-like protein OS=Homo sapiens GN=OASL PE=1 SV=2 - 
[OASL_HUMAN] OASL 0.25579861 1.260481661 
V-type proton ATPase catalytic subunit A OS=Homo sapiens GN=ATP6V1A PE=1 SV=2 - 
[VATA_HUMAN] VATA 0.29824966 1.408628372 
Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 - [FLNA_HUMAN] FLNA 0.33482367 1.554232937 
Keratin, type II cuticular Hb2 OS=Homo sapiens GN=KRT82 PE=1 SV=3 - [KRT82_HUMAN] KRT82 0.43559697 1.995296589 
Aldehyde dehydrogenase X, mitochondrial OS=Homo sapiens GN=ALDH1B1 PE=1 SV=3 - 
[AL1B1_HUMAN] AL1B1 0.32441193 1.465738772 
Peroxiredoxin-4 OS=Homo sapiens GN=PRDX4 PE=1 SV=1 - [PRDX4_HUMAN] PRDX4 0.30900571 1.3944815 
Ras-related protein Rab-11A OS=Homo sapiens GN=RAB11A PE=1 SV=3 - [RB11A_HUMAN] RB11A 0.36730435 1.623831415 
Mitochondrial 2-oxoglutarate/malate carrier protein OS=Homo sapiens GN=SLC25A11 PE=1 SV=3 - 
[M2OM_HUMAN] M2OM 0.35808641 1.583250084 
Histone H1.2 OS=Homo sapiens GN=HIST1H1C PE=1 SV=2 - [H12_HUMAN] H12 0.38007575 1.672402686 
Werner syndrome ATP-dependent helicase OS=Homo sapiens GN=WRN PE=1 SV=2 - 
[WRN_HUMAN] WRN 0.34668425 1.521981801 
Ras-related protein Rab-34 OS=Homo sapiens GN=RAB34 PE=1 SV=1 - [RAB34_HUMAN] RAB34 0.3725765 1.629081797 
26S protease regulatory subunit 6A OS=Homo sapiens GN=PSMC3 PE=1 SV=3 - [PRS6A_HUMAN] PRS6A 0.30481961 1.346546479 
Uncharacterized protein C9orf142 OS=Homo sapiens GN=C9orf142 PE=1 SV=2 - [CI142_HUMAN] CI142 0.34549183 1.504387684 
26S protease regulatory subunit 7 OS=Homo sapiens GN=PSMC2 PE=1 SV=3 - [PRS7_HUMAN] PRS7 0.32604426 1.426116581 
Apoptosis-inducing factor 1, mitochondrial OS=Homo sapiens GN=AIFM1 PE=1 SV=1 - 
[AIFM1_HUMAN] AIFM1 0.31967157 1.392802915 
GTP-binding protein SAR1a OS=Homo sapiens GN=SAR1A PE=1 SV=1 - [SAR1A_HUMAN] SAR1A 0.28651482 1.270474693 
Catenin alpha-1 OS=Homo sapiens GN=CTNNA1 PE=1 SV=1 - [CTNA1_HUMAN] CTNA1 0.32149497 1.385570404 
Ras-related protein Rab-21 OS=Homo sapiens GN=RAB21 PE=1 SV=3 - [RAB21_HUMAN] RAB21 0.41240153 1.769031771 
GTPase NRas OS=Homo sapiens GN=NRAS PE=1 SV=1 - [RASN_HUMAN] RASN 0.37499738 1.57905874 
Alpha-centractin OS=Homo sapiens GN=ACTR1A PE=1 SV=1 - [ACTZ_HUMAN] ACTZ 0.36680722 1.537658211 
Heat shock 70 kDa protein 4 OS=Homo sapiens GN=HSPA4 PE=1 SV=4 - [HSP74_HUMAN] HSP74 0.38595843 1.604565531 
Protein LYRIC OS=Homo sapiens GN=MTDH PE=1 SV=2 - [LYRIC_HUMAN] LYRIC 0.35492986 1.472629737 
Trifunctional purine biosynthetic protein adenosine-3 OS=Homo sapiens GN=GART PE=1 SV=1 - 
[PUR2_HUMAN] PUR2 0.42481598 1.778862572 
NADPH--cytochrome P450 reductase OS=Homo sapiens GN=POR PE=1 SV=2 - [NCPR_HUMAN] NCPR 0.39212397 1.621765623 
Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - [K2C5_HUMAN] K2C5 0.13349271 0.752727242 
DnaJ homolog subfamily C member 10 OS=Homo sapiens GN=DNAJC10 PE=1 SV=2 - 
[DJC10_HUMAN] DJC10 0.34391943 1.414984511 
60S ribosomal protein L13 OS=Homo sapiens GN=RPL13 PE=1 SV=4 - [RL13_HUMAN] RL13 0.43253684 1.800153146 
DNA repair protein XRCC1 OS=Homo sapiens GN=XRCC1 PE=1 SV=2 - [XRCC1_HUMAN] XRCC1 0.32530284 1.330506116 
Pyruvate kinase PKM OS=Homo sapiens GN=PKM PE=1 SV=4 - [KPYM_HUMAN] KPYM 0.33794832 1.370226957 
Ras-related C3 botulinum toxin substrate 2 OS=Homo sapiens GN=RAC2 PE=1 SV=1 - 
[RAC2_HUMAN] RAC2 0.31363982 1.28038519 
Lysosome-associated membrane glycoprotein 2 OS=Homo sapiens GN=LAMP2 PE=1 SV=2 - 
[LAMP2_HUMAN] LAMP2 0.35193005 1.419405831 
Lysosome-associated membrane glycoprotein 1 OS=Homo sapiens GN=LAMP1 PE=1 SV=3 - 
[LAMP1_HUMAN] LAMP1 0.34107977 1.377021807 
F-actin-capping protein subunit alpha-2 OS=Homo sapiens GN=CAPZA2 PE=1 SV=3 - 
[CAZA2_HUMAN] CAZA2 0.37689394 1.516186416 
AP-1 complex subunit beta-1 OS=Homo sapiens GN=AP1B1 PE=1 SV=2 - [AP1B1_HUMAN] AP1B1 0.39788201 1.604237577 
6-phosphofructokinase type C OS=Homo sapiens GN=PFKP PE=1 SV=2 - [K6PP_HUMAN] K6PP 0.42650416 1.729451276 
40S ribosomal protein S9 OS=Homo sapiens GN=RPS9 PE=1 SV=3 - [RS9_HUMAN] RS9 0.2790218 1.153108768 
Importin-9 OS=Homo sapiens GN=IPO9 PE=1 SV=3 - [IPO9_HUMAN] IPO9 0.32640061 1.31124865 
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Coatomer subunit gamma-1 OS=Homo sapiens GN=COPG1 PE=1 SV=1 - [COPG1_HUMAN] COPG1 0.42210069 1.701956187 
Podocalyxin OS=Homo sapiens GN=PODXL PE=1 SV=2 - [PODXL_HUMAN] PODXL 0.28949472 1.182913354 
Ras GTPase-activating-like protein IQGAP1 OS=Homo sapiens GN=IQGAP1 PE=1 SV=1 - 
[IQGA1_HUMAN] IQGA1 0.41525286 1.663126807 
Keratin, type II cytoskeletal 1b OS=Homo sapiens GN=KRT77 PE=2 SV=3 - [K2C1B_HUMAN] K2C1B 0.35673195 1.413005791 
F-box only protein 50 OS=Homo sapiens GN=NCCRP1 PE=1 SV=1 - [FBX50_HUMAN] FBX50 0.34565872 1.368767857 
60S ribosomal protein L22 OS=Homo sapiens GN=RPL22 PE=1 SV=2 - [RL22_HUMAN] RL22 0.32669002 1.299402802 
Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 - 
[G3P_HUMAN] G3P 0.38949522 1.53652297 
Calponin-2 OS=Homo sapiens GN=CNN2 PE=1 SV=4 - [CNN2_HUMAN] CNN2 0.35988316 1.417516636 
Signal recognition particle subunit SRP68 OS=Homo sapiens GN=SRP68 PE=1 SV=2 - 
[SRP68_HUMAN] SRP68 0.33860081 1.319454862 
Desmocollin-1 OS=Homo sapiens GN=DSC1 PE=1 SV=2 - [DSC1_HUMAN] DSC1 0.369571 1.416788801 
Lipase maturation factor 2 OS=Homo sapiens GN=LMF2 PE=1 SV=2 - [LMF2_HUMAN] LMF2 0.38682738 1.483043354 
Protein ERGIC-53 OS=Homo sapiens GN=LMAN1 PE=1 SV=2 - [LMAN1_HUMAN] LMAN1 0.35543847 1.355816827 
Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 - [ENOA_HUMAN] ENOA 0.38798308 1.464578119 
Ketosamine-3-kinase OS=Homo sapiens GN=FN3KRP PE=1 SV=2 - [KT3K_HUMAN] KT3K 0.36977413 1.393218637 
Cytoskeleton-associated protein 4 OS=Homo sapiens GN=CKAP4 PE=1 SV=2 - [CKAP4_HUMAN] CKAP4 0.44775572 1.717304652 
Thrombospondin-1 OS=Homo sapiens GN=THBS1 PE=1 SV=2 - [TSP1_HUMAN] TSP1 0.44380587 1.677996026 
T-complex protein 1 subunit delta OS=Homo sapiens GN=CCT4 PE=1 SV=4 - [TCPD_HUMAN] TCPD 0.36125216 1.325294909 
Annexin A11 OS=Homo sapiens GN=ANXA11 PE=1 SV=1 - [ANX11_HUMAN] ANX11 0.36752227 1.346405813 
Transgelin-2 OS=Homo sapiens GN=TAGLN2 PE=1 SV=3 - [TAGL2_HUMAN] TAGL2 0.39746037 1.454265233 
Translocon-associated protein subunit alpha OS=Homo sapiens GN=SSR1 PE=1 SV=3 - 
[SSRA_HUMAN] SSRA 0.38731906 1.40854017 
Fatty acid synthase OS=Homo sapiens GN=FASN PE=1 SV=3 - [FAS_HUMAN] FAS 0.45307195 1.684894605 
Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - [K1C14_HUMAN] K1C14 0.12310317 0.619400214 
Glutathione reductase, mitochondrial OS=Homo sapiens GN=GSR PE=1 SV=2 - [GSHR_HUMAN] GSHR 0.41169187 1.455207217 
CD97 antigen OS=Homo sapiens GN=CD97 PE=1 SV=4 - [CD97_HUMAN] CD97 0.39592567 1.38922594 
Glycogen phosphorylase, liver form OS=Homo sapiens GN=PYGL PE=1 SV=4 - [PYGL_HUMAN] PYGL 0.40311155 1.414981231 
40S ribosomal protein S19 OS=Homo sapiens GN=RPS19 PE=1 SV=2 - [RS19_HUMAN] RS19 0.41405872 1.435811634 
Plakophilin-1 OS=Homo sapiens GN=PKP1 PE=1 SV=2 - [PKP1_HUMAN] PKP1 0.37498802 1.290345442 
Proteasome activator complex subunit 3 OS=Homo sapiens GN=PSME3 PE=1 SV=1 - 
[PSME3_HUMAN] PSME3 0.41495726 1.429637724 
Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens GN=HNRNPA2B1 PE=1 SV=2 - 
[ROA2_HUMAN] ROA2 0.25703233 0.925334368 
Heterogeneous nuclear ribonucleoprotein K OS=Homo sapiens GN=HNRNPK PE=1 SV=1 - 
[HNRPK_HUMAN] HNRPK 0.44733408 1.547548637 
Trifunctional enzyme subunit alpha, mitochondrial OS=Homo sapiens GN=HADHA PE=1 SV=2 - 
[ECHA_HUMAN] ECHA 0.46254167 1.610428474 
Splicing factor 3B subunit 3 OS=Homo sapiens GN=SF3B3 PE=1 SV=4 - [SF3B3_HUMAN] SF3B3 0.40256545 1.358930626 
Structural maintenance of chromosomes protein 2 OS=Homo sapiens GN=SMC2 PE=1 SV=2 - 
[SMC2_HUMAN] SMC2 0.41226387 1.392690384 
Ubiquitin carboxyl-terminal hydrolase 10 OS=Homo sapiens GN=USP10 PE=1 SV=2 - 
[UBP10_HUMAN] UBP10 0.37808326 1.264795219 
Fructosamine-3-kinase OS=Homo sapiens GN=FN3K PE=1 SV=1 - [FN3K_HUMAN] FN3K 0.43861446 1.488461486 
AP-2 complex subunit beta OS=Homo sapiens GN=AP2B1 PE=1 SV=1 - [AP2B1_HUMAN] AP2B1 0.40338033 1.349584887 
Glyoxylate reductase/hydroxypyruvate reductase OS=Homo sapiens GN=GRHPR PE=1 SV=1 - 
[GRHPR_HUMAN] GRHPR 0.41818383 1.399105865 
Homeobox protein cut-like 1 OS=Homo sapiens GN=CUX1 PE=1 SV=3 - [CUX1_HUMAN] CUX1 0.38347408 1.265352525 
Vesicle-fusing ATPase OS=Homo sapiens GN=NSF PE=1 SV=3 - [NSF_HUMAN] NSF 0.3930468 1.293667113 
6-phosphogluconate dehydrogenase, decarboxylating OS=Homo sapiens GN=PGD PE=1 SV=3 - 
[6PGD_HUMAN] 6PGD 0.42208573 1.399326443 
Catenin beta-1 OS=Homo sapiens GN=CTNNB1 PE=1 SV=1 - [CTNB1_HUMAN] CTNB1 0.38514623 1.262178419 
Carbamoyl-phosphate synthase [ammonia], mitochondrial OS=Homo sapiens GN=CPS1 PE=1 SV=2 - 
[CPSM_HUMAN] CPSM 0.48006102 1.638219649 
T-complex protein 1 subunit gamma OS=Homo sapiens GN=CCT3 PE=1 SV=4 - [TCPG_HUMAN] TCPG 0.4627831 1.558857881 
Mitochondrial import inner membrane translocase subunit TIM50 OS=Homo sapiens GN=TIMM50 
PE=1 SV=2 - [TIM50_HUMAN] TIM50 0.41352266 1.35970998 
Sulfide:quinone oxidoreductase, mitochondrial OS=Homo sapiens GN=SQRDL PE=1 SV=1 - 
[SQRD_HUMAN] SQRD 0.42733926 1.406529914 
Heterogeneous nuclear ribonucleoprotein M OS=Homo sapiens GN=HNRNPM PE=1 SV=3 - 
[HNRPM_HUMAN] HNRPM 0.44794062 1.473718572 
Polyubiquitin-C OS=Homo sapiens GN=UBC PE=1 SV=3 - [UBC_HUMAN] UBC 0.21680966 0.767788446 
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Up-regulated during skeletal muscle growth protein 5 OS=Homo sapiens GN=USMG5 PE=1 SV=1 - 
[USMG5_HUMAN] USMG5 0.40765536 1.307829206 
Glutamine--tRNA ligase OS=Homo sapiens GN=QARS PE=1 SV=1 - [SYQ_HUMAN] SYQ 0.42831463 1.38094697 
Proteasome subunit alpha type-2 OS=Homo sapiens GN=PSMA2 PE=1 SV=2 - [PSA2_HUMAN] PSA2 0.28042156 0.919069937 
Protein LSM12 homolog OS=Homo sapiens GN=LSM12 PE=1 SV=2 - [LSM12_HUMAN] LSM12 0.4261328 1.358590375 
Barrier-to-autointegration factor OS=Homo sapiens GN=BANF1 PE=1 SV=1 - [BAF_HUMAN] BAF 0.43948075 1.409171901 
Zinc transporter ZIP14 OS=Homo sapiens GN=SLC39A14 PE=1 SV=3 - [S39AE_HUMAN] S39AE 0.3979488 1.25257645 
Lamina-associated polypeptide 2, isoforms beta/gamma OS=Homo sapiens GN=TMPO PE=1 SV=2 - 
[LAP2B_HUMAN] LAP2B 0.50693744 1.679944591 
Eukaryotic translation initiation factor 3 subunit C OS=Homo sapiens GN=EIF3C PE=1 SV=1 - 
[EIF3C_HUMAN] EIF3C 0.42954728 1.34780372 
Prolactin-inducible protein OS=Homo sapiens GN=PIP PE=1 SV=1 - [PIP_HUMAN] PIP 0.39717293 1.228654859 
Condensin complex subunit 3 OS=Homo sapiens GN=NCAPG PE=1 SV=1 - [CND3_HUMAN] CND3 0.42016375 1.296561257 
60S ribosomal protein L10a OS=Homo sapiens GN=RPL10A PE=1 SV=2 - [RL10A_HUMAN] RL10A 0.4458434 1.384562239 
Protein-glutamine gamma-glutamyltransferase K OS=Homo sapiens GN=TGM1 PE=1 SV=4 - 
[TGM1_HUMAN] TGM1 0.42936277 1.309496488 
Probable ATP-dependent RNA helicase DHX36 OS=Homo sapiens GN=DHX36 PE=1 SV=2 - 
[DHX36_HUMAN] DHX36 0.39148971 1.177170597 
Peroxisomal multifunctional enzyme type 2 OS=Homo sapiens GN=HSD17B4 PE=1 SV=3 - 
[DHB4_HUMAN] DHB4 0.45401996 1.391206972 
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform OS=Homo 
sapiens GN=PPP2R1A PE=1 SV=4 - [2AAA_HUMAN] 2AAA 0.46769539 1.444083136 
Cation-dependent mannose-6-phosphate receptor OS=Homo sapiens GN=M6PR PE=1 SV=1 - 
[MPRD_HUMAN] MPRD 0.42741072 1.283307314 
40S ribosomal protein S11 OS=Homo sapiens GN=RPS11 PE=1 SV=3 - [RS11_HUMAN] RS11 0.46316907 1.410350948 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit OS=Homo sapiens 
GN=DDOST PE=1 SV=4 - [OST48_HUMAN] OST48 0.47119415 1.41214611 
Protein DJ-1 OS=Homo sapiens GN=PARK7 PE=1 SV=2 - [PARK7_HUMAN] PARK7 0.44987056 1.308557944 
Heterogeneous nuclear ribonucleoprotein F OS=Homo sapiens GN=HNRNPF PE=1 SV=3 - 
[HNRPF_HUMAN] HNRPF 0.49009946 1.447388034 
Peroxiredoxin-6 OS=Homo sapiens GN=PRDX6 PE=1 SV=3 - [PRDX6_HUMAN] PRDX6 0.47122976 1.371403374 
Myosin-9 OS=Homo sapiens GN=MYH9 PE=1 SV=4 - [MYH9_HUMAN] MYH9 0.4401682 1.25084526 
26S protease regulatory subunit 8 OS=Homo sapiens GN=PSMC5 PE=1 SV=1 - [PRS8_HUMAN] PRS8 0.23221841 0.7018951 
Thyroid hormone receptor-associated protein 3 OS=Homo sapiens GN=THRAP3 PE=1 SV=2 - 
[TR150_HUMAN] TR150 0.41714132 1.16671338 
Cytochrome b-c1 complex subunit 2, mitochondrial OS=Homo sapiens GN=UQCRC2 PE=1 SV=3 - 
[QCR2_HUMAN] QCR2 0.42378002 1.179882774 
Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 - [CLUS_HUMAN] CLUS 0.42993158 1.199179256 
Spectrin alpha chain, non-erythrocytic 1 OS=Homo sapiens GN=SPTAN1 PE=1 SV=3 - 
[SPTN1_HUMAN] SPTN1 0.45037141 1.264075582 
60S ribosomal protein L8 OS=Homo sapiens GN=RPL8 PE=1 SV=2 - [RL8_HUMAN] RL8 0.45113358 1.235375696 
Torsin-1A-interacting protein 1 OS=Homo sapiens GN=TOR1AIP1 PE=1 SV=2 - [TOIP1_HUMAN] TOIP1 0.44951752 1.215413208 
Elongation factor 1-delta OS=Homo sapiens GN=EEF1D PE=1 SV=5 - [EF1D_HUMAN] EF1D 0.1828329 0.571492578 
Keratin, type I cytoskeletal 18 OS=Homo sapiens GN=KRT18 PE=1 SV=2 - [K1C18_HUMAN] K1C18 0.54809231 1.614717483 
DnaJ homolog subfamily A member 1 OS=Homo sapiens GN=DNAJA1 PE=1 SV=2 - 
[DNJA1_HUMAN] DNJA1 0.49338579 1.372333226 
Translocon-associated protein subunit delta OS=Homo sapiens GN=SSR4 PE=1 SV=1 - 
[SSRD_HUMAN] SSRD 0.42890653 1.143427527 
Leucine--tRNA ligase, cytoplasmic OS=Homo sapiens GN=LARS PE=1 SV=2 - [SYLC_HUMAN] SYLC 0.49837571 1.380559742 
Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - [K1C16_HUMAN] K1C16 0.091345742 0.39576671 
Protein disulfide-isomerase A3 OS=Homo sapiens GN=PDIA3 PE=1 SV=4 - [PDIA3_HUMAN] PDIA3 0.48780733 1.305846269 
Transaldolase OS=Homo sapiens GN=TALDO1 PE=1 SV=2 - [TALDO_HUMAN] TALDO 0.34282738 0.860028826 
Heterogeneous nuclear ribonucleoprotein Q OS=Homo sapiens GN=SYNCRIP PE=1 SV=2 - 
[HNRPQ_HUMAN] HNRPQ 0.4830513 1.256899936 
Phosphoglycerate mutase 2 OS=Homo sapiens GN=PGAM2 PE=1 SV=3 - [PGAM2_HUMAN] PGAM2 0.37023798 0.916039625 
Kinectin OS=Homo sapiens GN=KTN1 PE=1 SV=1 - [KTN1_HUMAN] KTN1 0.46038547 1.164067366 
Ras-related protein Rap-1b OS=Homo sapiens GN=RAP1B PE=1 SV=1 - [RAP1B_HUMAN] RAP1B 0.55255073 1.508042925 
26S protease regulatory subunit 10B OS=Homo sapiens GN=PSMC6 PE=1 SV=1 - [PRS10_HUMAN] PRS10 0.49129108 1.25537877 
ELAV-like protein 1 OS=Homo sapiens GN=ELAVL1 PE=1 SV=2 - [ELAV1_HUMAN] ELAV1 0.44800618 1.099429101 
Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] K22E 0.28349823 0.698321532 
Prelamin-A/C OS=Homo sapiens GN=LMNA PE=1 SV=1 - [LMNA_HUMAN] LMNA 0.52383792 1.356374581 
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 - [ALBU_HUMAN] ALBU 0.51879233 1.335742208 
Poly [ADP-ribose] polymerase 12 OS=Homo sapiens GN=PARP12 PE=1 SV=1 - [PAR12_HUMAN] PAR12 0.52707028 1.364851972 
CTP synthase 1 OS=Homo sapiens GN=CTPS1 PE=1 SV=2 - [PYRG1_HUMAN] PYRG1 0.55193812 1.463290008 
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Vasorin OS=Homo sapiens GN=VASN PE=1 SV=1 - [VASN_HUMAN] VASN 0.47139567 1.138600016 
Atlastin-3 OS=Homo sapiens GN=ATL3 PE=1 SV=1 - [ATLA3_HUMAN] ATLA3 0.51080531 1.26483274 
Glycogen phosphorylase, brain form OS=Homo sapiens GN=PYGB PE=1 SV=5 - [PYGB_HUMAN] PYGB 0.46646819 1.110813604 
UBX domain-containing protein 4 OS=Homo sapiens GN=UBXN4 PE=1 SV=2 - [UBXN4_HUMAN] UBXN4 0.4906418 1.185262348 
HLA class I histocompatibility antigen, A-68 alpha chain OS=Homo sapiens GN=HLA-A PE=1 SV=4 - 
[1A68_HUMAN] 1A68 0.57546055 1.484906295 
Glutathione S-transferase Mu 3 OS=Homo sapiens GN=GSTM3 PE=1 SV=3 - [GSTM3_HUMAN] GSTM3 0.39926416 0.887344261 
40S ribosomal protein S2 OS=Homo sapiens GN=RPS2 PE=1 SV=2 - [RS2_HUMAN] RS2 0.49978393 1.165146922 
Neural cell adhesion molecule L1 OS=Homo sapiens GN=L1CAM PE=1 SV=2 - [L1CAM_HUMAN] L1CAM 0.49856099 1.151141654 
Golgin subfamily A member 4 OS=Homo sapiens GN=GOLGA4 PE=1 SV=1 - [GOGA4_HUMAN] GOGA4 0.4071857 0.882566452 
Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 - [PRDX1_HUMAN] PRDX1 0.27986449 0.619516005 
Inosine-5'-monophosphate dehydrogenase 2 OS=Homo sapiens GN=IMPDH2 PE=1 SV=2 - 
[IMDH2_HUMAN] IMDH2 0.52620173 1.209231124 
Kinesin-1 heavy chain OS=Homo sapiens GN=KIF5B PE=1 SV=1 - [KINH_HUMAN] KINH 0.54202068 1.254316146 
Putative nucleoside diphosphate kinase OS=Homo sapiens GN=NME2P1 PE=5 SV=1 - 
[NDK8_HUMAN] NDK8 0.45559594 0.948135273 
Sequestosome-1 OS=Homo sapiens GN=SQSTM1 PE=1 SV=1 - [SQSTM_HUMAN] SQSTM 0.32427019 0.65423638 
Dynactin subunit 1 OS=Homo sapiens GN=DCTN1 PE=1 SV=3 - [DCTN1_HUMAN] DCTN1 0.53656524 1.16901546 
Calcium-binding mitochondrial carrier protein SCaMC-1 OS=Homo sapiens GN=SLC25A24 PE=1 
SV=2 - [SCMC1_HUMAN] SCMC1 0.52296156 1.115189207 
DNA replication licensing factor MCM7 OS=Homo sapiens GN=MCM7 PE=1 SV=4 - 
[MCM7_HUMAN] MCM7 0.58941364 1.346703435 
Lon protease homolog, mitochondrial OS=Homo sapiens GN=LONP1 PE=1 SV=2 - [LONM_HUMAN] LONM 0.53718722 1.139966106 
40S ribosomal protein S7 OS=Homo sapiens GN=RPS7 PE=1 SV=1 - [RS7_HUMAN] RS7 0.55338472 1.19071066 
ATP-citrate synthase OS=Homo sapiens GN=ACLY PE=1 SV=3 - [ACLY_HUMAN] ACLY 0.58578682 1.301296614 
Acetyl-CoA carboxylase 1 OS=Homo sapiens GN=ACACA PE=1 SV=2 - [ACACA_HUMAN] ACACA 0.56680351 1.210577714 
Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] K1C10 0.3969644 0.741680454 
Guanine nucleotide-binding protein subunit beta-2-like 1 OS=Homo sapiens GN=GNB2L1 PE=1 SV=3 
- [GBLP_HUMAN] GBLP 0.60499746 1.336613613 
Aspartate aminotransferase, mitochondrial OS=Homo sapiens GN=GOT2 PE=1 SV=3 - 
[AATM_HUMAN] AATM 0.35922825 0.652047915 
60S ribosomal protein L9 OS=Homo sapiens GN=RPL9 PE=1 SV=1 - [RL9_HUMAN] RL9 0.58841944 1.246576072 
Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 - [PROF1_HUMAN] PROF1 0.3370454 0.60552062 
Nicalin OS=Homo sapiens GN=NCLN PE=1 SV=2 - [NCLN_HUMAN] NCLN 0.5609259 1.13753325 
Histone H2B type 1-J OS=Homo sapiens GN=HIST1H2BJ PE=1 SV=3 - [H2B1J_HUMAN] H2B1J 0.64215553 1.473055686 
Chloride intracellular channel protein 1 OS=Homo sapiens GN=CLIC1 PE=1 SV=4 - [CLIC1_HUMAN] CLIC1 0.58626837 1.218665711 
Guanine nucleotide-binding protein G(i) subunit alpha-1 OS=Homo sapiens GN=GNAI1 PE=1 SV=2 
- [GNAI1_HUMAN] GNAI1 0.55430382 1.097007595 
Serpin B5 OS=Homo sapiens GN=SERPINB5 PE=1 SV=2 - [SPB5_HUMAN] SPB5 0.34743795 0.607487389 
Catalase OS=Homo sapiens GN=CAT PE=1 SV=3 - [CATA_HUMAN] CATA 0.59392428 1.21911949 
Ribonucleoside-diphosphate reductase large subunit OS=Homo sapiens GN=RRM1 PE=1 SV=1 - 
[RIR1_HUMAN] RIR1 0.30683458 0.532614963 
Large neutral amino acids transporter small subunit 1 OS=Homo sapiens GN=SLC7A5 PE=1 SV=2 - 
[LAT1_HUMAN] LAT1 0.16852385 0.349642712 
Methionine--tRNA ligase, cytoplasmic OS=Homo sapiens GN=MARS PE=1 SV=2 - [SYMC_HUMAN] SYMC 0.60653073 1.220020066 
Polymerase delta-interacting protein 2 OS=Homo sapiens GN=POLDIP2 PE=1 SV=1 - 
[PDIP2_HUMAN] PDIP2 0.41333255 0.685463022 
Proteasome subunit alpha type-6 OS=Homo sapiens GN=PSMA6 PE=1 SV=1 - [PSA6_HUMAN] PSA6 0.38445711 0.633345961 
Isoleucine--tRNA ligase, cytoplasmic OS=Homo sapiens GN=IARS PE=1 SV=2 - [SYIC_HUMAN] SYIC 0.65602249 1.415980705 
60S ribosomal protein L18 OS=Homo sapiens GN=RPL18 PE=1 SV=2 - [RL18_HUMAN] RL18 0.62966937 1.288298871 
C-1-tetrahydrofolate synthase, cytoplasmic OS=Homo sapiens GN=MTHFD1 PE=1 SV=3 - 
[C1TC_HUMAN] C1TC 0.33048898 0.527794677 
Histone deacetylase 10 OS=Homo sapiens GN=HDAC10 PE=1 SV=1 - [HDA10_HUMAN] HDA10 0.39788166 0.63259198 
DNA replication licensing factor MCM3 OS=Homo sapiens GN=MCM3 PE=1 SV=3 - 
[MCM3_HUMAN] MCM3 0.61207968 1.18605753 
Heterogeneous nuclear ribonucleoprotein C-like 2 OS=Homo sapiens GN=HNRNPCL2 PE=2 SV=1 - 
[HNRC2_HUMAN] HNRC2 0.60695332 1.139333499 
Signal transducer and activator of transcription 3 OS=Homo sapiens GN=STAT3 PE=1 SV=2 - 
[STAT3_HUMAN] STAT3 0.64929342 1.305108998 
Annexin A2 OS=Homo sapiens GN=ANXA2 PE=1 SV=2 - [ANXA2_HUMAN] ANXA2 0.51551163 0.846351872 
60 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPD1 PE=1 SV=2 - 
[CH60_HUMAN] CH60 0.54148591 0.89325964 
Heat shock protein 75 kDa, mitochondrial OS=Homo sapiens GN=TRAP1 PE=1 SV=3 - 
[TRAP1_HUMAN] TRAP1 0.29650393 0.450566089 
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Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 - [TBB5_HUMAN] TBB5 0.61963129 1.142470446 
WD repeat-containing protein 1 OS=Homo sapiens GN=WDR1 PE=1 SV=4 - [WDR1_HUMAN] WDR1 0.4146131 0.618557674 
T-complex protein 1 subunit theta OS=Homo sapiens GN=CCT8 PE=1 SV=4 - [TCPQ_HUMAN] TCPQ 0.45886719 0.699068228 
Peptidyl-prolyl cis-trans isomerase B OS=Homo sapiens GN=PPIB PE=1 SV=2 - [PPIB_HUMAN] PPIB 0.42119876 0.619613249 
14-3-3 protein gamma OS=Homo sapiens GN=YWHAG PE=1 SV=2 - [1433G_HUMAN] 1433G 0.43765795 0.634488564 
Secretory carrier-associated membrane protein 3 OS=Homo sapiens GN=SCAMP3 PE=1 SV=3 - 
[SCAM3_HUMAN] SCAM3 0.65533906 1.220660172 
Keratin, type II cuticular Hb6 OS=Homo sapiens GN=KRT86 PE=1 SV=1 - [KRT86_HUMAN] KRT86 0.37114638 0.519597238 
Fructose-bisphosphate aldolase A OS=Homo sapiens GN=ALDOA PE=1 SV=2 - [ALDOA_HUMAN] ALDOA 0.41098568 0.578953665 
F-box only protein 22 OS=Homo sapiens GN=FBXO22 PE=1 SV=1 - [FBX22_HUMAN] FBX22 0.64930832 1.181936111 
Cleavage and polyadenylation specificity factor subunit 7 OS=Homo sapiens GN=CPSF7 PE=1 SV=1 
- [CPSF7_HUMAN] CPSF7 0.63370556 1.105639648 
2-oxoglutarate dehydrogenase, mitochondrial OS=Homo sapiens GN=OGDH PE=1 SV=3 - 
[ODO1_HUMAN] ODO1 0.59354246 0.951368836 
F-actin-capping protein subunit alpha-1 OS=Homo sapiens GN=CAPZA1 PE=1 SV=3 - 
[CAZA1_HUMAN] CAZA1 0.65881449 1.18560838 
Palladin OS=Homo sapiens GN=PALLD PE=1 SV=3 - [PALLD_HUMAN] PALLD 0.65947926 1.184933848 
Glucose-6-phosphate isomerase OS=Homo sapiens GN=GPI PE=1 SV=4 - [G6PI_HUMAN] G6PI 0.4467901 0.611929619 
Single-stranded DNA-binding protein, mitochondrial OS=Homo sapiens GN=SSBP1 PE=1 SV=1 - 
[SSBP_HUMAN] SSBP 0.53708887 0.761722759 
Guanine nucleotide-binding protein G(k) subunit alpha OS=Homo sapiens GN=GNAI3 PE=1 SV=3 - 
[GNAI3_HUMAN] GNAI3 0.58354533 0.852590139 
T-complex protein 1 subunit epsilon OS=Homo sapiens GN=CCT5 PE=1 SV=1 - [TCPE_HUMAN] TCPE 0.54096836 0.745353117 
Prostaglandin E synthase 2 OS=Homo sapiens GN=PTGES2 PE=1 SV=1 - [PGES2_HUMAN] PGES2 0.6651386 1.098122445 
Keratin, type I cuticular Ha1 OS=Homo sapiens GN=KRT31 PE=2 SV=3 - [K1H1_HUMAN] K1H1 0.37453979 0.452157835 
Cofilin-1 OS=Homo sapiens GN=CFL1 PE=1 SV=3 - [COF1_HUMAN] COF1 0.56003851 0.755673907 
Eukaryotic translation elongation factor 1 epsilon-1 OS=Homo sapiens GN=EEF1E1 PE=1 SV=1 - 
[MCA3_HUMAN] MCA3 0.6844933 1.128055855 
Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 - [HORN_HUMAN] HORN 0.56928355 0.754244865 
Serine/arginine-rich splicing factor 1 OS=Homo sapiens GN=SRSF1 PE=1 SV=2 - [SRSF1_HUMAN] SRSF1 0.64662063 0.950124183 
Protein transport protein Sec24C OS=Homo sapiens GN=SEC24C PE=1 SV=3 - [SC24C_HUMAN] SC24C 0.63349503 0.907177023 
Malate dehydrogenase, mitochondrial OS=Homo sapiens GN=MDH2 PE=1 SV=3 - 
[MDHM_HUMAN] MDHM 0.55887812 0.709195695 
Vinculin OS=Homo sapiens GN=VCL PE=1 SV=4 - [VINC_HUMAN] VINC 0.40473214 0.452656365 
Aspartate--tRNA ligase, cytoplasmic OS=Homo sapiens GN=DARS PE=1 SV=2 - [SYDC_HUMAN] SYDC 0.70637578 1.175183724 
Protein-L-isoaspartate(D-aspartate) O-methyltransferase OS=Homo sapiens GN=PCMT1 PE=1 SV=4 - 
[PIMT_HUMAN] PIMT 0.69034308 1.086295761 
60S ribosomal protein L12 OS=Homo sapiens GN=RPL12 PE=1 SV=1 - [RL12_HUMAN] RL12 0.71827245 1.202736449 
Nascent polypeptide-associated complex subunit alpha OS=Homo sapiens GN=NACA PE=1 SV=1 - 
[NACA_HUMAN] NACA 0.38617033 0.415461718 
Annexin A1 OS=Homo sapiens GN=ANXA1 PE=1 SV=2 - [ANXA1_HUMAN] ANXA1 0.59643072 0.764870719 
Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 - [K2C1_HUMAN] K2C1 0.63792229 0.861893777 
Microtubule-associated protein 1B OS=Homo sapiens GN=MAP1B PE=1 SV=2 - [MAP1B_HUMAN] MAP1B 0.69354868 1.036870111 
Poly(rC)-binding protein 1 OS=Homo sapiens GN=PCBP1 PE=1 SV=2 - [PCBP1_HUMAN] PCBP1 0.6079511 0.760102035 
Carbonyl reductase [NADPH] 1 OS=Homo sapiens GN=CBR1 PE=1 SV=3 - [CBR1_HUMAN] CBR1 0.54006416 0.59994333 
Serpin H1 OS=Homo sapiens GN=SERPINH1 PE=1 SV=2 - [SERPH_HUMAN] SERPH 0.64761192 0.847936961 
40S ribosomal protein SA OS=Homo sapiens GN=RPSA PE=1 SV=4 - [RSSA_HUMAN] RSSA 0.71979862 1.116177859 
Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 - [HS90B_HUMAN] HS90B 0.73102397 1.169440417 
Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 - [DESP_HUMAN] DESP 0.74877942 1.259614618 
7-dehydrocholesterol reductase OS=Homo sapiens GN=DHCR7 PE=1 SV=1 - [DHCR7_HUMAN] DHCR7 0.71835762 1.101586133 
T-complex protein 1 subunit beta OS=Homo sapiens GN=CCT2 PE=1 SV=4 - [TCPB_HUMAN] TCPB 0.75569451 1.228478849 
Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial OS=Homo sapiens GN=OXCT1 
PE=1 SV=1 - [SCOT1_HUMAN] SCOT1 0.60409498 0.680895843 
60S ribosomal protein L27 OS=Homo sapiens GN=RPL27 PE=1 SV=2 - [RL27_HUMAN] RL27 0.71770453 1.033389985 
40S ribosomal protein S25 OS=Homo sapiens GN=RPS25 PE=1 SV=1 - [RS25_HUMAN] RS25 0.74574256 1.141464353 
Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 - [TPIS_HUMAN] TPIS 0.62794644 0.71455233 
Tubulin beta-4B chain OS=Homo sapiens GN=TUBB4B PE=1 SV=1 - [TBB4B_HUMAN] TBB4B 0.62186915 0.69957348 
Lysine--tRNA ligase OS=Homo sapiens GN=KARS PE=1 SV=3 - [SYK_HUMAN] SYK 0.68706656 0.852195973 
Lipoprotein lipase OS=Homo sapiens GN=LPL PE=1 SV=1 - [LIPL_HUMAN] LIPL 0.75750875 1.149080423 
HLA class I histocompatibility antigen, B-51 alpha chain OS=Homo sapiens GN=HLA-B PE=1 SV=1 - 
[1B51_HUMAN] 1B51 0.42009485 0.36007599 
Filaggrin-2 OS=Homo sapiens GN=FLG2 PE=1 SV=1 - [FILA2_HUMAN] FILA2 0.62115854 0.6468984 
Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4 - [EF2_HUMAN] EF2 0.77235121 1.190269989 
40S ribosomal protein S26 OS=Homo sapiens GN=RPS26 PE=1 SV=3 - [RS26_HUMAN] RS26 0.74281198 1.014306028 
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Protein disulfide-isomerase A6 OS=Homo sapiens GN=PDIA6 PE=1 SV=1 - [PDIA6_HUMAN] PDIA6 0.78424138 1.229492801 
Elongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 PE=1 SV=1 - [EF1A1_HUMAN] EF1A1 0.76924706 1.114749957 
GTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 SV=3 - [RAN_HUMAN] RAN 0.75725663 1.044285802 
Thioredoxin reductase 1, cytoplasmic OS=Homo sapiens GN=TXNRD1 PE=1 SV=3 - 
[TRXR1_HUMAN] TRXR1 0.77752733 1.147894501 
Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP PE=1 SV=1 - [LG3BP_HUMAN] LG3BP 0.77144569 1.11119444 
L-lactate dehydrogenase B chain OS=Homo sapiens GN=LDHB PE=1 SV=2 - [LDHB_HUMAN] LDHB 0.67996049 0.72214853 
Collagen alpha-1(VIII) chain OS=Homo sapiens GN=COL8A1 PE=1 SV=2 - [CO8A1_HUMAN] CO8A1 0.75314224 0.976013674 
Microtubule-associated protein 4 OS=Homo sapiens GN=MAP4 PE=1 SV=3 - [MAP4_HUMAN] MAP4 0.73033792 0.87513273 
Annexin A5 OS=Homo sapiens GN=ANXA5 PE=1 SV=2 - [ANXA5_HUMAN] ANXA5 0.79071581 1.141973074 
Junction plakoglobin OS=Homo sapiens GN=JUP PE=1 SV=3 - [PLAK_HUMAN] PLAK 0.79230058 1.138007819 
14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 - [1433Z_HUMAN] 1433Z 0.71596527 0.780139158 
Proteasome subunit alpha type-7 OS=Homo sapiens GN=PSMA7 PE=1 SV=1 - [PSA7_HUMAN] PSA7 0.79788941 1.108739262 
Keratin, type II cytoskeletal 4 OS=Homo sapiens GN=KRT4 PE=1 SV=4 - [K2C4_HUMAN] K2C4 0.5790385 0.455494971 
Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 SV=2 - [ACTN1_HUMAN] ACTN1 0.80181926 1.084195559 
Transportin-1 OS=Homo sapiens GN=TNPO1 PE=1 SV=2 - [TNPO1_HUMAN] TNPO1 0.80804759 1.079990617 
Glutathione S-transferase P OS=Homo sapiens GN=GSTP1 PE=1 SV=2 - [GSTP1_HUMAN] GSTP1 0.75928891 0.830461741 
T-complex protein 1 subunit zeta OS=Homo sapiens GN=CCT6A PE=1 SV=3 - [TCPZ_HUMAN] TCPZ 0.81152755 1.059308788 
Glucose-6-phosphate 1-dehydrogenase OS=Homo sapiens GN=G6PD PE=1 SV=4 - [G6PD_HUMAN] G6PD 0.81647205 1.079374489 
Clathrin heavy chain 1 OS=Homo sapiens GN=CLTC PE=1 SV=5 - [CLH1_HUMAN] CLH1 0.79535979 0.950273579 
Annexin A3 OS=Homo sapiens GN=ANXA3 PE=1 SV=3 - [ANXA3_HUMAN] ANXA3 0.77714354 0.854669435 
U2 small nuclear ribonucleoprotein A' OS=Homo sapiens GN=SNRPA1 PE=1 SV=2 - 
[RU2A_HUMAN] RU2A 0.79543227 0.937984724 
Histone deacetylase 6 OS=Homo sapiens GN=HDAC6 PE=1 SV=2 - [HDAC6_HUMAN] HDAC6 0.82432789 1.087519528 
60S ribosomal protein L11 OS=Homo sapiens GN=RPL11 PE=1 SV=2 - [RL11_HUMAN] RL11 0.83718419 1.156734388 
Tubulin alpha-1C chain OS=Homo sapiens GN=TUBA1C PE=1 SV=1 - [TBA1C_HUMAN] TBA1C 0.19303416 0.11759222 
Phenylalanine--tRNA ligase alpha subunit OS=Homo sapiens GN=FARSA PE=1 SV=3 - 
[SYFA_HUMAN] SYFA 0.83705473 1.067372827 
Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2 PE=1 SV=5 - [PRDX2_HUMAN] PRDX2 0.81307936 0.915036492 
Emerin OS=Homo sapiens GN=EMD PE=1 SV=1 - [EMD_HUMAN] EMD 0.84768236 1.13337495 
LanC-like protein 1 OS=Homo sapiens GN=LANCL1 PE=1 SV=1 - [LANC1_HUMAN] LANC1 0.80951667 0.881835078 
26S proteasome non-ATPase regulatory subunit 1 OS=Homo sapiens GN=PSMD1 PE=1 SV=2 - 
[PSMD1_HUMAN] PSMD1 0.83400893 1.021983707 
Ezrin OS=Homo sapiens GN=EZR PE=1 SV=4 - [EZRI_HUMAN] EZRI 0.82095945 0.883863518 
Ubiquitin-like protein ISG15 OS=Homo sapiens GN=ISG15 PE=1 SV=5 - [ISG15_HUMAN] ISG15 0.82079071 0.870252782 
Alpha-actinin-4 OS=Homo sapiens GN=ACTN4 PE=1 SV=2 - [ACTN4_HUMAN] ACTN4 0.8629458 1.162253814 
Phosphate carrier protein, mitochondrial OS=Homo sapiens GN=SLC25A3 PE=1 SV=2 - 
[MPCP_HUMAN] MPCP 0.85301244 1.067929972 
Protein transport protein Sec61 subunit beta OS=Homo sapiens GN=SEC61B PE=1 SV=2 - 
[SC61B_HUMAN] SC61B 0.85974902 1.016589459 
Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 - [DSG1_HUMAN] DSG1 0.84409022 0.883486634 
Aminoacyl tRNA synthase complex-interacting multifunctional protein 2 OS=Homo sapiens 
GN=AIMP2 PE=1 SV=2 - [AIMP2_HUMAN] AIMP2 0.85846728 0.958553513 
Phosphoglycerate kinase 1 OS=Homo sapiens GN=PGK1 PE=1 SV=3 - [PGK1_HUMAN] PGK1 0.86094272 0.897523259 
Cell division control protein 42 homolog OS=Homo sapiens GN=CDC42 PE=1 SV=2 - 
[CDC42_HUMAN] CDC42 0.90424842 0.961216456 
Rho GDP-dissociation inhibitor 1 OS=Homo sapiens GN=ARHGDIA PE=1 SV=3 - [GDIR1_HUMAN] GDIR1 0.91743696 1.013352512 
Peptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 SV=2 - [PPIA_HUMAN] PPIA 0.91156214 0.922416244 
Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN] DCD 0.915416 0.948884709 
Elongation factor Tu, mitochondrial OS=Homo sapiens GN=TUFM PE=1 SV=2 - [EFTU_HUMAN] EFTU 0.92033321 0.976743739 
D-3-phosphoglycerate dehydrogenase OS=Homo sapiens GN=PHGDH PE=1 SV=4 - [SERA_HUMAN] SERA 0.92613137 1.050268379 
Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] K1C9 0.9270305 1.037118205 
Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP90AA1 PE=1 SV=5 - [HS90A_HUMAN] HS90A 0.9250654 0.963735625 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 OS=Homo sapiens GN=ATP2A2 PE=1 SV=1 
- [AT2A2_HUMAN] AT2A2 0.9510445 0.97440195 
Elongation factor 1-gamma OS=Homo sapiens GN=EEF1G PE=1 SV=3 - [EF1G_HUMAN] EF1G 0.95536131 0.982077325 
Rab GDP dissociation inhibitor beta OS=Homo sapiens GN=GDI2 PE=1 SV=2 - [GDIB_HUMAN] GDIB 0.95968509 1.012138902 
T-complex protein 1 subunit alpha OS=Homo sapiens GN=TCP1 PE=1 SV=1 - [TCPA_HUMAN] TCPA 0.95989448 0.97336327 
26S proteasome non-ATPase regulatory subunit 3 OS=Homo sapiens GN=PSMD3 PE=1 SV=2 - 
[PSMD3_HUMAN] PSMD3 0.96060973 0.969215162 
Keratin, type II cytoskeletal 6A OS=Homo sapiens GN=KRT6A PE=1 SV=3 - [K2C6A_HUMAN] K2C6A 0.96183759 0.976063288 
Translational activator GCN1 OS=Homo sapiens GN=GCN1L1 PE=1 SV=6 - [GCN1L_HUMAN] GCN1L 0.9628855 0.976749206 
Vesicle-trafficking protein SEC22b OS=Homo sapiens GN=SEC22B PE=1 SV=4 - [SC22B_HUMAN] SC22B 0.97020113 1.022500836 
Tubulin alpha-4A chain OS=Homo sapiens GN=TUBA4A PE=1 SV=1 - [TBA4A_HUMAN] TBA4A 0.96906078 0.975549538 
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Hepatocyte growth factor receptor OS=Homo sapiens GN=MET PE=1 SV=4 - [MET_HUMAN] MET 0.97391498 1.003859664 
L-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=2 - [LDHA_HUMAN] LDHA 0.9819358 1.013311145 
Alpha-globin transcription factor CP2 OS=Homo sapiens GN=TFCP2 PE=1 SV=2 - [TFCP2_HUMAN] TFCP2 0.98222518 1.009385404 
Endoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=1 - [ENPL_HUMAN] ENPL 0.98475915 1.00963962 
Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 SV=5 - [K2C6B_HUMAN] K2C6B 0.98542249 0.990657468 
Histone H3.1 OS=Homo sapiens GN=HIST1H3A PE=1 SV=2 - [H31_HUMAN] H31 0.98936349 0.993920553 
Ras-related protein Rab-10 OS=Homo sapiens GN=RAB10 PE=1 SV=1 - [RAB10_HUMAN] RAB10 0.99242854 0.99921296 
 
 
 
 
  
  
157 
Appendix 3 
 
 
 
Figure A1: Two models of the 3D structure of TPD54. Upper model shows the protein 
with four helices, and potentially two sets of coiled-coil regions. The lower model shows 
two helices and one coiled-coil region. Blue is N-terminal and red is C-terminal region. 
Grey fragment shows the localisation of the potential phosphoserine. 
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